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The ubiquitin-proteasome pathway consists of ubiquitin, substrate proteins, E1 
enzymes, E2 enzymes, E3 enzymes, and proteasome, which acts in a series of 
enzymatic reaction chains to ubiquitinate substrate proteins such as surplus and 
misfolded proteins for degradation by the proteasome to maintain the balance between 
protein synthesis and degradation in a cell and tissue. Moreover, deubiquitinating 
enzymes can remove the attached ubiquitin chain, which results in a reverse 
ubiquitination-deubiquitination process involved in multiple biological processes in 
a cell and tissue. The changes of components in the ubiquitin-proteasome pathway 
are associated with multiple pathophysiological processes, such as cancers and 
neurodegenerative diseases. This book presents the new advances in concepts, 
analytical methodology, and application of ubiquitin-proteasome pathway for 
clarification of molecular mechanisms and discovery of new therapeutic targets and 
drugs in different diseases.
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Scope of the Series
Biochemistry, the study of chemical transformations occurring within living organ-
isms, impacts all of life sciences, from molecular crystallography and genetics, to 
ecology, medicine and population biology. Biochemistry studies macromolecules - 
proteins, nucleic acids, carbohydrates and lipids –their building blocks, structures, 
functions and interactions. Much of biochemistry is devoted to enzymes, proteins 
that catalyze chemical reactions, enzyme structures, mechanisms of action and 
their roles within cells. Biochemistry also studies small signaling molecules, co-
enzymes, inhibitors, vitamins and hormones, which play roles in the life process. 
Biochemical experimentation, besides coopting the methods of classical chemistry, 
e.g., chromatography, adopted new techniques, e.g., X-ray diffraction, electron 
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microscopy, NMR, radioisotopes, and developed sophisticated microbial genetic 
tools, e.g., auxotroph mutants and their revertants, fermentation etc. More recently, 
biochemistry embraced the ‘big data’ omics systems.
Initial biochemical studies have been exclusively analytic: dissecting, purifying and 
examining individual components of a biological system; in exemplary words of 
Efraim Racker, (1913 - 1991) “Don’t waste clean thinking on dirty enzymes.” Today 
however, biochemistry is becoming more agglomerative and comprehensive, setting 
out to integrate and describe fully a particular biological system. The “big data” me-
tabolomics can define the complement of small molecules, e.g., in a soil or biofilm 
sample; proteomics can distinguish all the proteins comprising e.g., serum; metage-
nomics can identify all the genes in a complex environment e.g., bovine rumen. This 
Biochemistry Series will address both the current research on biomolecules, and the 
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Preface
The ubiquitin-proteasome pathway consists of ubiquitin, substrate proteins, 
E1 enzymes, E2 enzymes, E3 enzymes, and proteasome. Ubiquitin is a highly 
conserved small protein with 76 amino acids and about 8.5 kDa. E1 enzymes are 
ubiquitin-activating enzymes. E2 enzymes are ubiquitin-conjugating enzymes. E3 
enzymes are ubiquitin-ligases. Proteasome is a 26S complex, an organelle in the cell, 
which contains one 20S core and two 19S lids. The ubiquitin-proteasome pathway 
consists of a series of enzymatic reactions: E1 binds ubiquitin to activate ubiquitin 
in ATP-dependent fashion, the activated ubiquitin is conjugated with E2, and then 
ubiquitin-conjugated E2 in concert with E3 ligases recognizes substrate proteins 
and chemically covalently attaches ubiquitin (monomer or polyubiquitin chain) to 
substrate proteins (ubiquitinated proteins). The ubiquitinated proteins are delivered 
to the proteasome for degradation into peptides and amino acids to be used for 
synthesis of new proteins. Here, substrate proteins include surplus proteins and 
misfolded proteins in a cell or tissue. Also, there are the deubiquitinating enzymes 
that can remove the attached ubiquitin chain. Thus, ubiquitination/deubiquitination 
is a reverse process in cells. The ubiquitin-proteasome pathway plays crucial roles in 
degrading most intracellular proteins, and maintaining the balance between protein 
synthesis and degradation. The changes of components in the ubiquitin-proteasome 
pathway are associated with multiple pathophysiological processes, such as cancers, 
and neurodegenerative diseases. For example, the mutated or overexpressed E3 
ligases can act as oncogenes, and also some E3 ligases and deubiquitinating enzymes 
are tumor suppressors. Moreover, the ubiquitin-proteasome pathway is involved in 
multiple biological processes, including DNA repair, mitophagy, angiogenesis, RTK 
signaling, NF-kB signaling, and mitochondrial maintenance, which are dynamically 
regulated by ubiquitination. Also, it is involved in synaptic functions to regulate the 
functions of the nervous system.
This book focuses on the changes of the components of the ubiquitin-proteasome 
pathway, the methodology to study the ubiquitin-proteasome pathway, protein 
ubiquitination, and application of the ubiquitin-proteasome pathway in different 
diseases. Chapter 1 addresses the branching and mixing – new signals of the 
ubiquitin signaling system in the following aspects: the ubiquitin-conjugating 
system, different ubiquitin-like modifications, ubiquitin-chain topology 
(homotypic chains, heterotypic chains, and ubl-ubiquitin chains), and detection 
methods of ubiquitinated targets and chains including biochemical and genetic 
methods, mass spectrometry-based methods, ubiquitin topology analysis, and 
detection of branched chains. Chapter 2 addresses the ubiquitin-independent 
proteasomal degradation mediated by antizyme, which enriched the concept and 
content of the ubiquitin-proteasome pathway: ubiquitin-dependent proteasomal 
degradation through ubiquitination, and ubiquitin-independent proteasomal 
degradation through antizyme. Chapter 3 addresses lys63-linked polyubiquitination 
of transforming growth factor beta type I receptor (TBRI) specifies oncogenic 
signaling, and the regulation of its associated signaling pathways. Chapter 4 
addresses ubiquitination and deubiquitination, and their potential clinical 
application value in melanoma. Chapter 5 addresses the new discoveries of more 
members (AREL1, HACE1, HECTD1, HECTD4, G2E3, and TRIP12) of the HECT E3 
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ubiquitin ligase family and their biological functions and activities except for the 
classical E6AP and NEDD4 family, whose dysfunction is closely associated with 
different diseases. Chapter 6 uses the quantitative ubiquitinomics to investigate the 
abnormal ubiquitination of the ubiquitin-proteasome system in lung squamous cell 
carcinoma, which provides important insight into understanding the nature and 
importance of these alterations in the ubiquitin-proteasome system in a cancerous 
relative to normal lungs.
This book presents the new advances in concepts, methodology, and application 
of the ubiquitin-proteasome pathway. However, one must realize that this book 
contains only a fraction of the very important ubiquitin-proteasome pathway 
studies in medical sciences, which serves as a spur to stimulate and encourage 
researchers who study the ubiquitin-proteasome pathway to come forward with 
its scientific merits to research and clinical practice of the ubiquitin-proteasome 
pathway, especially in the aspects of clarification of molecular mechanisms and 
discovery of new therapeutic targets and drugs for diseases.
Xianquan Zhan, MD, PhD, FRSM
Professor of Cancer Proteomics and PPPM,
University Creative Research Initiatives Center,
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Posttranslational modifications allow cells and organisms to adapt to their 
environment without the need to synthesize new proteins. The ubiquitin system 
is one of the most versatile modification systems as it does not only allow a simple 
on–off modification but, by forming a chain of ubiquitin molecules, allows convey-
ing multiple signals. The structure of the chains is dependent on the linkage to the 
previous ubiquitin molecule as every lysine can serve as an acceptor point for this 
modification. Different chain types code for specific signals ranging from protein 
degradation to protein targeting different cellular compartments. Recently the code 
of ubiquitin signals has been further expanded as branching and mixing of differ-
ent chain types has been detected. As an additional layer of complexity, modifica-
tions of the ubiquitin chain by ubiquitin-like modifiers, like NEDD8, SUMO, or 
ISG15, have been found. Here we will discuss the different chain types and the 
technical challenges which are associated with analyzing ubiquitin topology-based 
signaling.
Keywords: ubiquitin, chain topology, ubiquitin-like, branched ubiquitin
1. The ubiquitin-conjugating system
Since its discovery in the 1980s, the ubiquitin signaling system has gained 
recognition as one of the most versatile, yet complicated, posttranslational signal-
ing systems. The central component of the system is the small protein ubiquitin 
(76 aa). Ubiquitin itself is always expressed as an immature precursor protein, 
either fused to a ribosomal protein or as a head-to-tail fusion of five or six ubiquitin 
moieties. The precursor protein is processed co-translationally and cleaved off the 
fusion protein right at the ribosome [1] liberating the mature ubiquitin protein. 
The modification of a target protein with ubiquitin as a PTM utilizes an enzymatic 
cascade. In the first step, an ubiquitin-activating enzyme (E1) is binding ubiquitin 
while hydrolyzing one molecule of ATP to AMP forming a thiol ester of ubiquitin’s 
C-terminus with a cysteine residue in its active center. The activated ubiquitin can 
then be transferred to an ubiquitin-conjugating enzyme (E2) which again forms 
a thiol ester with a cysteine in its active center. Depending on the cascade which 
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The modification of a target protein with ubiquitin as a PTM utilizes an enzymatic 
cascade. In the first step, an ubiquitin-activating enzyme (E1) is binding ubiquitin 
while hydrolyzing one molecule of ATP to AMP forming a thiol ester of ubiquitin’s 
C-terminus with a cysteine residue in its active center. The activated ubiquitin can 
then be transferred to an ubiquitin-conjugating enzyme (E2) which again forms 
a thiol ester with a cysteine in its active center. Depending on the cascade which 
is used, the final transfer is catalyzed by one of three classes of ubiquitin ligases, 
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really interesting new gene (RING), ring between ring (RBR), or homologous to E6 
C-terminus ligases (HECT ligases) (Figure 1). While RING-type ligases are associ-
ating with the E2 enzyme and bringing the target protein in close proximity to the 
E2/E3 complex, RBR and HECT-E3 are able to bind ubiquitin itself. The final trans-
fer of ubiquitin to the target is then catalyzed without the help of an E2 enzyme.
This modification leads to a single modification of the substrate protein with 
ubiquitin but can also be extended by multiple rounds of modification with ubiq-
uitin itself being the acceptor of the modification, leading to the formation of the 
ubiquitin chain. The structure of the chain is dependent on which linkage is used 
within the ubiquitin chain. The chains highly varies in shape from a very compact 
structure for a K48-linked chain [2–4] to a long stretched shape in the case of K63 
[5, 6] and linear ubiquitination [3]. Each of the different chain topologies is associ-
ated with different biological functions. Besides the signaling through different 
chain topologies, ubiquitin signaling can also occur through modifications by a 
single ubiquitin (monoubiquitin) or multiple monoubiquitinations.
Like for many other PTM systems, the ubiquitin signaling system has pos-
sibilities to erase the signal by either disassembling the polyubiquitin chain or by 
removing ubiquitin from its target. These enzymes are called ubiquitin hydrolases 
or ubiquitin de-conjugating enzymes (DUBs). Most DUBs belong to the enzymatic 
class of cysteine hydrolases, which carry a cysteine in their active center. Research 
on DUB specificity has shown that these enzymes possess a high linkage specificity 
indicating clear regulatory functions in the cell and are not acting as simple quality 
check enzymes [7].
2. Ubiquitin-like modifiers (Ubl)
Besides ubiquitin, there are a number of proteins which share significant simi-
larity to ubiquitin. They fall essentially into two groups: proteins with a ubiquitin-
like domain and small proteins with a similar size as ubiquitin. The small Ubls like 
ubiquitin, SUMO, NEDD8, Urm1, Apg8, Apg12, ISG15, Fat10, and Ufm1 are highly 
Figure 1. 
The ubiquitin-conjugating system. Ubiquitin (gray folded structure) is expressed as fusions either with 
ribosomal subunits or as ubiquitin multimers, which are cleaved co-translational. The mature ubiquitin 
(orange) is released and under the consumption of one ATP bound to the activating enzyme (E1). The activated 
ubiquitin is then passed on to the conjugating enzyme (E2), which finally catalyzes the transfer to a substrate 
protein involving an E3 ligase. The reaction can then be repeated and catalyzes the formation of a polyubiquitin 
chain. Depending on the lysine residue in ubiquitin used, the chain can have different structures, as indicated in 
yellow for a linear ubiquitin chain or in red for a K48-linked chain.
3
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conserved among eukaryotes. Many of these small proteins have been found to 
be covalently conjugated to a substrate protein, utilizing their own conjugation 
cascades, which usually consists of an activating enzyme and a conjugating enzyme 
(see Table 1).
2.1 NEDD8
Neuronal precursor cell-expressed developmentally downregulated protein 8 
(NEDD8) is structurally the closest relative to ubiquitin. Its E1 enzyme is split into 
two different parts which are forming the activation enzyme (NAE1/UBA3) [8]. 
The activated NEDD8 moiety is transferred to the NEDD8-conjugating enzyme E2s 
(UBC12/UBE2M or UBE2F) and substrate-specific NEDD8 E3 ligase [9]. Unlike 
the large group of ubiquitin E3 ligases, there are only about 10 different NEDD8 E3 
ligases [9], and most of them belong to the group of RING E3 ligases.
The best-characterized physiological neddylation substrates are the cullin 
proteins (Cul-1, Cul-2, Cul-3, Cul-4A, Cul-4B, and Cul-5) which form the back-
bone structure of cullin-RING ligases (CRLs). The conjugation of the cullin subunit 
modulates the activity of E3 ligase [10]. Deconjugation of the NEDD8 is catalyzed 
by the signalosome complex which removes NEDD8 from the cullin [11–14].
Recently, several other proteins have been identified, which are modified by 
NEDD8 including ubiquitin itself, p53, mouse double minute 2, and epidermal 
growth factor receptor (EGFR) [15–17].
2.2 SUMO
Small ubiquitin-related modifier (SUMO) is probably the best-studied Ubl pro-
tein. It is highly conserved among eukaryotes with one gene in lower eukaryotes like 
baker’s yeast (Smt3) [18] which developed into three homologs in humans, SUMO-
1, SUMO-2, and SUMO-3. SUMO-2 and SUMO-3 are closely related, while SUMO-1 
is more divergent. SUMO-1 does not form polymeric chains, while SUMO-2 and 
SUMO-3 mainly form K11-linked homotypic SUMO chains [19, 20]. SUMO-1 can 
be linked to the end of a poly-SUMO-2/SUMO-3 chain, effectively terminating 
chain growth [20]. Like NEDD8, SUMO is activated by a dimeric activating enzyme 
(SAE1/SAE2). The recognition of the target proteins is done by the conjugating 
enzyme Ubc9 which recognizes the main SUMOylation motif ΨKxE (Ψ = hydro-
phobic residue) [21–23]. Some reactions are further enhanced by the action of other 
E3 ligases, like RANBP2. These E3 ligases catalyze the transfer by recruiting the 
substrate or catalyzing the transfer of SUMO from Ubc9 [24, 25]. Similar to other 
Ubls, modification with SUMO can be reversed by specific proteases as summarized 
in Pichler [26].
Most SUMO-1 is conjugated to RANGAP1 near the nuclear pore. SUMO-2 is 
partially cytosolic, while SUMO-3 is mainly located in nuclear bodies. In unstressed 
cells, most SUMO-2 and SUMO-3 are not conjugated. Upon stress induction  
Ubl E1 E2
NEDD8 UBA3 (UBE1C), APPBP1 (NAE1) UBE2M
SUMO SAE1, SAE2 UBE2I
ISG15 UBA7 UbcH8
Table 1. 
Ubiquitin-like modifiers that have been found linked to ubiquitin chains and their enzymatic activation 
cascade.
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SUMO-3 mainly form K11-linked homotypic SUMO chains [19, 20]. SUMO-1 can 
be linked to the end of a poly-SUMO-2/SUMO-3 chain, effectively terminating 
chain growth [20]. Like NEDD8, SUMO is activated by a dimeric activating enzyme 
(SAE1/SAE2). The recognition of the target proteins is done by the conjugating 
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phobic residue) [21–23]. Some reactions are further enhanced by the action of other 
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substrate or catalyzing the transfer of SUMO from Ubc9 [24, 25]. Similar to other 
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in Pichler [26].
Most SUMO-1 is conjugated to RANGAP1 near the nuclear pore. SUMO-2 is 
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Ubl E1 E2
NEDD8 UBA3 (UBE1C), APPBP1 (NAE1) UBE2M
SUMO SAE1, SAE2 UBE2I
ISG15 UBA7 UbcH8
Table 1. 
Ubiquitin-like modifiers that have been found linked to ubiquitin chains and their enzymatic activation 
cascade.
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(e.g., folding stress) both SUMO-2 and SUMO-3 get conjugated to target proteins 
[27]. SUMO-1 conjugation has been proposed to regulate trafficking between 
nucleus and cytosol but also change protein–protein interaction [26, 28, 29]. SUMO 
modification plays an important role in a number of cellular processes like DNA 
replication, cell cycle regulation, nuclear trafficking, signal transduction, and pro-
tein degradation [30–32]. Recently, large-scale studies identified more than 1000 
SUMO targets and increased the number of cellular processes even further [33].
2.3 ISG15
Unlike other small ubiquitin-like modifiers interferon-stimulated gene prod-
uct 15 (ISG15) contains two ubiquitin-fold domains. It is massively induced by 
interferon treatment, ischemia, DNA damage, and aging as a monomer as well as a 
conjugated protein (reviewed in [34]). ISGylation requires a three-step enzymatic 
cascade involving an E1 activating enzyme (Ube1L), an E2 conjugating enzyme 
(UbcH8), and an E3 ligase (Herc5 or TRIM25/EFP) [35]. ISGylation is reversed by 
Ub-specific protease USP18 [36].
Several protein targets and cellular functions have been identified, which are 
regulated by ISGylation. These include the regulation of DNA damage response, 
autophagy, protein synthesis, the downregulation of the ubiquitin-proteasome 
system, and the regulation of HIFɑ in response to hypoxia [37–42].
A particular interest is the finding that modification of nascent proteins by 
ISGylation occurs after viral infection [43]. Virus infection induces host antiviral 
responses, including induction of type I interferons [44–47]. The transcription fac-
tor IRF3 recruits HERC5 and induces conjugation of ISG15 onto IRF3. This modi-
fication attenuates the interaction between Pin1 and IRF3, thus antagonizing IRF3 
ubiquitination and degradation. Consistently, host antiviral responses are boosted 
or crippled in the presence or absence of HERC5, respectively [48–50].
3. Ubiquitin chain topology
Ubiquitination occurs in proteins at one or multiple lysine residues. Ubiquitin 
itself, containing seven lysine residues, can be ubiquitinated at each one of these 
lysine residues, as well as at the N-terminal methionine [51, 52]. Proteins can be 
monoubiquitinated, where a single ubiquitin is conjugated to a lysine residue in 
the substrate; multi-monoubiquitinated, where a single ubiquitin is conjugated to 
multiple lysine residues in the substrate; or polyubiquitinated, where the ubiquitin 
conjugated to the substrate is ubiquitinated itself. Polyubiquitinated chains can be 
divided into homotypic chains and heterotypic chains, and like for linear chains, 
different chain topologies lead to different structures and functions in the cell 
[53–58]. To add to this complexity, ubiquitin chains themselves can also be modified 
by ubiquitin-like modifiers (Figure 2).
3.1 Homotypic chains
Homotypic chains are composed of several ubiquitins linked together through 
the same lysine or N-terminal methionine residues. This leads to a total of eight 
possible chain types. Each chain adopts a different conformation: K6, K11, and K48 
adopt “compact” conformations, while K27, K29, K33, K63, and M1 adopt “open” 
conformations, allowing recognition of these chains by different ubiquitin-binding 
partners implicated in several signaling pathways [53–59]. A short description of 
the functions of homotypic chains is given below.
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Studying K6 chains is challenging since this chain is among the less abundant 
ubiquitin chains [60, 61]. Although its function is still not very clear, K6 has been 
implicated in mitophagy regulation [62–64] and DNA damage response [65]. More 
recently Michel et al. showed that HECT E3 ligase HUWE1, previously implicated 
in cellular processes like DNA repair, stress response, cell death, differentiation, 
and mitophagy [66, 67], assembles K6 chains [68]. Mitophagy is the process by 
which cells maintain the energy metabolism by removing damaged mitochondria. 
During this process, PINK1 accumulates on the surface of the mitochondrial outer 
membrane and recruits cytosolic PARKIN, an E3 ubiquitin ligase [69]. PARKIN 
then ubiquitinates mitochondrial proteins by generating canonical (K48 and K63) 
and noncanonical chains (K6 and K11) eventually leading to mitophagy [63]. USP30 
is the only known DUB anchored to the mitochondria outer membrane which has 
been seen to act as a regulator of mitophagy. Despite having been seen to cleave K6, 
K11, K48, and K53 chains, USP30 prefers K6 chains [62, 64]. Under normal condi-
tions, USP30 prevents mitophagy of normal mitochondria by maintaining ubiquiti-
nation at low levels. Under stress conditions and mitochondrial damage, PARKIN is 
recruited, highly increasing ubiquitination levels and inducing mitophagy. PARKIN 
and PINK1 are both mutated in patients with Parkinson’s disease [70, 71].
Although not many roles are known for K11 chains, it has been shown that 
these chains are key players in cell cycle regulation and proteasome degradation. 
The anaphase-promoting complex/cyclosome (APC/C) is an E3 ubiquitin ligase 
and essential for cell cycle regulation. Along with Ube2C, APC/C targets key 
players in the cell cycle, like securin and cyclin B1, for proteasomal degradation by 
assembling K11 chains, thus allowing the transition from metaphase to anaphase 
[72–75]. In 2013, Mevissen et al. showed the ovarian tumor (OTU) DUBs Cezanne’s 
and Cezanne2’s linkage specificity towards K11 chains [76]. In 2014, Bremm and 
co-workers described Cezanne as a new regulator of HIF1 α homeostasis [77], where 
HIF1 α is ubiquitinated with K11 chains. The knockdown of Cezanne increases the 
amount of K11 polyubiquitin chains and decreases the activity of HIF1 α . HIF1 α 
degradation was not disrupted by inhibition of the proteasome suggesting an alter-
native degradation pathway—possible through chaperone-mediated autophagy—to 
HIF1 α [77]. Cezanne can bind and disassemble K11 chains on APC/C substrates 
Figure 2. 
Complex ubiquitin chains. Homotypic ubiquitin chains can be extended by a different type of chain leading 
to a mixed ubiquitin chain. If the ubiquitin chain is modified not at the last ubiquitin moiety, a branched 
ubiquitin chain is created. For mixed ubiquitin/Ubl chains, two attachment points are possible: either as a cap 
structure, modifying the last ubiquitin, or as a branching point on one of the ubiquitins in the middle.
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(e.g., folding stress) both SUMO-2 and SUMO-3 get conjugated to target proteins 
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(UbcH8), and an E3 ligase (Herc5 or TRIM25/EFP) [35]. ISGylation is reversed by 
Ub-specific protease USP18 [36].
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regulated by ISGylation. These include the regulation of DNA damage response, 
autophagy, protein synthesis, the downregulation of the ubiquitin-proteasome 
system, and the regulation of HIFɑ in response to hypoxia [37–42].
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ISGylation occurs after viral infection [43]. Virus infection induces host antiviral 
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Ubiquitination occurs in proteins at one or multiple lysine residues. Ubiquitin 
itself, containing seven lysine residues, can be ubiquitinated at each one of these 
lysine residues, as well as at the N-terminal methionine [51, 52]. Proteins can be 
monoubiquitinated, where a single ubiquitin is conjugated to a lysine residue in 
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conjugated to the substrate is ubiquitinated itself. Polyubiquitinated chains can be 
divided into homotypic chains and heterotypic chains, and like for linear chains, 
different chain topologies lead to different structures and functions in the cell 
[53–58]. To add to this complexity, ubiquitin chains themselves can also be modified 
by ubiquitin-like modifiers (Figure 2).
3.1 Homotypic chains
Homotypic chains are composed of several ubiquitins linked together through 
the same lysine or N-terminal methionine residues. This leads to a total of eight 
possible chain types. Each chain adopts a different conformation: K6, K11, and K48 
adopt “compact” conformations, while K27, K29, K33, K63, and M1 adopt “open” 
conformations, allowing recognition of these chains by different ubiquitin-binding 
partners implicated in several signaling pathways [53–59]. A short description of 
the functions of homotypic chains is given below.
5
Branching and Mixing: New Signals of the Ubiquitin Signaling System
DOI: http://dx.doi.org/10.5772/intechopen.91795
Studying K6 chains is challenging since this chain is among the less abundant 
ubiquitin chains [60, 61]. Although its function is still not very clear, K6 has been 
implicated in mitophagy regulation [62–64] and DNA damage response [65]. More 
recently Michel et al. showed that HECT E3 ligase HUWE1, previously implicated 
in cellular processes like DNA repair, stress response, cell death, differentiation, 
and mitophagy [66, 67], assembles K6 chains [68]. Mitophagy is the process by 
which cells maintain the energy metabolism by removing damaged mitochondria. 
During this process, PINK1 accumulates on the surface of the mitochondrial outer 
membrane and recruits cytosolic PARKIN, an E3 ubiquitin ligase [69]. PARKIN 
then ubiquitinates mitochondrial proteins by generating canonical (K48 and K63) 
and noncanonical chains (K6 and K11) eventually leading to mitophagy [63]. USP30 
is the only known DUB anchored to the mitochondria outer membrane which has 
been seen to act as a regulator of mitophagy. Despite having been seen to cleave K6, 
K11, K48, and K53 chains, USP30 prefers K6 chains [62, 64]. Under normal condi-
tions, USP30 prevents mitophagy of normal mitochondria by maintaining ubiquiti-
nation at low levels. Under stress conditions and mitochondrial damage, PARKIN is 
recruited, highly increasing ubiquitination levels and inducing mitophagy. PARKIN 
and PINK1 are both mutated in patients with Parkinson’s disease [70, 71].
Although not many roles are known for K11 chains, it has been shown that 
these chains are key players in cell cycle regulation and proteasome degradation. 
The anaphase-promoting complex/cyclosome (APC/C) is an E3 ubiquitin ligase 
and essential for cell cycle regulation. Along with Ube2C, APC/C targets key 
players in the cell cycle, like securin and cyclin B1, for proteasomal degradation by 
assembling K11 chains, thus allowing the transition from metaphase to anaphase 
[72–75]. In 2013, Mevissen et al. showed the ovarian tumor (OTU) DUBs Cezanne’s 
and Cezanne2’s linkage specificity towards K11 chains [76]. In 2014, Bremm and 
co-workers described Cezanne as a new regulator of HIF1 α homeostasis [77], where 
HIF1 α is ubiquitinated with K11 chains. The knockdown of Cezanne increases the 
amount of K11 polyubiquitin chains and decreases the activity of HIF1 α . HIF1 α 
degradation was not disrupted by inhibition of the proteasome suggesting an alter-
native degradation pathway—possible through chaperone-mediated autophagy—to 
HIF1 α [77]. Cezanne can bind and disassemble K11 chains on APC/C substrates 
Figure 2. 
Complex ubiquitin chains. Homotypic ubiquitin chains can be extended by a different type of chain leading 
to a mixed ubiquitin chain. If the ubiquitin chain is modified not at the last ubiquitin moiety, a branched 
ubiquitin chain is created. For mixed ubiquitin/Ubl chains, two attachment points are possible: either as a cap 
structure, modifying the last ubiquitin, or as a branching point on one of the ubiquitins in the middle.
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stabilizing them leading to cell proliferation [78]. Finally, K11 chains were shown 
to replace K48 chains in the transcription factor Met4 activating it [79], so far only 
seen to be ubiquitinated with K48 chains leading to transcription repression [80]. 
Although the exact composition of the newly synthesized K11 chains is still not 
known, the authors suggest that these chains can either be homotypic K11 chains or 
heterotypic K11/K48 chains [79].
K27 chains are still the least studied of all ubiquitin chains. E3 protein ligase 
HACE1 has been shown to assemble K27 chains onto both optineurin and YB-1 
[81, 82], indicating a role in secretion through the multivesicular body (MVB) 
pathway. The ubiquitin ligase RNF168 assembles K27 ubiquitin chains on chromatin 
linking them to the DNA damage response pathway [83]. During pathogen infec-
tion, K27 chain assembly triggers immune response through the recruitment of 
TBK1 [84, 85]. The NEDD4 family E3 ligases, Itch and WWP2, promote K27 polyu-
biquitination of SHP-1 enhancing the strength of the T-cell receptor (TCR) signal 
and in turn negatively regulating in TH2 cell differentiation [86]. USP19, a deubiq-
uitinating enzyme, removes K27 chains from TRIF, thus inhibiting its recruitment 
by TLR3/TLR4 and consequently inhibiting TLR3−/TLR4-mediated innate immune 
response [87]. The E3 ligase Hectd3 assembles K27 chains on Malt1 and Stat3 
promoting differentiation of pathogenic TH17 cells in experimental autoimmune 
encephalomyelitis (EAE), a mouse model for human multiple sclerosis [88].
K29 has been implicated in the Wnt signaling pathway. The E3 ubiquitin ligase, 
EDD, promotes K29 ubiquitination of  β -catenin leading to higher protein levels and 
enhanced activity [89]. E3 ubiquitin ligase SMURF1 promotes K29 ubiquitination 
of axin, thus disrupting its association with LRP5/LRP6 and inhibiting the Wnt sig-
naling pathway [90]. The ubiquitin thioesterase ZRANB1, also known as TRABID, 
preferentially hydrolyzes K29 and K33 chains [4, 55, 57, 91]. Although TRABID/
ZRANB1 was proposed to bind and hydrolyze K63 chains from the APC tumor 
suppressor protein acting as a positive regulator of the Wnt signaling pathway [92], 
no evidence has been shown, linking TRABID and K29 chains in the Wnt signaling 
pathway. More recently, TRABID has been implicated in epigenetic regulation, 
where it regulates Il12 and Il23 genes by TLR. TRABID associates with and stabilizes 
Jmjd2d by hydrolyzing K29 chains regulating histone modifications and expression 
of Il12a, Il12b, and Il23a genes [93].
K33 chains have seen to be implicated in autoimmunity. RING-type E3 ligase 
Cbl-b and HECT-type E3 ligase Itch assemble K33 chains to the TCR- ζ and nega-
tively regulate its phosphorylation and consequently TCR signaling [94]. Later 
in 2014, Lin et al. reported the inhibition of the type I IFN signaling due to the 
interaction of the DUB USP38 and TBK1, after viral infection. USP38 hydrolyzes 
K33 chains from TBK1 promoting K48 polyubiquitination by DTX4/TRIP for its 
degradation through NLRP4 [95]. During infection with uropathogenic E.coli, 
compartmentalized TLR4 signaling is triggered, and TRAF3 is K33 polyubiquiti-
nated leading to the expulsion of intracellular bacteria by the exocyst complex [96]. 
After TGF- β stimulation, USP2a removes K33 polyubiquitin chains from the TGFBR 
promoting the recruitment of R-SMADs and consequently promoting metasta-
sis [97]. A role of K33 chains in trafficking was also suggested. KLHL20, a BTB 
domain-containing adapter protein, recruits Cul-3 assembling K33 chains to Cm7. 
The ubiquitination of Cm7 promotes its recruitment to the trans-Golgi network 
(TGN) [98].
More recently, K33 chains have been implicated in autophagy. E3 ligase RNF166 
binds and assembles K33 chains to the autophagy adaptor p62. This mechanism 
seems to be essential in targeting bacteria to autophagy [99]. SMURF1 induces K29- 
and K33-linked polyubiquitin of UVRAG, triggering a mechanism that promotes 
autophagosome maturation and inhibits HCC growth. TRABID/ZRANB1 forms a 
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complex with UVRAG and cleaves SMURF1-induced K29- and K33-linked polyu-
biquitin chains from UVRAG inhibiting autophagosome flux and leading to poor 
prognosis [100].
M1 chains and their importance in signaling pathways and disease have been 
extensively reviewed [101, 102]. M1 chains are generated by the linear ubiquitin 
chain assembly complex (LUBAC), composed by HOIP, HOIL-1, and SHARPIN 
[103–105]. M1 chains play a crucial role in TNF signaling and immune response 
[104–109]. Formation of complex 1 starts when TNF binds TNFR1, resulting in 
the recruitment of TRADD and RIPK1. After binding to TNFR1, TRADD recruits 
TRAF2 which then recruits cIAP1 or cIAP2, two E3 protein ligases which assemble 
K11, K48, and K63 chains to several components of the complex. LUBAC is then 
recruited by the complex and assembles M1 chains to several components of the 
complex including NEMO, an essential modulator of NF- κ B, RIPK1, TRADD, and 
TNFR1. This process then recruits the TAK1-TAB protein complex and the IKK 
complex (IKK α , IKK β, and NEMO). While the TAK1-TAB complex activates MAPK 
cascades triggering JNK and p38 MAPK leading to the activation of the transcrip-
tion factor AP-1, the IKK complex activates NF- κ B signaling. In the absence of 
LUBAC, complex 2 instead of complex 1 is formed leading to cell death either by 
apoptosis or programmed necrosis.
K48 is the most abundant and well-studied ubiquitin chains and a major signal 
for proteasome degradation [60, 61, 110]. It was initially proposed that signal-
ing through a polyubiquitin chain was mandatory for proteasome degradation 
[111–113]. However, several publications seem to show that monoubiquitination can 
also target proteins for proteasome degradation [114–116].
K63 is the second most abundant ubiquitin chain in cells [60, 61] and it is 
implicated in immune response, DNA repair, endocytosis, and protein trafficking 
(reviewed in [117–119]). K63 chains seem to be essential for the activation of the 
IKK signaling pathway through TRAF6 [120]. TRAF6 also induces K63 ubiquitina-
tion of Akt which is then phosphorylated, activated, and recruited to the membrane 
[121]. RIG-I is regulated by K63 chains where TRIM25 assembles K63 chains to 
RIG-I [122]. K63 ubiquitination of IRAK1 is required for the activation of NF-κB 
signaling [123]. INF- β signaling pathway is activated when STING is ubiquitinated 
with K63 chains assembled by TRIM56 [124]. K63 ubiquitination and protein 
trafficking and DNA damage have been extensively reviewed [119, 125]. Two of the 
most well-studied examples on protein trafficking are the MHC I and EGFR. MHC 
class I molecules are polyubiquitinated with K63 chains leading to degradation 
by an endolysosomal pathway [126]. EGFR is also ubiquitinated and promotes its 
internalization [127, 128]. More recently, it has been shown that K63 chains bind to 
DNA, enhancing the recruitment of repair factors [129].
3.2 Heterotypic chains
Heterotypic chains are composed of several ubiquitin molecules linked together 
through different lysines or N-terminal methionine residues and can be classified as 
mixed chains or branched chains. In mixed chains, each ubiquitin is modified only 
once by another ubiquitin molecule, while in branched chains each ubiquitin can 
be modified by two or more ubiquitin molecules. Chains sharing the same linkage 
types can still have different architectures and thus different structures, resulting 
in a huge number of possible conjugate combinations affecting different signaling 
pathways (reviewed in [130–132]). Due to their architecture, the study of hetero-
typic chains represents a challenge, and their functions in cells are still not clear 
(Figure 2).
K11/K48, K48/K63, and M1/K63 are three of the most studied branched chains.
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types can still have different architectures and thus different structures, resulting 
in a huge number of possible conjugate combinations affecting different signaling 
pathways (reviewed in [130–132]). Due to their architecture, the study of hetero-
typic chains represents a challenge, and their functions in cells are still not clear 
(Figure 2).
K11/K48, K48/K63, and M1/K63 are three of the most studied branched chains.
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K11 and K48 both target proteins for degradation. Branched K11/K48 ubiq-
uitin chains seem to increase this signal leading to a more efficient recognition 
of substrates by the proteasome. The APC/C complex assembles K11 chains to 
substrates, targeting them for protein degradation. During mitosis, the APC/C 
complex conjugates K11/K48 branched chains to the kinase Nek2A leading to a 
more efficient recognition by the proteasome for degradation [133]. The binding 
efficiency of homotypic K11 chains to the proteasome is much lower than that of 
homotypic K48 chains and heterotypic K48/K11 chains, and that both K48 chains 
and K11/K48 chains efficiently target cyclin B1 for proteasome degradation [134]. 
The development of a bispecific antibody to K11/K48 chains allowed the detection 
of APC/C complex assembling K11/K48 chains during mitosis. Under proteotoxic 
stress, leading to the accumulation of newly synthesized and misfolded proteins, 
these linkages seem to accumulate. These chains seem to have a quality control 
role where they prevent protein aggregation by proteasomal degradation. Among 
the effectors of these chains are endogenous p97, BAG6, UBQLN2, p62, UBR5, 
and HUWE1 [135]. More recently, the structure of branched K11/K48-linked 
tri-ubiquitin was solved, showing the presence of a novel binding surface exclusive 
to branched K11/K48-linked polyUb as a result of a unique interface between the 
branched K11 and K48. This interface binds to Rpn1, one of the proteasomal units 
able to recognize polyUb, and increases binding efficiency [136].
Opposed to K48, K63 chains are non-proteolytic chains playing important 
roles in different signaling pathways. The combination of K48 and K63 chains in 
branched chains seems to play an important role in NF- κ B signaling [137]. Induced 
by IL-1 β signaling, HUWE1 cooperates with K63 ubiquitinated TRAF6 to assemble 
K48 chains to the previously assembled K63 chains. The addition of the K48 chains 
does not interfere with the recognition by TAB2 but protects K63 chains from 
deubiquitination by CYLD, enhancing the NF- κ B signaling [137]. Interestingly, 
K63 branched chains seem to target proteins for proteasome degradation. The 
ubiquitin ligase ITCH is involved in apoptosis regulation through the ubiquitination 
of TXNIP [138]. ITCH assembles K63 chains to TXNIP that act as a recruitment 
signal for UBR5 which then assembles K48 branched chains. Because ITCH is a 
tumor-promoting and anti-apoptotic factor and TXNIP is a tumor suppressor and 
pro-apoptotic factor, it is possible that during apoptosis, ITCH accelerates TXNIP 
degradation counteracting its effects [139].
K63/M1 chains, just as M1 and K63 homotypic chains, seem to play a signifi-
cant role in the innate immune response. Upon activation of MyD88, TNFR1/
TRADD, TLR3/TRIF, and NOD1/RIP2 signaling pathways, the formation of K63/
M1 branched chains are induced leading to activation of the IKKs [108, 140]. The 
inflammation-associated protein A20 has both an OTU-type deubiquitinase domain 
and a ZnF4 motif that binds ubiquitin [141]. After phosphorylation, A20 promotes 
disassembly of K63 chains during TNFR1 signaling leading to cell death. However, 
the second step of linear ubiquitination forming branched chains protects TNFR1-
associated proteins from K63 disassembling, maintaining the signaling and leading 
to inflammation [142].
Several other heterotypic chains were found to date. Table 2 gives an overview 
of those chains and their biological significance.
3.3 Ubl/ubiquitin chains
Ubiquitin chains can also be modified by ubiquitin-like modifiers (Figure 2) 
[149–153], and although not much is known about these chains, they increase even 
more the complexity of the ubiquitin code. Ubiquitin chains have been found to be 
modified by SUMO at K6, K11, K27, K48, and K63. Despite the unclear biological 
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role of these modifications, under proteasome inhibition or heat shock conditions, 
K6 and K27 chains seem to accumulate [151]. ISG15 can form mixed chains with 
ubiquitin at K29. These chains have a non-proteolytic function and seem to regulate 
the turnover of ubiquitylated proteins [152]. NEDD8 was found to form branched 
chains with K48 in human cells acting as a chain terminator [153].
4. Detection methods of ubiquitinated target and chains
4.1 Biochemical and genetic methods
Over the years, different biochemical and genetic methods were developed to 
detect ubiquitin, ubiquitin-like modifiers, and ubiquitin chains. Although antibod-
ies were available from early on, problems with specificity led to the use of differ-
ent N-terminally epitope-tagged forms of ubiquitin. Here, antibodies against the 
epitope tag were used for detection. These constructs were elegantly combined with 
molecular biological methods, which replaced single lysine residues in ubiquitin 
with arginine, preventing the formation of ubiquitin chains on these positions. A 
loss of the chain signal was interpreted as the specific modification by ubiquitin 
chain with a specific topology. (For a more comprehensive overview see [154]).
For the enrichment of ubiquitin chains of a specific type, biochemical methods 
and specific antibodies have been developed. While the antibodies were used with 
varying success due to specificity problems, the use of tandem-repeated ubiquitin-
binding entities (TUBE) constructs has gained importance. Here ubiquitin-binding 
domains with specificity for certain chain topologies are multimerized and used as a 
pull-down construct [155].
Ubiquitin chain restriction (UbiCRest) is another alternative to identify polyu-
biquitin chains [76, 156]. In this approach, ovarian tumor family deubiquitinases 
are incubated with substrates and used as restriction enzymes to detect linkage sites 
and determine the relative abundance of Ub chains on substrates [76, 156].
4.2 Mass spectrometry-based methods
Mass spectrometry-based proteomics has been used to detect ubiquitination 
sites for almost 20 years. In 2001, Peng et al. reported that ubiquitinated peptides 
have a 114 Da mass shift due to the diglycine left behind on a lysine sidechain of 
ubiquitin from another ubiquitin, after trypsin digestion [157]. In 2003 the same 
authors, applying their rationale, identified more than 70 ubiquitin-conjugated 
Chain Function Reference
K11/K48 Proteasomal degradation [133–136]
K48/K63 NF- κ B signaling
apoptosis
[137, 139]
K63/M1 Innate immune response [108, 140, 142]
K6/K48 ? [143]
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proteins and 7 ubiquitination sites (K6, K11, K27, K29, K33, K48, and K63) in 
ubiquitin itself, being 4 of these sites reported for the first time in vivo [158]. In 
2009, Tokunaga et al. reported the identification of linear polyubiquitin in NEMO 
by mass spectrometry, showing that the NF-κB activation pathway is regulated by 
LUBAC through the polyubiquitination of NEMO [106]. Due to the low abundance 
of modified peptides in samples, several enrichment strategies were developed 
to enrich ubiquitinated peptides and improve ubiquitination identification. The 
development of an antibody against diglycine linked to the ε-amino group of lysine 
opened the door to the large-scale identification of ubiquitinated substrate proteins 
[159]. Although the approach was used very successfully by several laboratories 
leading to the identification of close to 20,000 ubiquitination sites [160–162] it has 
some drawbacks. One is that the diglycine remnant left by ubiquitin is not unique, 
and both NEDD8 and ISG15 leave an identical remnant after trypsin digestion. 
Additionally, the antibody does not recognize linear ubiquitination. Recently, 
Akimov et al. developed a new antibody specific to a remnant four-mer peptide of 
the ubiquitin C-terminus after LysC digestion, identifying 60,000 ubiquitination 
sites [163]. Other relative quantification methods like stable isotope labeling by/
with amino acids in cell culture (SILAC), tandem mass tags (TMT), and label-free 
quantification have been successfully applied [160, 164–166]; however, these meth-
ods are using data-dependent measurements, and although they are most suited 
for PTMs discovery, they cannot provide information on absolute quantities and/or 
stoichiometry information.
4.3 Ubiquitin topology analysis
While discovery proteomics based on data-dependent methods (DDA) allows 
the identification of new proteins and can detect the presence of posttranslational 
modifications, the reliable identification and quantification of peptides in several 
samples is hampered by the way how peptides are selected by the mass spectrom-
eter for sequencing. Here, the most intense ion at a very moment is selected, which 
can lead to the selection of different peptides in consecutive mass spectrometric 
analysis runs. Contrary to discovery proteomics methods, targeted proteomics tries 
to identify a given set of peptides in every sample, making this method particularly 
suited for the analysis of ubiquitin topology experiments [167–169].
The most common techniques for targeted proteomics are selected reaction 
monitoring (SRM) and parallel reaction monitoring (PRM). Both methods have 
specific requirements for the mass spectrometer used for the analysis. SRM is 
bound to a triple-quadrupole mass spectrometer, while PRM measurements require 
an Orbitrap mass spectrometer. For both methods, a list of peptides is preselected, 
and the corresponding masses are selected continuously. The selected masses are 
fragmented in a collision cell, and the fragment masses are monitored. In the case 
of the ubiquitin topology analysis, the key peptides for the ubiquitin chains are 
targeted [168]. By comparing this signal with its isotope-labeled version spiked 
into the mix at a known concentration, it is possible to determine the concentration 
of the peptide [170]. For the analysis of ubiquitin chain topology, the analysis is 
focused on unique peptides for each of the ubiquitin chain topologies. By digesting 
a ubiquitin chain with trypsin under denaturing conditions, ubiquitin peptides 
are generated. Ubiquitin carries an arginine residue at position 74. Trypsin cleaves 
after this residue and leaves the double glycine residue on the lysine side chain. 
This creates a branched peptide with an additional mass of 114 Da at the point 
of modification. For the targeted analysis are seven branched peptides—for each 
lysine in ubiquitin one—selected and monitored either by SRM or PRM (reviewed 
in [154, 171]).
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4.4 Detection of branched chains
The detection of heterotypic chains represents a challenge. Specific antibodies can 
only recognize ubiquitin or one chain at a time [172–174]. Mass spectrometry-based 
proteomics methodologies are based on the digestion of proteins with a protease, gen-
erally trypsin, which cuts after lysines or arginines [175]. Branched chains harbor two 
or more lysines that are ubiquitinated. Detection of double-ubiquitinated ubiquitin is 
difficult due to two reasons: first, if branch points are separated by several lysines in 
ubiquitin, the two branch points are separated into two separate peptides, leading to 
a loss of the information of the double modification. Second, if the two branch points 
are on adjacent lysines, the resulting peptide is too long to be measured on a mass 
spectrometer. An alternative is the coupling of antibody-based enrichment with mass 
spectrometric analysis [80, 155, 159]. Limited proteolysis associated with middle-
down proteomics has been used to characterize polyubiquitin chain structures 
[143, 145]. Top-down proteomics associated with ultraviolet photodissociation was 
also applied to determine polyubiquitin chain topology [176]. In 2014, Meyer et al. 
inserted a TEV cleavage site in ubiquitin which after cleavage allowed for the discrim-
ination between branched and unbranched chains [133]. The authors showed that 
APC/C synthesizes branched chains that enhance proteasome degradation. Later in 
2016, Ohtake et al. used a mutagenesis approach to detect K48/K63 branched chains 
[137]. The authors replaced ubiquitin’s arginine 54 by alanine allowing detection of 
these chains by mass spectrometry and showed how K48 branched chains protect the 
deubiquitination of K63. In 2017, Yau et al. developed bispecific antibodies against 
K11/K48 chains, showing their enhanced signal for protein degradation [135]. More 
recently, Swatek et al. showed that the leader protease of foot and mouth disease virus 
cleaves di-ubiquitin between arginine 74 and the C-terminal diglycine, originating 
one truncated ubiquitin (residues 1–74) and a diglycine modified ubiquitin (residues 
1–74) [177]. The authors used the approach coupled to intact MS to identify and 
quantify ubiquitin chains with one, two, or three branches in whole-cell lysates.
5. Conclusion
Over the last decades, the ubiquitin signaling system has been further and 
further probed, and today it is clear that it is one of the most complex posttransla-
tional cellular signaling systems. It is involved in almost all cellular processes, and 
the possibilities in terms of signaling are staggering. Understanding the different 
signals, which are coded in the ubiquitin chains, is one of the biggest challenges of 
the ubiquitin field, and the identification of branched and mixed chains and the 
cross talk with the universe of ubiquitin-like modifiers poses even more challenges. 
The new tools which are becoming available in combination with new mass spec-
trometric analysis tools will open the horizon for even more layers of signaling and 
promise to unravel this hidden chapter of biology.
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Most of the proteins in eukaryotic cells are degraded by the proteasome in an 
ubiquitin-dependent manner. However, ubiquitin-independent protein degrada-
tion pathway by the 26S proteasome exists in the cells. Ornithine decarboxylase 
(ODC) is a well-known protein that is degraded by the 26S proteasome without 
ubiquitination. Degradation of ODC requires the protein, “antizyme (AZ),” that 
is induced by polyamine and binds to the ODC monomer to inhibit ODC activity 
and target it to the 26S proteasome for proteolytic degradation. Namely, AZ con-
tributes the feedback regulation of intracellular polyamine level. ODC has been 
considered to be the only protein that AZ binds and accelerates its degradation. 
However, recently AZ-mediated proteasomal protein degradation will gradually 
increase. Most recently, we found that one of the antizyme families, AZ2, acceler-
ates c-Myc degradation by the proteasome without ubiquitination. In this chapter, 
we introduce latest several ubiquitin-independent proteasomal degradation 
mediated by antizyme.
Keywords: antizyme, ubiquitin-independent degradation, ornithine decarboxylase, 
26S proteasome, polyamines, c-Myc
1. Introduction
In eukaryotic cells, intracellular protein degradation is mainly regulated by 
the ubiquitin-proteasome system, where abnormal and unwanted proteins are 
targeted by polyubiquitin, which is produced from monoubiquitin by ubiquitin-
activating enzyme (E1) and ubiquitin-conjugating enzyme (E2) [1]. The proteins 
that conjugated polyubiquitin by ubiquitin ligase (E3) are finally targeted to the 
26S proteasome [2]. However, there is accumulating evidence that ubiquitin-
independent proteasomal protein degradation pathway exists in the cells [3, 4]. 
Although ubiquitin-dependent proteasomal protein degradation is carried out 
normally by 26S proteasome, there are many reports that ubiquitin-independent 
proteasomal protein degradations are executed by the only 20S proteasome with-
out the energy of ATP hydrolysis [4]. Among others, some ubiquitin-independent 
degradation pathways are known to be carried out using not the 20S but the 26S 
proteasome with the energy of ATP hydrolysis. In this chapter, we introduce 
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independent proteasomal protein degradation pathway exists in the cells [3, 4]. 
Although ubiquitin-dependent proteasomal protein degradation is carried out 
normally by 26S proteasome, there are many reports that ubiquitin-independent 
proteasomal protein degradations are executed by the only 20S proteasome with-
out the energy of ATP hydrolysis [4]. Among others, some ubiquitin-independent 
degradation pathways are known to be carried out using not the 20S but the 26S 
proteasome with the energy of ATP hydrolysis. In this chapter, we introduce 
ubiquitin-independent proteasomal degradation pathway mediated by polyamine 
regulating protein, “antizyme.”
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2. What is antizyme?
Polyamines are highly charged bioactive substances presented ubiquitously in 
species from bacteria to human. Polyamines are necessary for cell growth and are 
involved in highly diversified cellular functions such as cell division, apoptosis, 
autophagy, oxidative stress, and ion channel activity. There are three major poly-
amines, putrescine, spermidine, and spermine, in the cells [5, 6]. Intracellular poly-
amine concentration is highly regulated by the protein “antizyme” [7–10] that is 
widely distributed from yeast to human [11]. Antizyme (AZ) is induced in response 
to the increased concentration of intracellular polyamines through the polyamine-
induced translational frameshifting mechanism [12]. AZ mRNA consists of two 
ORFs (ORF1 and ORF2). In the low polyamine concentration, translation of 
ORF1 is terminated at stop codon “UGA” of ORF1, and short product is produced 
(Figure 1). But in the increasing cellular polyamine concentration, reading frame 
Figure 1. 
Negative feedback regulation of cellular polyamine by antizyme. Three cis-acting elements, UGA stop codon, 
upstream stimulator, and pseudoknot structure, are known to be important for +1 frameshifting (bottom 
column). Putrescine, spermidine, and spermine are major polyamines in the mammalian cell. Putrescine 
synthesized from ornithine by ODC could be metabolized to spermidine and spermine in the cells. PAT is a 
polyamine transporter that uptakes polyamines from outside of the cells.
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shifts +1 direction at the end of ORF1 (Figure 1 bottom column). In this case, 
following ORF1, ORF2 is translated and full length active product “antizyme” is 
produced [12, 13]. The induced AZ protein binds to ornithine decarboxylase (ODC) 
monomer, a key enzyme in polyamine biosynthesis, and catalyzes the conversion 
from ornithine to putrescine and inhibits its activity. AZ-bound ODC is targeted 
to the 26S proteasome for degradation without ubiquitination (Figure 1) [14]. AZ 
also suppresses polyamine uptake by inhibiting membrane polyamine transporter 
(Figure 1) [15, 16]. Thus, AZ provides the negative feedback regulation of cellular 
polyamines. In addition, AZ is regulated by the protein, antizyme inhibitor (AZIN), 
that is homologous to ODC and can bind to AZ with higher affinity than ODC but 
lacking the enzymatic activity [17, 18].
In mammals, cells express three members of AZ protein family, AZ1–3 (Table 1) 
[19]. AZ1 and AZ2 are distributed ubiquitously in most of the tissues, whereas 
AZ3 is testis specific [20–22]. Both AZ1 and AZ2 bind to ODC and accelerate its 
Table 1. 
Characteristics of antizyme family.
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degradation in the cells [9, 23], but AZ3 has no activity for acceleration of ODC 
degradation [24]. The rate of ODC degradation by AZ1 is faster than that by AZ2 
[23, 25]. Polyamine (putrescine) concentration of AZ1 knockdown cells is markedly 
increased, compared to that of AZ2 knockdown and control cells [26]. Therefore, 
it is thought that AZ1 mainly regulates cellular polyamine concentration. On the 
other hand, although AZ2 is highly homologous to AZ1 [25], it is considered that 
AZ2 is not a backup of AZ1 because of some differences between each other. AZ2 
was found as one of the genes upregulated in neuronal cells by the drug that induces 
seizure [27]. Nucleic acid sequence of AZ2 is evolutionally conserved higher than 
that of AZ1 [11]. AZ2 is localized mainly in the nucleus [26] and is phosphorylated 
in the cells [28]. We will mention about AZ2 specific function with its interacting 
protein that we found very recently in this chapter.
3.  Antizyme-interacting proteins and ubiquitin-independent 
proteasomal degradation
3.1 Antizyme 1-interacting proteins
It had been considered that ODC is the only protein degraded through 
AZ-mediated ubiquitin-independent proteasomal degradation system. However, 
recently several AZ1-interacting proteins other than ODC have been reported 
(Table 2). Although it has already been reported that those proteins are degraded 
by the ubiquitin-proteasome pathway, AZ1 could also accelerate those degradation 
without ubiquitination (Tables 1 and 2, Figure 1). Smad1, which is involved in 
bone morphogenetic protein (BMP) signaling pathway [29, 30], is the first reported 
protein that interacts AZ1 other than ODC [31]. In this case, newly synthesized 
HsN3, which is β-subunit for 20S proteasome, forms ternary complex with AZ1 and 
smad1. This complex may bind to 20S proteasome, and next 19S complex is docked 
on 20S, and then smad1 is degraded by the 26S proteasome.
Newman et al. reported that AZ1 has the ability to accelerate the degradation of 
cyclin D1, one of the cell cycle regulatory protein families [32]. Cyclin D1 interacts 
with cyclin-dependent kinase (CDK), and accumulation of cyclin D1-CDK complex 
is important for cell cycle progression [33]. This protein is already known to be 
degraded by ubiquitin-proteasome pathway [34]. They demonstrated that AZ1 
induction by polyamine or overexpression of AZ1 accelerates cyclin D1 degradation, 
and knockdown of AZ1 suppresses it. Furthermore, in vitro experiment using puri-
fied cyclin D1, AZ1, and rabbit reticulocyte extracts as a source of 26S proteasome, 
AZ1 accelerated cyclin D1 degradation in a ATP-dependent manner. AZ1 could 
also degrade ubiquitin-deficient mutant of cyclin D1 in the cells [32]. In vitro size 
distribution analysis for binding between AZ1, cyclin D1, and ODC suggested that 
binding sites of AZ1 for cyclin D1 and ODC do not overlap each other, and cyclin 
D1 binds to the N-terminus of AZ1 and ODC binds at the C-terminus, respectively. 
Binding affinity of AZ1 to cyclin D1 is fourfold lower than that to ODC [35]. 
Although physiological significance is not clear, it showed that those three proteins 
form cyclin D1-AZ1-ODC ternary complex.
The oncogene Aurora A encodes a protein kinase that exerts essential roles in 
mitotic events and is important for induction of centrosome amplification [36]. 
Overexpression of Aurora A in many cancers induces aneuploidy, centrosome 
anomaly, poor prognosis, and invasiveness [37, 38]. Aurora A is ubiquitinated by 
the E3 ubiquitin (Ub) ligase, anaphase-promoting complex/cyclosome (APC/C) 
that is activated by both cell-division cycle protein 20 (Cdc20) and Cdh1, 
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substrate-recognition subunit of APC/C, and is degraded by the proteasome 
[39, 40]. However, Lim and Gopalan demonstrated that AZ1 could accelerate 
Aurora A degradation with ubiquitin-independent manner, where Aurora A kinase-
interacting protein 1 (AURKAIP1), a negative regulator of Aurora A, enhances 
the binding of AZ1 to Aurora A and facilitates the recognition of Aurora A by the 
proteasome [41].
Table 2. 
The proteins degraded by antizyme-mediated ubiquitin-independent proteasomal pathway.
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Mps1 is protein kinase required for centrosome duplication in regulating the 
spindle assembly checkpoint [42, 43]. Accumulation of Mps1 at the centrosome 
causes aberrant centriole assembly [44, 45]. In fact in various tumor cells, centro-
somal Mps1 pool is increased, which causes abnormal centrosome duplication [44]. 
Thus degradation of Mps1 is important for proper pool of Mps1 at the centrosome. 
Although degradation of Mps1 is known to be mediated by the proteasome, amino 
acid residue 420–507 of the human Mps1 that is sufficient for its degradation does 
not contain APC/C recognition motifs, suggesting the commitment of Mps1 to 
ubiquitin-independent proteasomal degradation [45]. Kasbek et al. reported that 
AZ1 localizes to the centrosomes and binds to Mps1 to control the levels of centro-
somal Mps1 by accelerating the degradation of Mps1 [46]. Fluorescent microscopy 
analysis showed that centrosomal Mps1 level is dependent on AZ1 expression, 
overexpression of AZ1 decreases the centrosome Mps1 level, and conversely, AZ1 
knockdown by siRNA increases that. Furthermore, deletion of degradation signal 
of Mps1 abolished the regulation of centrosomal Mps1 level by AZ1. In addition, 
overexpressing AZIN in the cells to trap AZ1 and inhibit its function increased 
centrosomal Mps1 level. Thus the balance of AZ1 and Mps1 level in the centrosome 
is important for the centrosome duplication process.
P73 is a homolog of p53 and exists as two major forms, TAp73 or Delta-N (DN) 
p73. TAp73 is full-length form and exerts proapoptotic function, whereas DNp73, 
which is amino-terminal transactivation domain lacking the form of p73, exhibits 
dominant-negative inhibitor activity for both p73 and p53, resulting in antiapop-
totic properties [47]. Therefore, in the stress condition like DNA damage, reduction 
of DNp73 level is needed to execute apoptosis [48–50]. It is known that degradation 
of both TAp73 and DNp73 is mediated by E3-ubiquitin ligase Itch in a proteasome-
dependent manner in normal condition [51]. However, in Itch-decreased condition 
such as DNA damage by UV irradiation, stabilization of TAp73 was observed, but 
DNp73 was not [51]. Therefore, it was considered that the degradation of TAp73 
and DNp73 is regulated by different mechanisms. Dulloo et al. reported that 
reduction of DNp73 in the stress condition is due to the degradation of DNp73 by 
AZ1-mediated ubiquitin-independent proteasomal pathway [52]. They showed that 
degradation of DNp73 could be induced by genotoxic stresses such as UV irradia-
tion and doxorubicin treatment. Inhibition of ubiquitin-activating enzyme E1 by 
the inhibitor PYR41 could not block DNp73 degradation, indicating that it relies 
on ubiquitin-independent pathway. They demonstrated that polyamine induced 
AZ1 to bind to DNp73 for accelerating its degradation. Interestingly, AZ1-mediated 
DNp73 degradation is dependent on transcription factor c-Jun that is activated by 
stress signals. Overexpression and knocking down of AZ1 also showed that even 
in the presence of c-Jun, AZ1 is necessary for genotoxic stress to induce DNp73 
degradation. Although it is not clear how c-Jun operates AZ1 expression, c-Jun may 
act upstream of polyamine biosynthesis pathway.
Thus, several proteins degraded by AZ1-mediated proteasome pathway are 
found, but AZ2-interacting protein or AZ2-mediated proteasomal degradation 
other than ODC has not been reported. We recently found two AZ2-interacting 
proteins, and one of the two was the protein that accelerated its proteasomal degra-
dation by AZ2 without ubiquitination (see next section).
3.2 Antizyme 2-interacting proteins
As mentioned above, AZ2 also binds to ODC and accelerates its degradation in 
the cells [9]. However, we have considered that AZ2 has specific function other than 
AZ1 because of the differences such as nuclear localization [26, 28], highly gene 
conservation between species [20], and high expression in neuronal cells [53].  
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We performed comprehensive analysis of AZ2-interacting protein using two-hybrid 
technique. Two AZ2-interacting proteins were identified. One is ATP citrate lyase 
(ACLY), which is the enzyme catalyzing acetyl-CoA production in cytosol [54] 
and related to lipid anabolism and acetylation of cellular components [55]. We 
found that ACLY binds not only to AZ2 but also to AZ1 by immunoprecipitation 
assay [56]. Degradation assay for ACLY was performed in expectation of ubiquitin-
independent proteasomal degradation. However, AZs have no ability to accelerate 
ACLY degradation. Surprisingly, AZ1 and AZ2 activate catalytic activity of ACLY 
[56]. The other is proto-oncogene c-Myc that is a transcription factor with a basic 
region/helix–loop–helix/leucine zipper domain and forms heterodimer with Max 
for DNA binding [57, 58]. c-Myc functions as a master regulator of a variety of 
cellular processes such as cell growth, differentiation, survival, and apoptosis [58]. 
In cell growth, c-Myc targets ODC gene [59] and promotes synthesis of polyamine 
that is important for stabilization of nucleic acids, transcription, translation, and +1 
frameshifting on AZ mRNA [6].
It is known that degradation of c-Myc is mediated by ubiquitin-proteasome path-
way, where c-Myc is phosphorylated at Thr-58 (pT58) and Ser-62 (pS62) by extra-
cellular signal-regulated kinase, ERK, and glycogen synthase kinase 3β, GSK-3β, 
respectively [60, 61]. After dephosphorylation at Ser-62 by protein phosphatase 2A, 
PP2A, pT58-c-Myc is ubiquitinated by E3-ubiquitin ligase Fbxw7 for proteasomal 
degradation [60, 62]. At first, AZ2-interacting protein identified by the compre-
hensive analysis mentioned above was not c-Myc but a protein that has basic region/
helix–loop–helix/leucine zipper domain and interacts with c-Myc (Murai et al., 
manuscript in preparation). However, in the process of analyzing the interaction 
with AZ2, we found that AZ2 interacts with c-Myc in the cells by immunoprecipita-
tion assay. Subcellular localization analysis of both proteins using fluorescent protein 
tags or antibody conjugated fluorescent probe revealed that AZ2 co-localized with 
Figure 2. 
AZ2-mediated c-MYC degradation in the nucleolus. Two distinct c-Myc degradation pathways exist in the cells. 
It is thought that AZ2 pathway functions under the stress condition (polyamine increased condition) such as 
glucose-free and hypoxia.
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AZ1-mediated ubiquitin-independent proteasomal pathway [52]. They showed that 
degradation of DNp73 could be induced by genotoxic stresses such as UV irradia-
tion and doxorubicin treatment. Inhibition of ubiquitin-activating enzyme E1 by 
the inhibitor PYR41 could not block DNp73 degradation, indicating that it relies 
on ubiquitin-independent pathway. They demonstrated that polyamine induced 
AZ1 to bind to DNp73 for accelerating its degradation. Interestingly, AZ1-mediated 
DNp73 degradation is dependent on transcription factor c-Jun that is activated by 
stress signals. Overexpression and knocking down of AZ1 also showed that even 
in the presence of c-Jun, AZ1 is necessary for genotoxic stress to induce DNp73 
degradation. Although it is not clear how c-Jun operates AZ1 expression, c-Jun may 
act upstream of polyamine biosynthesis pathway.
Thus, several proteins degraded by AZ1-mediated proteasome pathway are 
found, but AZ2-interacting protein or AZ2-mediated proteasomal degradation 
other than ODC has not been reported. We recently found two AZ2-interacting 
proteins, and one of the two was the protein that accelerated its proteasomal degra-
dation by AZ2 without ubiquitination (see next section).
3.2 Antizyme 2-interacting proteins
As mentioned above, AZ2 also binds to ODC and accelerates its degradation in 
the cells [9]. However, we have considered that AZ2 has specific function other than 
AZ1 because of the differences such as nuclear localization [26, 28], highly gene 
conservation between species [20], and high expression in neuronal cells [53].  
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We performed comprehensive analysis of AZ2-interacting protein using two-hybrid 
technique. Two AZ2-interacting proteins were identified. One is ATP citrate lyase 
(ACLY), which is the enzyme catalyzing acetyl-CoA production in cytosol [54] 
and related to lipid anabolism and acetylation of cellular components [55]. We 
found that ACLY binds not only to AZ2 but also to AZ1 by immunoprecipitation 
assay [56]. Degradation assay for ACLY was performed in expectation of ubiquitin-
independent proteasomal degradation. However, AZs have no ability to accelerate 
ACLY degradation. Surprisingly, AZ1 and AZ2 activate catalytic activity of ACLY 
[56]. The other is proto-oncogene c-Myc that is a transcription factor with a basic 
region/helix–loop–helix/leucine zipper domain and forms heterodimer with Max 
for DNA binding [57, 58]. c-Myc functions as a master regulator of a variety of 
cellular processes such as cell growth, differentiation, survival, and apoptosis [58]. 
In cell growth, c-Myc targets ODC gene [59] and promotes synthesis of polyamine 
that is important for stabilization of nucleic acids, transcription, translation, and +1 
frameshifting on AZ mRNA [6].
It is known that degradation of c-Myc is mediated by ubiquitin-proteasome path-
way, where c-Myc is phosphorylated at Thr-58 (pT58) and Ser-62 (pS62) by extra-
cellular signal-regulated kinase, ERK, and glycogen synthase kinase 3β, GSK-3β, 
respectively [60, 61]. After dephosphorylation at Ser-62 by protein phosphatase 2A, 
PP2A, pT58-c-Myc is ubiquitinated by E3-ubiquitin ligase Fbxw7 for proteasomal 
degradation [60, 62]. At first, AZ2-interacting protein identified by the compre-
hensive analysis mentioned above was not c-Myc but a protein that has basic region/
helix–loop–helix/leucine zipper domain and interacts with c-Myc (Murai et al., 
manuscript in preparation). However, in the process of analyzing the interaction 
with AZ2, we found that AZ2 interacts with c-Myc in the cells by immunoprecipita-
tion assay. Subcellular localization analysis of both proteins using fluorescent protein 
tags or antibody conjugated fluorescent probe revealed that AZ2 co-localized with 
Figure 2. 
AZ2-mediated c-MYC degradation in the nucleolus. Two distinct c-Myc degradation pathways exist in the cells. 
It is thought that AZ2 pathway functions under the stress condition (polyamine increased condition) such as 
glucose-free and hypoxia.
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c-Myc in the nucleus. Treatment of proteasome inhibitor MG132 changes the nuclear 
co-localization of both proteins to nucleolar co-localization [26]. Overexpression of 
AZ2 or addition of polyamine in the cells accelerated c-Myc degradation, and knock-
down of AZ2 with siRNA suppressed it. Furthermore, E1 inhibitor PYR-41 could not 
suppress AZ2-mediated proteasomal c-Myc degradation [26]. These results suggest 
that AZ2-mediated ubiquitin-independent nucleolar c-Myc degradation pathway 
other than ubiquitin-dependent one exists in the cells (Figure 2).
4. Conclusions
In this chapter, antizyme-mediated ubiquitin-independent proteasomal deg-
radation has been discussed. All the proteins mentioned above are already known 
as the proteins degraded by ubiquitin-proteasomal pathway. It is not clear how 
antizyme-mediated ubiquitin-independent degradation of these proteins is physio-
logically significant. Normally subcellular localization of ODC is mainly in the cyto-
plasm and at least not in the nucleolus even in the presence of MG132. In addition, 
ODC is necessary for cell growth, and the affinity of interaction between antizyme 
and ODC is high [63]; in such condition, ODC probably occupies almost all anti-
zymes in the cytosol, and antizymes hardly function for other antizyme-interacting 
proteins [64]. In this context, because subcellular localization of both AZ2 and its 
interacting protein c-Myc is in the nucleus or nucleolus, cytosolic protein ODC 
could not interact with AZ2 there. ODC is one of the c-Myc-targeting proteins, and 
AZ2 may function upstream of c-Myc especially under the stress condition such as 
glucose free and hypoxic condition [26]. Further studies are needed to elucidate the 
significance of antizyme-proteasome degradation pathway.
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co-localization of both proteins to nucleolar co-localization [26]. Overexpression of 
AZ2 or addition of polyamine in the cells accelerated c-Myc degradation, and knock-
down of AZ2 with siRNA suppressed it. Furthermore, E1 inhibitor PYR-41 could not 
suppress AZ2-mediated proteasomal c-Myc degradation [26]. These results suggest 
that AZ2-mediated ubiquitin-independent nucleolar c-Myc degradation pathway 
other than ubiquitin-dependent one exists in the cells (Figure 2).
4. Conclusions
In this chapter, antizyme-mediated ubiquitin-independent proteasomal deg-
radation has been discussed. All the proteins mentioned above are already known 
as the proteins degraded by ubiquitin-proteasomal pathway. It is not clear how 
antizyme-mediated ubiquitin-independent degradation of these proteins is physio-
logically significant. Normally subcellular localization of ODC is mainly in the cyto-
plasm and at least not in the nucleolus even in the presence of MG132. In addition, 
ODC is necessary for cell growth, and the affinity of interaction between antizyme 
and ODC is high [63]; in such condition, ODC probably occupies almost all anti-
zymes in the cytosol, and antizymes hardly function for other antizyme-interacting 
proteins [64]. In this context, because subcellular localization of both AZ2 and its 
interacting protein c-Myc is in the nucleus or nucleolus, cytosolic protein ODC 
could not interact with AZ2 there. ODC is one of the c-Myc-targeting proteins, and 
AZ2 may function upstream of c-Myc especially under the stress condition such as 
glucose free and hypoxic condition [26]. Further studies are needed to elucidate the 
significance of antizyme-proteasome degradation pathway.
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Transforming growth factor β (TGFβ) is a multifunctional cytokine with potent 
regulatory effects on cell fate during embryogenesis, in the normal adult organism, 
and in cancer cells. In normal cells, the signal from the TGFβ ligand is transduced 
from the extracellular space to the cell nucleus by transmembrane serine–threonine 
kinase receptors in a highly specific manner. The dimeric ligand binding to the TGFβ 
Type II receptor (TβRII) initiates the signal and then recruits the TGFβ Type I recep-
tor (TβRI) into the complex, which activates TβRI. This causes phosphorylation of 
receptor-activated Smad proteins Smad2 and Smad3 and promotes their nuclear 
translocation and transcriptional activity in complex with context-dependent 
transcription factors. In several of our most common forms of cancer, this pathway 
is instead regulated by polyubiquitination of TβRI by the E3 ubiquitin ligase TRAF6, 
which is associated with TβRI. The activation of TRAF6 promotes the proteolytic 
cleavage of TβRI, liberating its intracellular domain (TβRI-ICD). TβRI-ICD enters 
the cancer cell nucleus in a manner dependent on the endosomal adaptor proteins 
APPL1/APPL2. Nuclear TβRI-ICD promotes invasion by cancer cells and is recog-
nized as acting distinctly and differently from the canonical TGFβ-Smad signaling 
pathway occurring in normal cells.
Keywords: TRAF6, APPL1/2, TGFβ, biomarkers, cancer
1. Introduction
Ubiquitination is a crucial biological process both in normal homeostasis and in 
diseases including cancer and immunity-related disorders. In cancers, ubiquitination 
of various signaling molecules acts to both promote and suppress tumors [1]. In this 
chapter, we will focus on the tumor-promoting role of TRAF6 in different cancers.
1.1 Ubiquitination and TRAF6
Within the lifespan of proteins, it is difficult for them to avoid post-translational 
modifications, which determine their localization and function. Protein ubiqui-
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1. Introduction
Ubiquitination is a crucial biological process both in normal homeostasis and in 
diseases including cancer and immunity-related disorders. In cancers, ubiquitination 
of various signaling molecules acts to both promote and suppress tumors [1]. In this 
chapter, we will focus on the tumor-promoting role of TRAF6 in different cancers.
1.1 Ubiquitination and TRAF6
Within the lifespan of proteins, it is difficult for them to avoid post-translational 
modifications, which determine their localization and function. Protein ubiqui-
tination was discovered in the early 1980s, and is a dynamic post-translational 
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modification regulating many cellular processes. The best known role for ubiquitina-
tion is targeting proteins for their destruction by the proteasome. In recent years, 
however, nonproteolytic functions of ubiquitination, including in signal transduction, 
cell division and differentiation, endocytosis, and the DNA damage response, have 
been rapidly discovered [2].
Ubiquitin is a highly conserved protein of 76 amino acids that becomes covalently 
attached to the ε-amino group of lysine (Lys) residues of target proteins. There are 
three types of ubiquitination: mono-ubiquitination, multi-mono-ubiquitination, 
and polyubiquitination. Polyubiquitin chains are formed by the addition of ubiq-
uitin residues to an ubiquitin molecule already linked to a protein and acting as an 
additional residue. The key features of ubiquitin are seven Lys residues (Lys6, Lys11, 
Lys27, Lys29, Lys33, Lys48, and Lys63) and an N-terminal Met residue, all of which 
can be further ubiquitinated to give rise to polyubiquitin chains of distinct linkages. 
Lys63-linked polyubiquitination is involved in endocytosis, signal transduction, 
and DNA-damage tolerance [3, 4]. During recent years has also linear ubiquitination 
been identified to occur through N-terminal Met residue of ubiquitin. It is created 
by the linear ubiquitin chain assembly complex (LUBAC), which so far is the only 
ubiquitin ligase known to build linear ubiquitin chains de novo. Linear ubiquitination 
is crucial for regulation of innate and adaptive immune responses, including inflam-
matory responses and regulation of signals leading to cell death [5–7].
Ubiquitination is catalyzed by a sophisticated enzymatic cascade involving three 
enzymes, an ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme 
(E2), and an ubiquitin ligase (E3). E3 ligase usually determines the mechanism of 
ubiquitin transfer to target proteins, as it can recognize substrate and mediate the 
addition of ubiquitin [3, 8]. E3 ligases have been classified into three subfamilies: 
HECT (homologous to E6-AP C terminus) ligases, RING (really interesting new 
gene)/U-box ligases, and RBR (RING-between-RING) ligases [3]. TRAF6 is a 
Ring/U-box E3 ligase belonging to the tumor necrosis factor (TNF) receptor-
associated factor (TRAF) family.
TRAF family cytoplasmic proteins were originally identified as TNF receptor 
signaling adaptors that bind directly to the cytoplasmic region of TNF-R2. To date, 
six different TRAF family members (TRAF1–6) have been found in mammals. 
TRAF7 is controversially classified as a member of the TRAF family, as it lacks a 
TRAF homology domain and does not directly bind to any member of the TNFR 
superfamily, two key features used to define the TRAF family. The TRAF domain, 
located in the C-terminal portion of TRAF family proteins, is composed of an 
N-terminal less-conserved coiled-coil region (TRAF-N) and a C-terminal highly 
conserved subdomain (TRAF-C). The TRAF domain mediates protein–protein inter-
actions, including association with upstream regulators and downstream effectors 
and homo- and hetero-dimerization of TRAF proteins. Thus, TRAF family members 
are involved in a variety of signal transduction pathways by interaction with recep-
tors. These include the TNF, Toll-like receptor, NLR, TGFβ signaling pathways, and 
others. Through these interactions, TRAF family members participate in the regula-
tion of a broad range of cellular processes, including proliferation, differentiation, 
apoptosis, and survival. With the exception of TRAF1, however, TRAFs also contain 
an N-terminal RING domain, indicating that they are E3 ubiquitin ligases [9, 10].
TRAF6 was isolated for the first time in 1996 in a yeast two-hybrid screen 
with CD40 as bait [11], and later independently found to mediate the expression 
of interleukin 1 (IL-1) signaling, based on a screen of an EST expression library 
[12]. TRAF6 is well conserved across species and broadly expressed in mammalian 
tissues such as brain, lung, liver, etc. As an E3 ligase, TRAF6 interacts with the 
E2 complex Ubc13-Uev1A and participates in a number of signal transduction 
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pathways, including those of nuclear factor kappa B (NF-κB), toll-like receptor 
4 (TLR4), and TGFβ, the last of which is further discussed later in this chapter. 
Knockdown of TRAF6 or inhibition of TRAF6 E3 ligase activity in vitro suppresses 
the proliferation, survival, migration, invasion, and metastasis of many human 
epithelial cell lines [10].
TRAF6−/− mice, with a complete lack of normal T and B cell areas, exhibit 
perinatal or postnatal death due to severe splenomegaly, osteopetrosis, lymph node 
deficiency, and thymic atrophy [9]. All these findings indicate the critical and 
highly various roles of TRAF6 in cytokine signaling, innate immune responses, and 
perinatal and postnatal survival [9, 13].
1.2 The TGFβ signaling pathway and its role in cancer
Cells communicate by sending and receiving signals through cytokines and 
membrane-associated proteins. Among the secreted growth factors and cytokines, 
the TGFβ family attracts a lot of attention because it controls cell fate decisions during 
embryonic development, tissue homeostasis, and regeneration. All cells in the 
developing embryo and the adult can respond to TGFβ, as it regulates proliferation, 
differentiation, adhesion, movement, and apoptosis in a cell-context–dependent 
manner. Perturbation of TGFβ signaling is often seen in inflammatory diseases, 
fibrotic diseases, and cancers [14, 15].
1.2.1 Basics of TGFβ signaling
The TGFβ superfamily consists of more than 30 members in humans, and they 
are grouped into different subfamilies based on sequence similarity and functional 
criteria, including TGFβ isoforms, activins, bone morphogenetic proteins (BMPs), 
growth and differentiation factors (GDFs), activin, nodal, and anti-mullerian 
hormone (AMH). The TGFβ subfamily comprises three different isoforms: TGFβ1, 
TGFβ2, and TGFβ3. All of them act in an autocrine, paracrine, and sometimes 
endocrine manner [14, 16].
Mammalian genomes encode two subfamilies of TGFβ receptors, seven type 
I (TβRI) and five type II (TβRII) serine/threonine kinase receptors, which are 
classified by their structures and functions. Both types of receptors are single-
pass transmembrane kinases and share structural similarities: they have an 
N-terminal cysteine-rich extracellular domain, an α-helical transmembrane 
domain, a short juxtamembrane sequence, and a C-terminal cytoplasmic kinase 
domain with 11 subdomains organized in an N-lobe and a C-lobe. A conserved 
glycine/serine-rich sequence, the GS domain, is present in the juxtamembrane 
domain only in TβRI [17, 18].
The most-studied mediators of TGFβ signaling pathways are Smad proteins. 
TGFβ signaling pathways include canonical Smad-dependent and non-canonical 
Smad- independent pathways [15, 19].
1.2.2 Smad-dependent TGFβ signaling pathways
Smad proteins are named after two proteins: small body size (Sma) in 
Caenorhabditis elegans and mothers against decapentaplegic (Mad) in Drosophila 
melanogaster. The mammalian genome encodes eight Smads which form three 
subfamilies based on their structures and functions: receptor-activated Smads 
(R-Smads; Smad 1, 2, 3, 5, and 8); a single common mediator of Smad (Co-Smad; 
Smad4); and two inhibitory Smads (I-Smads; Smad6 and Smad7). Smad2 and 
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growth and differentiation factors (GDFs), activin, nodal, and anti-mullerian 
hormone (AMH). The TGFβ subfamily comprises three different isoforms: TGFβ1, 
TGFβ2, and TGFβ3. All of them act in an autocrine, paracrine, and sometimes 
endocrine manner [14, 16].
Mammalian genomes encode two subfamilies of TGFβ receptors, seven type 
I (TβRI) and five type II (TβRII) serine/threonine kinase receptors, which are 
classified by their structures and functions. Both types of receptors are single-
pass transmembrane kinases and share structural similarities: they have an 
N-terminal cysteine-rich extracellular domain, an α-helical transmembrane 
domain, a short juxtamembrane sequence, and a C-terminal cytoplasmic kinase 
domain with 11 subdomains organized in an N-lobe and a C-lobe. A conserved 
glycine/serine-rich sequence, the GS domain, is present in the juxtamembrane 
domain only in TβRI [17, 18].
The most-studied mediators of TGFβ signaling pathways are Smad proteins. 
TGFβ signaling pathways include canonical Smad-dependent and non-canonical 
Smad- independent pathways [15, 19].
1.2.2 Smad-dependent TGFβ signaling pathways
Smad proteins are named after two proteins: small body size (Sma) in 
Caenorhabditis elegans and mothers against decapentaplegic (Mad) in Drosophila 
melanogaster. The mammalian genome encodes eight Smads which form three 
subfamilies based on their structures and functions: receptor-activated Smads 
(R-Smads; Smad 1, 2, 3, 5, and 8); a single common mediator of Smad (Co-Smad; 
Smad4); and two inhibitory Smads (I-Smads; Smad6 and Smad7). Smad2 and 
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Smad3 act as signal transducers for TGFβ, activin, and nodals, whereas Smad1, 
Smad5, and Smad8 mediate signals by BMPs and GDFs.
Upon TGFβ ligand binding, the two types of receptors are brought together and 
induce the formation of a heterotetrameric complex. The constitutively active type 
II receptor phosphorylates the type I receptor in its highly conserved GS domain, 
leading to the activation of its kinase. The active serine/threonine type I receptor 
propagates signaling by phosphorylating R-Smads, which in turn form a trimeric 
complex with Smad4 and then translocate to the nucleus. In the nucleus, the Smad 
complex works together with other transcription factors, coactivators, and corepres-
sors to regulate the expression of genes such as snail family transcriptional repressor 
1 (Snail1), plasminogen activator inhibitor type 1(PAI1), and matrix metallopepti-
dase 2 (MMP2). In summary, canonical Smad-dependent TGFβ signaling pathways 
regulate cell proliferation, apoptosis, and the epithelial-mesenchymal transition 
(EMT) [20, 21].
1.2.3 Smad-independent TGFβ signaling pathways
TGFβ non-canonical signaling pathways include the c-Jun N-terminal kinase 
(JNK), p38 mitogen-activated protein kinase (MAPK), phosphatidylinositol-3′-kinase 
(PI3K), and extracellular signal-regulated kinase (Erk) signaling pathways [19].
TGFβ-activated kinase-1 (TAK1) is a serine/threonine kinase and member of 
the mitogen-activated protein kinase (MAPK) kinase kinase (MAPKKK) family. 
TRAF6 associates with a conserved consensus motif in TβRI. Upon TGFβ stimula-
tion, the interaction of TRAF6 and TβRI is important for the autoubiquitination 
of TRAF6 and subsequent Lys63-polyubiquitination and activation of TAK1. 
Once activated, TAK1 phosphorylates protein mitogen-activated kinase kinase 3/6 
(MKK3/6), activating the JNK and p38 signaling pathways to drive apoptosis or 
EMT [22, 23].
1.2.4 TGFβ receptor endocytosis
Endocytosis is a process by which cells internalize extracellular materials and 
portions of their plasma membrane together with cell surface receptors. It has been 
divided into two categories, clathrin-dependent and clathrin-independent endo-
cytosis [24]. TGFβRs can be internalized via both clathrin-dependent and clathrin-
independent caveolae-mediated endocytosis [14, 25].
Both TβRII and TβRI appear to undergo rapid internalization in the presence 
and absence of ligand stimulation. After internalization, TGFβRs are found in the 
phosphatidylinositol-3-phosphate (PI3P)-enriched and early endosome antigen 
(EEA1)-positive endosomes, which recruit Smad anchor for receptor activation 
(SARA) to facilitate phosphorylation of R-Smads. Phosphorylated R-Smads in 
endosomes then dissociate from SARA and the receptors, and translocate to the 
nucleus together with Smad4 to regulate target gene expression [26].
In caveolae-mediated endocytosis, TGFβ signaling is turned off by the inter-
action between TGFβRs and Smad7-Smurf2, which leads to the degradation of 
TGFβRs [27].
1.2.5 TGFβ signaling in cancer
TGFβ signaling in cancer is a double-edged sword, acting as both a tumor sup-
pressor in normal and pre-malignant cells and as a tumor promoter in malignant 
cells. The response to TGFβ is context dependent. TGFβ is produced by cancer cells 
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or stromal cells in large amounts within the cancer microenvironment, influenc-
ing not only on the cancer cells but also non-tumor cells, such as fibroblasts and 
immune cells [15, 28].
In the early malignant stage, TGFβ suppresses tumor progression by inducing 
apoptosis and inhibiting proliferation. However, malignant cells always escape this 
tumor-suppressive response through loss of the core TGFβ pathway or its suppres-
sive arms, thereby turning TGFβ into a stimulator of cancer progression. As a tumor 
promoter, TGFβ is involved in angiogenesis, tumor growth, evasion of immune 
surveillance, migration, invasion, and metastasis [15, 29].
1.3 PI3K/AKT pathway
The PI3K pathway is one of the most commonly activated pathways in human 
cancers, regulating cell proliferation, survival, metabolism, and vesicle trafficking. 
This pathway’s activation is initiated by various molecules, such as insulin, glucose, 
growth factors, and cytokines [30, 31]. PI3Ks are classified into three classes based 
on sequence homology and substrate specificity. Class I PI3Ks have two subfamilies, 
IA and IB, classified according to their different regulatory mechanisms. Class 
IA PI3K, a heterodimer, consists of a p110 catalytic subunit and a p85 regulatory 
subunit. Class I PI3K generates PtdIns [3,4,5]P3 (PIP3) from PtdIns [4,5]P2 (PIP2) 
in vivo. PIP3 acts as a second messenger to activate downstream signaling pathways, 
including AKT/mTOR (mechanistic target of rapamycin kinase) pathways. Class IA 
PI3Ks are the focus of this chapter [31, 32].
The primary structure of p85 includes an N-terminal Src homology 3 (SH3) 
domain, a RhoGap homology region located between two proline-rich domains, 
and two SH2 domains (nSH2 and cSH2 domains) separated by a p110-binding iSH2 
domain [33]. Upon binding to an activated receptor tyrosine kinase (RTK) or G 
protein-coupled receptor (GPCP), p85 interacts with receptors directly or indirectly 
via the SH2 domains, which mediate the translocation of the p85-p110 complex to 
the cell membrane. This induces a conformational change and activates the catalytic 
activity of p110 to phosphorylate PIP2 to generate PIP3 [30, 33].
The serine/threonine protein kinase AKT has three isoforms, AKT1, AKT2, 
and AKT3. PIP3 binding induces a conformational change in AKT that recruits 
phosphoinositide-dependent kinase (PDK1) to phosphorylate AKT on Thr308. The 
mTOR complex 2 (mTORC2) phosphorylates AKT on Ser473, fully activating AKT. 
All three isoforms are activated in the same manner [31, 34]. In addition to phos-
phorylation, other post-translational modifications regulate the activity of AKT. 
These include dephosphorylation, glycosylation, acetylation, ubiquitination, and 
SUMOylation. Lys48-linked polyubiquitination of AKT is mediated by multiple E3 
ligases, such as BRCA1, Chip, MULAN, and TTC, and has been shown to promote 
proteasome-dependent degradation. By contrast, Lys63-linked polyubiquitination, 
which is mediated by TRAF6, Skp2, and NEDD4, is implicated in the membrane 
localization and phosphorylation of AKT [34, 35]. After activation, AKT regulates 
downstream signaling pathways by phosphorylating protein targets, including 
protein kinases, transcription factors, metabolic enzymes, cell cycle proteins, and 
others [34].
It has been reported that TGFβ can activate the PI3K signaling pathway directly 
or indirectly. Of note, upon TGFβ stimulation, the phosphorylation of AKT acts in 
a Smad-independent manner [36–38]. Moreover, p85 constitutively interacts with 
TβRII and binds to TβRI after TGFβ stimulation [39]. The crosstalk between the 
PI3K/AKT and TGFβ signaling pathways attracts a lot of attention, as both of them 
play important roles in cancer.
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ing not only on the cancer cells but also non-tumor cells, such as fibroblasts and 
immune cells [15, 28].
In the early malignant stage, TGFβ suppresses tumor progression by inducing 
apoptosis and inhibiting proliferation. However, malignant cells always escape this 
tumor-suppressive response through loss of the core TGFβ pathway or its suppres-
sive arms, thereby turning TGFβ into a stimulator of cancer progression. As a tumor 
promoter, TGFβ is involved in angiogenesis, tumor growth, evasion of immune 
surveillance, migration, invasion, and metastasis [15, 29].
1.3 PI3K/AKT pathway
The PI3K pathway is one of the most commonly activated pathways in human 
cancers, regulating cell proliferation, survival, metabolism, and vesicle trafficking. 
This pathway’s activation is initiated by various molecules, such as insulin, glucose, 
growth factors, and cytokines [30, 31]. PI3Ks are classified into three classes based 
on sequence homology and substrate specificity. Class I PI3Ks have two subfamilies, 
IA and IB, classified according to their different regulatory mechanisms. Class 
IA PI3K, a heterodimer, consists of a p110 catalytic subunit and a p85 regulatory 
subunit. Class I PI3K generates PtdIns [3,4,5]P3 (PIP3) from PtdIns [4,5]P2 (PIP2) 
in vivo. PIP3 acts as a second messenger to activate downstream signaling pathways, 
including AKT/mTOR (mechanistic target of rapamycin kinase) pathways. Class IA 
PI3Ks are the focus of this chapter [31, 32].
The primary structure of p85 includes an N-terminal Src homology 3 (SH3) 
domain, a RhoGap homology region located between two proline-rich domains, 
and two SH2 domains (nSH2 and cSH2 domains) separated by a p110-binding iSH2 
domain [33]. Upon binding to an activated receptor tyrosine kinase (RTK) or G 
protein-coupled receptor (GPCP), p85 interacts with receptors directly or indirectly 
via the SH2 domains, which mediate the translocation of the p85-p110 complex to 
the cell membrane. This induces a conformational change and activates the catalytic 
activity of p110 to phosphorylate PIP2 to generate PIP3 [30, 33].
The serine/threonine protein kinase AKT has three isoforms, AKT1, AKT2, 
and AKT3. PIP3 binding induces a conformational change in AKT that recruits 
phosphoinositide-dependent kinase (PDK1) to phosphorylate AKT on Thr308. The 
mTOR complex 2 (mTORC2) phosphorylates AKT on Ser473, fully activating AKT. 
All three isoforms are activated in the same manner [31, 34]. In addition to phos-
phorylation, other post-translational modifications regulate the activity of AKT. 
These include dephosphorylation, glycosylation, acetylation, ubiquitination, and 
SUMOylation. Lys48-linked polyubiquitination of AKT is mediated by multiple E3 
ligases, such as BRCA1, Chip, MULAN, and TTC, and has been shown to promote 
proteasome-dependent degradation. By contrast, Lys63-linked polyubiquitination, 
which is mediated by TRAF6, Skp2, and NEDD4, is implicated in the membrane 
localization and phosphorylation of AKT [34, 35]. After activation, AKT regulates 
downstream signaling pathways by phosphorylating protein targets, including 
protein kinases, transcription factors, metabolic enzymes, cell cycle proteins, and 
others [34].
It has been reported that TGFβ can activate the PI3K signaling pathway directly 
or indirectly. Of note, upon TGFβ stimulation, the phosphorylation of AKT acts in 
a Smad-independent manner [36–38]. Moreover, p85 constitutively interacts with 
TβRII and binds to TβRI after TGFβ stimulation [39]. The crosstalk between the 
PI3K/AKT and TGFβ signaling pathways attracts a lot of attention, as both of them 
play important roles in cancer.
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1.4 APPL proteins
APPL1 was first identified as an AKT2-binding protein in a yeast two-hybrid 
screen in 1999 [40]. APPL1 was initially called DIP-13α (DCC-interacting protein 
13α), as it interacts with the tumor suppressor protein DCC (deleted in colorectal 
cancer) [41]. APPL proteins, which include APPL1 and APPL2, are named after 
their unique structure, the multifunctional adaptor proteins that contain a pleck-
strin homology (PH) domain, phosphotyrosine binding (PTB) domain, and leucine 
zipper motif [40]. APPL1 and APPL2 share 54% sequence identity and many 
identical binding partners. Both are found only in eukaryotes [42]. Briefly, APPL1 
consists of the N-terminal Bin1/amphiphysin/rvs167 BAR domain (originally 
identified as the leucine zipper motif), followed by a pleckstrin homology domain 
(PH domain), a BPP (region “between PH and PTB domains”) domain, a PTB 
domain, and a C-terminal CC domain [42, 43]. The BAR, PH, and PTB domains are 
the key functional domains. The BAR and PH domains usually act as a unit involved 
in sensing and stabilizing membrane curvature and anchor the host proteins to 
membrane compartments. The PTB domain interacts with phospholipids, receptors 
such as DCC, and signaling molecules including AKT2. In summary, APPL proteins 
regulate important physiological processes via their unique domains [44].
APPL1 is a marker of early endosomes that are precursors of classical PI3P-
positive endosomes [45]. Depletion of PI3P by PI3K inhibitors leads to the reversion 
of EEA1-positive endosomes to the APPL1 stage, enlargement of APPL1 endosomes, 
and enhanced growth factor signaling [45]. APPL proteins are implicated in signal-
ing pathways such as the EGF [46], NF-κB [47], and TGFβ signaling pathways [48]. 
Through its roles in endocytosis and signal transduction, APPL1 has been reported 
to mediate proliferation, apoptosis, and migration [44, 49].
2.  TGFβ causes Lys63-linked polyubiquitination of TβRI by TRAF6, 
inducing the formation of the intracellular domain of TβRI (TβRI-
ICD), which promotes tumor invasion by inducing the transcription 
of target genes in the nucleus
We identified the intracellular domain of TβRI by using two different TβRI anti-
bodies: v22, which recognizes the C-terminal part of TβRI; and H100, which was 
raised against the N-terminal part of TβRI. Upon TGFβ stimulation, the C-terminal 
fragment of TβRI accumulates in the nucleus. However, the N-terminal part of TβRI 
still localizes mainly to the cell membrane [50].
We have previously shown that TRAF6 interacts with a consensus binding site 
in TβRI [22]. Interestingly, TRAF6 is known to cause Lys63-linked polyubiquiti-
nation of TβRI, as well as the generation of TβRI-ICD. It has been reported that 
TNFα-converting enzyme (TACE) induces the cleavage of TβRI through the ERK 
MAP-kinase pathway [51]. We confirmed that TACE cleaves TβRI by using both 
an activator of protein kinase C (PKC), which can activate TACE, and an inhibitor 
of TACE. The TACE cleavage site in TβRI is the Gly-Leu bond at position 120–121, 
which is close to the transmembrane domain. The G120I mutant has intact kinase 
activity but does not accumulate in the nucleus in response to TGFβ [50]. PKCζ, 
which interacts with TRAF6 [52], is required for the formation and nuclear translo-
cation of TβRI-ICD [50].
By immunofluorescence and co-immunoprecipitation, TβRI-ICD has been 
shown to associate with p300 in the nucleus in a PKCζ-dependent manner. 
Moreover, p300 mediates the acetylation of TβRI-ICD [50]. In the nucleus, 
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TβRI-ICD regulates the transcription of target genes, such as SNAI1 and MMP2, 
promoting the invasiveness of cancer cells. Interestingly, the cleavage of TβRI 
occurs only in malignant prostate cancer cells (PC-3 U), but not in normal primary 
human prostate epithelial cells. Nuclear accumulation of TβRI-ICD is also observed 
in prostate cancer, breast cancer, and bladder cancer, suggesting that preventing 
nuclear translocation of TβRI-ICD could be a new target in cancer treatment [50] 
(Figure 1).
3.  TRAF6 induces Lys63-linked polyubiquitination and activation of 
PS1, leading to the cleavage of TβRI and promoting tumor invasion
Presenilin 1 (PS1) is the catalytic core of the γ-secretase complex, which medi-
ates the cleavage of many cell surface type I transmembrane receptors, such as APP, 
Notch, and CD44 [53]. TRAF6 is reported to interact with PS1, which enhances the 
Figure 1. 
Proposed model for canonical and TRAF6-mediated non-canonical TGFβ signaling pathways. Upon TGFβ 
stimulation, constitutively TβRII activates TβRI, leading to the phosphorylation of Smad2 and Smad3. 
R-Smads, which form a trimeric complex with Smad4, translocate to the nucleus for target genes expression, 
such as PAI1 and Smad7. In response to TGFβ, TRAF6 induces the formation of TβRI-ICD, which is generated 
by the proteolytic enzymes TACE and PS1. APPL proteins are necessary for the nuclear translocation of 
TβRI-ICD. In the nucleus, TβRI-ICD interacts with p300 and promotes tumor invasion indirectly or directly 
by inducing the transcription of target genes, such as SNAI1, MMP2, and TβRI. TRAF6 also causes the 
polyubiquitination of p85α, leading to the activation of the PI3K-AKT signaling pathway.
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TβRI-ICD regulates the transcription of target genes, such as SNAI1 and MMP2, 
promoting the invasiveness of cancer cells. Interestingly, the cleavage of TβRI 
occurs only in malignant prostate cancer cells (PC-3 U), but not in normal primary 
human prostate epithelial cells. Nuclear accumulation of TβRI-ICD is also observed 
in prostate cancer, breast cancer, and bladder cancer, suggesting that preventing 
nuclear translocation of TβRI-ICD could be a new target in cancer treatment [50] 
(Figure 1).
3.  TRAF6 induces Lys63-linked polyubiquitination and activation of 
PS1, leading to the cleavage of TβRI and promoting tumor invasion
Presenilin 1 (PS1) is the catalytic core of the γ-secretase complex, which medi-
ates the cleavage of many cell surface type I transmembrane receptors, such as APP, 
Notch, and CD44 [53]. TRAF6 is reported to interact with PS1, which enhances the 
Figure 1. 
Proposed model for canonical and TRAF6-mediated non-canonical TGFβ signaling pathways. Upon TGFβ 
stimulation, constitutively TβRII activates TβRI, leading to the phosphorylation of Smad2 and Smad3. 
R-Smads, which form a trimeric complex with Smad4, translocate to the nucleus for target genes expression, 
such as PAI1 and Smad7. In response to TGFβ, TRAF6 induces the formation of TβRI-ICD, which is generated 
by the proteolytic enzymes TACE and PS1. APPL proteins are necessary for the nuclear translocation of 
TβRI-ICD. In the nucleus, TβRI-ICD interacts with p300 and promotes tumor invasion indirectly or directly 
by inducing the transcription of target genes, such as SNAI1, MMP2, and TβRI. TRAF6 also causes the 
polyubiquitination of p85α, leading to the activation of the PI3K-AKT signaling pathway.
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autoubiquitination of TRAF6 [54]. To further investigate the molecular mechanism 
of TβRI cleavage, we examined the possible involvement of PS1.
TGFβ stimulation enhances the abundance and activity of PS1. PS1 interacts 
with TβRI in a TRAF6-dependent manner. TRAF6 causes Lys63-linked polyubiq-
uitination of PS1 in response to TGFβ, leading to the activation of PS1. After the 
initial cleavage of TβRI by TACE, activated PS1 mediates a second cleavage between 
Val129 and Ile 130 in the transmembrane domain of TβRI, leading to the generation 
and nuclear translocation of TβRI-ICD [55].
In the nucleus, TβRI-ICD induces its own gene expression to promote cell 
invasion (Figure 1). Experiments using γ-secretase inhibitors showed that PS1 is 
required for TGFβ-induced cell invasion in vitro. Furthermore, γ-secretase inhibi-
tors also reduce the generation of TβRI-ICD and tumor growth in a prostate cancer 
xenograft model in vivo, suggesting a novel therapeutic strategy for cancers [55].
4.  Lys178 in TβRI is the acceptor lysine of Lys63-linked 
polyubiquitination by TRAF6, which is involved in TGFβ-induced 
invasion and cell cycle regulation
In in vitro and in vivo ubiquitination assays, TβRI Lys178, the only lysine close 
to the TRAF6 consensus binding site, has been identified as the acceptor lysine 
in polyubiquitination by TRAF6. Overexpression of HA-TβRI-K178R inhibits 
the formation and nuclear translocation of TβRI-ICD in response to TGFβ. The 
HA-TβRI-K178R mutant has no effect on the kinase activity of TβRI, indicating that 
it does not interfere with the phosphorylation of Smad2. However, transfection of 
cells with HA-TβRI-K178R does alter p38 activation [56].
We identified additional genes targeted by nuclear TβRI-ICD by using qRT-PCR. 
Overexpression of HA-TβRI-K178R changes the expression of genes implicated 
in invasiveness and cell cycle regulation, such as Vimentin, Twist1, N-cadherin, 
CCND1, and p73. As expected, the expression of PAI1 is unchanged, due to the 
intact kinase activity of HA-TβRI-K178R. Fewer cells enter G1 from G0 in HA-TβRI-
K178R-transfected cells compared with HA-TβRI-transfected cells after incubation 
with TGFβ for 48 hours, as CCND1 is poorly regulated in the mutant-transfected 
cells. PC-3 U cells expressing HA-TβRI-K178R were less invasive than cells express-
ing HA-TβRI. In summary, the polyubiquitination of TβRI on Lys178 influences 
both cell cycle regulation and invasion [56].
5.  APPL proteins are required for the nuclear translocation of the TGFβ 
type I receptor intracellular domain
Next, we started to investigate the mechanism of nuclear translocation of 
TβRI-ICD. As APPL proteins are involved in cargo trafficking from the endosomal 
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enhances the formation of the APPL1-TβRI complex. Moreover, treatment 
with PI3K inhibitors such as LY294002 and wortmannin enlarges APPL1 early 
endosomes and prevents the maturation of APPL1 endosomes to EEA1-positive 
endosomes, and causes increased association of APPL1 with TβRI. In contrast, 
TβRI kinase activity is not necessary for the interaction between APPL1 and TβRI. 
Furthermore, endogenous APPL1 has been shown in a nuclear fractionation assay to 
interact with TβRI-ICD in the nucleus after TGFβ stimulation [48].
It has been reported that APPL1 undergoes Lys63-linked polyubiquitination 
mediated by TRAF6 in response to insulin in primary mouse hepatocytes [57]. 
We found that TRAF6 also causes Lys63-linked polyubiquitination of APPL1 after 
TGFβ stimulation of human prostate (PC-3 U) cells. Of note, TRAF6 is required 
for both the formation of the APPL1-TβRI complex and the interaction between 
APPL1 and β-tubulin. In summary, we conclude that APPL proteins are required 
for the nuclear translocation of TβRI-ICD, possibly via the microtubule system [48] 
(Figure 1).
Nuclear TβRI-ICD promotes the invasion of various cancer cells by inducing the 
transcription of pro-invasion genes, such as MMP2 and MMP9 [50]. After silenc-
ing the expression of APPL1/2, TGFβ-induced invasion is reduced, probably due 
to a decline in the nuclear accumulation of TβRI-ICD, in both a prostate cancer cell 
line (PC-3 U) and a breast cancer cell line (MDA-MB-231). MMP2 and MMP9 gene 
expression also decreases after APPL1/2 knock-down. We also found that APPL1 
staining is correlated with a high Gleason Score (indicating the tumor invasiveness 
and bad prognosis), consistent with previous reports [48, 58]. Interestingly, using 
an in situ proximity ligation assay, we found more APPL1–TβRI-ICD complexes in 
high-Gleason Score patients. In summary, APPL1–TβRI-ICD is a potential prognos-
tic marker for prostate cancer patients [48].
6.  TGFβ activates the PI3K/AKT signaling pathway by TRAF6-mediated 
polyubiquitination of p85α
It has been reported that TGFβ can activate AKT. However, the detailed 
mechanism is still unclear. We found that, upon TGFβ stimulation, TβRI forms a 
complex with AKT and the phosphorylation of AKT correlates with its interac-
tion with TβRI and TRAF6 [59]. As TRAF6 causes Lys63-linked polyubiquitina-
tion and activation of AKT upon IGF-1, LPS, and IL-1β stimulation [60], we 
investigated whether TRAF6 plays the same role in the TGFβ signaling pathway. 
Using an in vivo ubiquitination assay in PC-3 U cells, we demonstrated that TGFβ 
induces Lys63-linked polyubiquitination of AKT, which is mediated by TRAF6. 
TGFβ stimulation induces recruitment of the activated-AKT–TRAF6–TβRI 
complex to cell membrane ruffles. The interaction between TβRI and AKT does 
not require TβRI kinase activity, but depends on the regulatory subunit of PI3K, 
p85α. Furthermore, p85α is also involved in the activation and ubiquitination of 
AKT [59].
The interaction between TRAF6 and p85α is enhanced after TGFβ stimulation. 
TGFβ induces the Lys63-linked polyubiquitination of p85α in a TRAF6-dependent 
manner (Figure 1). The kinase activities of TβRI and TβRII are not involved in p85α 
ubiquitination. p85α was found to associate with TβRI upon TGFβ stimulation, 
but not with TβRII, and TβRI kinase activity is not necessary for the interaction 
between p85α and TβRI. We found that TGFβ induces PI3K activity in a TRAF6-
dependent manner, but independently of TβRI kinase activity, and that TGFβ 
promotes cell migration and invasion via the PI3K pathway and TRAF6 [59]. Using 
mass spectrometry and an in vivo ubiquitination assay, we identified Lys513 and/or 
Ubiquitin - Proteasome Pathway
46
autoubiquitination of TRAF6 [54]. To further investigate the molecular mechanism 
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Lys519 in the iSH2 domain as the major residue(s) of Lys63-linked polyubiquitina-
tion of p85α. Overexpression of a K513/K519 double mutant not only suppresses 
PI3K activity and AKT phosphorylation, but also inhibits cell migration and 
invasion. Finally, using an in situ proximity ligation assay performed in prostate 
cancer tissue samples, we found that polyubiquitination of p85α is correlated with 
the aggressiveness of the prostate cancer, suggesting that the polyubiquitination of 
p85α could be a prognostic marker for this disease [59]. As both the TGFβ and PI3K 
pathways are deregulated in cancers, finding the link between these two pathways 
will be important for future cancer research [61].
7. Conclusions
Ubiquitination regulates a broad spectrum of physiological processes, including 
cell proliferation, apoptosis, differentiation, and others [1, 2]. We have shown that, 
upon TGFβ stimulation, TRAF6 causes Lys63-linked polyubiquitination of p85α, 
leading to the activation of the AKT signaling pathway [59]. Moreover, TGFβ, via 
TRAF6, causes Lys63-linked polyubiquitination of TβRI and its PKCζ-dependent 
cleavage by TACE [50]. After this initial cleavage by TACE, PS1 is activated by 
TRAF6-mediated polyubiquitination, which results in a second cleavage of TβRI, by 
PS1 [55]. APPL proteins are involved in the nuclear translocation of TβRI-ICD [48]. 
In the nucleus, TβRI-ICD promotes the transcription of pro-invasion genes, such as 
SNAI1, MMP2, and TβRI itself [50, 55]. TβRI-ICD can be found in cancer cell lines, 
but not in normal prostate epithelial cell lines or in the normal prostate epithelium 
[50]. Inhibitors of γ-secretase, which prevent the generation of TβRI-ICD, suppress 
cell invasion in vitro and tumor growth in vivo, indicating a possible novel therapeu-
tic target in cancer [55].
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Malignant melanoma is one of the most invasive tumors with increasing 
mortality, low overall survival rates and limited effective therapeutic strategies. 
Ubiquitination is a post-translational protein modification, which is regulated by a 
series of ubiquitination-associated enzymes. Ubiquitination plays a critical role in 
diverse pathophysiological activities of cellular and participates in the pathogenesis 
of various cancers, including melanoma. This study aims to provide a conclusive of 
ubiquitination and deubiquitination, and their potential clinical application value in 
melanoma in the following aspects: melanoma pathogenesis-related components and 
processes in the ubuiquitin-proteasome system (UPS), ubiquitination in melanoma 
immunological microenvironment modulation, ubiquitination of key transcription 
factors in melanoma and melanoma therapeutic strategy via targeting the UPS.
Keywords: ubiquitination, deubiquitinating enzymes, melanoma, pathogenesis, 
application
1. Introduction
Malignant melanoma is one of the most invasive tumors with increasing 
 mortality, low overall survival rates, and limited effective therapeutic strategies 
[1]. Although melanoma is the third most prevalent skin cancer, the two other skin 
malignancies, basal cell and squamous cells, are the malignant [2]. A variety of 
factors, including genetic mutations, sun exposure, and poor lifestyle habits, are 
involved in the development of melanoma [3].
There is a dynamic protein balance in cells to maintain homeostasis for cell 
and organism. Intracellular protein degradation by two pathways, autophagy 
and lysosomal degradation pathway and the ubiquitin-proteasome pathway, is 
primarily involved in tumor growth. Ubiquitination is one of post-translational 
modifications of most vital proteins. Ubiquitin, a closely conserved small protein 
composed of 76 amino acids, is link with the ubiquitin-activating enzyme (E1), the 
ubiquitin-conjugating enzyme (E2), and the ubiquitin ligase (E3) [4]. Specifically, 
mono-ubiquitination was considered as only one single ubiquitin bond to the lysine, 
while poly-ubiquitination was considered as ubiquitin chains attached to the lysine 
[5]. Then the ubiquitinated proteins are transported to the 26S proteasome for 
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and organism. Intracellular protein degradation by two pathways, autophagy 
and lysosomal degradation pathway and the ubiquitin-proteasome pathway, is 
primarily involved in tumor growth. Ubiquitination is one of post-translational 
modifications of most vital proteins. Ubiquitin, a closely conserved small protein 
composed of 76 amino acids, is link with the ubiquitin-activating enzyme (E1), the 
ubiquitin-conjugating enzyme (E2), and the ubiquitin ligase (E3) [4]. Specifically, 
mono-ubiquitination was considered as only one single ubiquitin bond to the lysine, 
while poly-ubiquitination was considered as ubiquitin chains attached to the lysine 
[5]. Then the ubiquitinated proteins are transported to the 26S proteasome for 
degradation. Ubiquitination is involved in the development of different tumors 
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by regulation important genes or signaling pathways. However, the ubiquitination 
process can be reversed by the deubiquitinating enzymes (DUBs) via cleaving 
ubiquitin chains from substrates to prevent protein degradation, which participates 
in a wide range of cellular signaling pathways, such as the apoptosis, cell cycle, 
autophagy, DNA damage, inflammation signaling, and protein downregulation [6]. 
Up to date, there were reported over 600 E3 ubiquitin ligase and 100 DUBs [7].
A significant number of studies have confirmed that ubiquitination and de-
ubiquitination play a critical role in melanoma pathogenesis, and have indicated 
that the key molecular goal of the mechanism may be the therapeutic strategies 
for the treatment of melanoma. Here, we provide a conclusive introduction about 
protein ubiquitin modification in relative genes, signaling pathways, and in immune 
system in melanoma pathogenesis, which concludes the latest DUB studies in 
melanoma. Besides, we summarize potential therapeutic targets of ubiquitination 
and de-ubiquitination in melanoma.
2. Melanoma pathogenesis related components and processes of the UPS
2.1 Fbxw7
The F-box/WD repeat-containing protein 7 (Fbxw7) belongs to the F-box protein 
family, which is the component of an SCF E3 ubiquitin ligase [8]. Fbxw7 is considered 
to be a tumor suppressor gene [9]. The degradation of Fbxw7 results in accumulation 
of its substrates, leading to oncogenesis. In a study, the mutation prevalence was found 
to be 8.1% FBXW7 in melanoma through exome sequencing in a cohort of 103 melano-
mas. A potential therapeutic approach for melanoma could be the loss and mutation of 
FBXW7 in melanoma contributing to prolonged activation of NOTCH and targeting 
NOTCH signaling [10]. FBXW7 deficiency can also unleash heat shock factor 1 (HSF1) 
and then result in melanoma invasion and metastasis [11]. Meanwhile, FBXW7 can 
regulate the melanoma metastasis through activating the MAPK/ERK signaling [12]. 
The microphthalmia-associated transcription factor (MITF) is a key regulator of 
melanocyte development, differentiation, and melanoma biology [13, 14]. FBXW7 is 
recognized as a regulator of MITF via post-transcriptional mechanisms [15].
2.2 SKP2
S-phase kinase-associated protein 2 (Skp2), also be called FBXL1 or p45, is 
also a member of the F-box proteins [16]. Skp2 is characterized as a cancer-related 
protein. In general, in primary melanoma and metastasis melanoma, SKP2 is 
significantly up-regulated, which is related to the prognosis, as it is reported that 
nuclear Skp2 expression is strongly associated with a lower survival rate during 
melanoma [17, 18]. In tumorigenesis, Skp2 stabilizes the MTH1 expression via K63-
linked polyubiquitination, and then promotes melanoma cell survival by protecting 
DNA integrity upon pharmacologic oxidative stress [19]. Meanwhile, skp2 has a 
direct interaction with melanoma antigen-A11 (MAGE-A11), which may boost 
Skp2-mediated degradation of cyclin A [20].
2.3 HACE1
HECT domain and ankyrin repeat-containing E3 ubiquitin protein ligase 1 
(HACE1), has been showed to act as a tumour suppressor gene in various kinds of 
cancers [21]. There is a significantly downregulation of HACE1 in colorectal cancer 
(CRC), and the decreased expression is highly associated with poor clinical features of 
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patients. HACE1 inhibits YAY1 signaling and then can reverse EMT in CRC [22]. Loss 
of HACE1 activates RAC-family GTPases to mediate oxidative stress that increases 
genotoxic cellular ROS generation and then results in lung tumor formation [23]. Even 
though HACE1 behaves as an anti-oncogene in most reports, its function in melanoma 
may be cell-specific tumorigenesis. HACE1 plays a pro-oncogenic role in melanoma by 
regulating fibronectin (FN) secretion and K27 ubiquitination of FN [24].
2.4 ITCH
ITCH, a member of HECT-type ubiquitin E3 ligases, plays a significantly role 
in regulating cell growth and apoptosis [25]. In melanoma, ITCH mediates BRAF 
polyubiquitination through the K27-linkage result in sustained activation of BRAF/
ΜEK/ERK signaling, which leads to the survival of melanoma cells [26]. Moreover, 
ITCH can be regulated by microRNAs (miRNAs), such as miR-10b and miR-520f, 
and then be involved in the melanoma proliferation and metastasis [27, 28].
2.5 UBE2C
UBE2C belonging to the E2 family is operating in combination with the anaphase-
promoting complex/cyclosome (APC/C) E3 ligase. It regulates the cell cycle through 
mitosis via destructing mitotic cyclin B1 [29]. Silence of UBE2C induces G2/M phase 
arrest of melanoma cells by suppressing both the level and the activity of M- phase-
promoting factor (MPF), a complex consisting of CDK1 and cyclin B1 [30, 31].
2.6 UBE2S
Ubiquitin-conjugating enzyme E2S (UBE2S) belongs to the E2 protein family, 
and is involved in development of various cancers. Recently, it has been shown 
that UBE2S plays a vital role in regulating DNA damage-induced transcriptional 
silencing, by catalyzing Lys11-linkage ubiquitination [32]. Another recent research 
showed that UBE2S is overexpressed in melanoma, and the expression was signifi-
cantly related to the cancer staging and grading, with a higher magnitude found for 
tumor node metastasis staging T4. Moreover, silence of UBE2S may cause mela-
noma cell proliferation inhibition via inducing cell cycle G1/S phase arrest, and cell 
apoptosis. In BALB/C nude mice, shUBE2S can suppress tumor growth and inhibit 
epithelial-mesenchymal transition (EMT) [33].
2.7 MKRN2
Makorin ring finger protein 2 (MKRN2) is known as a novel ubiquitin E3 ligase, 
and is capable of targeting the p65 subunit of NF-κB [34]. Research indicates that 
there is a greater expression of MKRN2 in melanoma cell lines relative to normal 
skin cell lines. The silence of MKRN2 can inhibit melanoma cell growth in a P53-
dependent manner. Moreover, MKRN2 can interact with ubiquitylated P53 [35]. This 
study suggests that MKRN2 may be a potential therapeutic target for melanoma.
2.8 Ub-like proteins
There are also several ubiquitin-like proteins (UBLs) in addition to Ub, such 
as NEDD8 (neural precursor cell expressed, developmentally down-regulated8), 
SUMO (small ubiquitin-like modifiers), and ISG15 (interferon-stimulated gene 15).
NEDD8 mediates the stabilization of various proteins, and plays a significant 
role in the incidence and development of malignant melanoma. NEDD8 is a 
Ubiquitin - Proteasome Pathway
56
by regulation important genes or signaling pathways. However, the ubiquitination 
process can be reversed by the deubiquitinating enzymes (DUBs) via cleaving 
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in a wide range of cellular signaling pathways, such as the apoptosis, cell cycle, 
autophagy, DNA damage, inflammation signaling, and protein downregulation [6]. 
Up to date, there were reported over 600 E3 ubiquitin ligase and 100 DUBs [7].
A significant number of studies have confirmed that ubiquitination and de-
ubiquitination play a critical role in melanoma pathogenesis, and have indicated 
that the key molecular goal of the mechanism may be the therapeutic strategies 
for the treatment of melanoma. Here, we provide a conclusive introduction about 
protein ubiquitin modification in relative genes, signaling pathways, and in immune 
system in melanoma pathogenesis, which concludes the latest DUB studies in 
melanoma. Besides, we summarize potential therapeutic targets of ubiquitination 
and de-ubiquitination in melanoma.
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to be 8.1% FBXW7 in melanoma through exome sequencing in a cohort of 103 melano-
mas. A potential therapeutic approach for melanoma could be the loss and mutation of 
FBXW7 in melanoma contributing to prolonged activation of NOTCH and targeting 
NOTCH signaling [10]. FBXW7 deficiency can also unleash heat shock factor 1 (HSF1) 
and then result in melanoma invasion and metastasis [11]. Meanwhile, FBXW7 can 
regulate the melanoma metastasis through activating the MAPK/ERK signaling [12]. 
The microphthalmia-associated transcription factor (MITF) is a key regulator of 
melanocyte development, differentiation, and melanoma biology [13, 14]. FBXW7 is 
recognized as a regulator of MITF via post-transcriptional mechanisms [15].
2.2 SKP2
S-phase kinase-associated protein 2 (Skp2), also be called FBXL1 or p45, is 
also a member of the F-box proteins [16]. Skp2 is characterized as a cancer-related 
protein. In general, in primary melanoma and metastasis melanoma, SKP2 is 
significantly up-regulated, which is related to the prognosis, as it is reported that 
nuclear Skp2 expression is strongly associated with a lower survival rate during 
melanoma [17, 18]. In tumorigenesis, Skp2 stabilizes the MTH1 expression via K63-
linked polyubiquitination, and then promotes melanoma cell survival by protecting 
DNA integrity upon pharmacologic oxidative stress [19]. Meanwhile, skp2 has a 
direct interaction with melanoma antigen-A11 (MAGE-A11), which may boost 
Skp2-mediated degradation of cyclin A [20].
2.3 HACE1
HECT domain and ankyrin repeat-containing E3 ubiquitin protein ligase 1 
(HACE1), has been showed to act as a tumour suppressor gene in various kinds of 
cancers [21]. There is a significantly downregulation of HACE1 in colorectal cancer 
(CRC), and the decreased expression is highly associated with poor clinical features of 
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of HACE1 activates RAC-family GTPases to mediate oxidative stress that increases 
genotoxic cellular ROS generation and then results in lung tumor formation [23]. Even 
though HACE1 behaves as an anti-oncogene in most reports, its function in melanoma 
may be cell-specific tumorigenesis. HACE1 plays a pro-oncogenic role in melanoma by 
regulating fibronectin (FN) secretion and K27 ubiquitination of FN [24].
2.4 ITCH
ITCH, a member of HECT-type ubiquitin E3 ligases, plays a significantly role 
in regulating cell growth and apoptosis [25]. In melanoma, ITCH mediates BRAF 
polyubiquitination through the K27-linkage result in sustained activation of BRAF/
ΜEK/ERK signaling, which leads to the survival of melanoma cells [26]. Moreover, 
ITCH can be regulated by microRNAs (miRNAs), such as miR-10b and miR-520f, 
and then be involved in the melanoma proliferation and metastasis [27, 28].
2.5 UBE2C
UBE2C belonging to the E2 family is operating in combination with the anaphase-
promoting complex/cyclosome (APC/C) E3 ligase. It regulates the cell cycle through 
mitosis via destructing mitotic cyclin B1 [29]. Silence of UBE2C induces G2/M phase 
arrest of melanoma cells by suppressing both the level and the activity of M- phase-
promoting factor (MPF), a complex consisting of CDK1 and cyclin B1 [30, 31].
2.6 UBE2S
Ubiquitin-conjugating enzyme E2S (UBE2S) belongs to the E2 protein family, 
and is involved in development of various cancers. Recently, it has been shown 
that UBE2S plays a vital role in regulating DNA damage-induced transcriptional 
silencing, by catalyzing Lys11-linkage ubiquitination [32]. Another recent research 
showed that UBE2S is overexpressed in melanoma, and the expression was signifi-
cantly related to the cancer staging and grading, with a higher magnitude found for 
tumor node metastasis staging T4. Moreover, silence of UBE2S may cause mela-
noma cell proliferation inhibition via inducing cell cycle G1/S phase arrest, and cell 
apoptosis. In BALB/C nude mice, shUBE2S can suppress tumor growth and inhibit 
epithelial-mesenchymal transition (EMT) [33].
2.7 MKRN2
Makorin ring finger protein 2 (MKRN2) is known as a novel ubiquitin E3 ligase, 
and is capable of targeting the p65 subunit of NF-κB [34]. Research indicates that 
there is a greater expression of MKRN2 in melanoma cell lines relative to normal 
skin cell lines. The silence of MKRN2 can inhibit melanoma cell growth in a P53-
dependent manner. Moreover, MKRN2 can interact with ubiquitylated P53 [35]. This 
study suggests that MKRN2 may be a potential therapeutic target for melanoma.
2.8 Ub-like proteins
There are also several ubiquitin-like proteins (UBLs) in addition to Ub, such 
as NEDD8 (neural precursor cell expressed, developmentally down-regulated8), 
SUMO (small ubiquitin-like modifiers), and ISG15 (interferon-stimulated gene 15).
NEDD8 mediates the stabilization of various proteins, and plays a significant 
role in the incidence and development of malignant melanoma. NEDD8 is a 
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ubiquitin-like protein composed of 81 amino acids, with around 60% of the sequence 
that is the same as ubiquitin [36]. The covalent binding of NEDD8 to substrates is 
known as neddylation. Similar to the ubiquitination, an enzyme cascade is needed 
for this progression. Neddylation is involved in protein ubiquitination, and is closely 
associated with the degradation of certain proteins in the cell cycle and apoptosis-
related factors [37]. Cullin is one of the most researched neddylation substrates [38]. 
Besides, studies have also investigated that NEDD8 substrates are diverse. Some 
proteins can be modified by NEDD8, including p53 [39], MDM2 [40], and VHL [41]. 
UBA3, as the subunit of NEDD8-activating enzyme, plays a critical role in the linkage 
of NEDD8 with cullin proteins. Previous studies have shown that in highly prolifera-
tive cell lines, NEDD8 conjugation is up-regulated and increased in melanoma cell 
lines [42]. After knockdown of UBA3, the proliferation of M14 melanoma cells was 
suppressed both in vitro and in vivo. Hence, interference of the neddylation might 
offer a hopeful method for melanoma therapy [43].
SUMO has been described to alter protein interactions rather than directly involv-
ing in protein degradation [44]. Sumoylation involves a 3-step pathway analogous 
to the ubiquitination pathway. Dysregulation of sumoylation has been implicated 
in multiple cancers, including melanomas. Ubc9, the single SUMO E2 conjugating 
enzyme, is overexpressed in advanced-stage melanomas where it protects melanoma 
cells from chemotherapy-induced apoptosis [45]. Moreover, SUMOylation-defective 
MITF germline mutation may be more susceptible to melanoma [46].
ISG15, a ubiquitin-like modifier, is implicated in both tumor oncogenic and sup-
pressive programs [47]. It is activated by a three steps enzymatic cascade consisting 
of a specific E1-activating enzyme (UBE1L), E2 conjugating enzyme (typically 
UBCH8) and E3 ligase (commonly HERC5A), which promotes ISG15 transfer to 
protein substrates [48]. Previous study shows that ISG15 can be removed from its 
target proteins by USP18 and then the effects of ISGylation was reversed [49, 50]. A 
study identifies PTEN as a new substrate of the ISGylation post-translational modi-
fication pathway and USP18 can regulate PTEN stability. Inhibition of ISGylation 
may be a therapeutically relevant in melanoma [47].
2.9 Deubiquitinating enzymes (DUBs)
To date, several DUBs have confirmed to be consistent with melanoma tumori-
genesis and metastasis. USP54 is overexpressed in intestinal stem cells, and is 
defined to promote cancer progression and regulate embryonic development and 
normal growth of adult mice. USP54 upregulates in melanoma, the loss of USP54 
is dispensable for metastasis of melanoma cells [51]. An IFN stimulated to regulate 
type-I IFN signaling in the anti-viral immune response has been reported to be 
USP18 [52]. It is also reported that IFN-γ can stimulate USP18 protein expression 
in melanoma cells. Through IFN-γ-induced USP18 expression in melanoma cells 
and -regulated CTL CD8 + immune cell activity in the tumor microenvironment, 
endogenous IFN-γ signaling influences melanoma tumorigenesis [53]. In 2014, 
Harish Potu et al. reported that USP5 mediates the change in ubiquitinylated protein 
content and unanchors Ub chains in BRAF mutant cells treated with vemurafenib. 
BRAF can activate USP5, contributing by suppressing p53 and FAS induction, to 
inhibit cell cycle checkpoint regulation and apoptosis [54]. In 2018, USP4 upregula-
tion in melanoma, especially in metastatic melanoma, was discovered by Weinan 
Guo et al. The archive of TCGA skin cutaneous melanoma (SKCM) confirms this 
finding. USP4 can protect melanoma cells from cisplatin-induced apoptosis in a 
p53-dependent manner. Moreover, USP4 up-regulation plays an important role in 
melanoma invasion and migration by promoting EMT [55]. The USP15 knockdown 
lowers the expression of MDM2 in melanoma cells, and then leads to upregulation 
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of p53 and MDM2 target genes p21 and Puma. Moreover, Usp15−/− melanoma mice 
models have an increased frequency of CD8+ effector T cells tumor-infiltrating [56].
Ubiquitin specific peptidase 9, X-linked (Usp9x), a member of the USP family, is 
upregulated in many cancers, which has a positive and negative impact on tumori-
genicity depending on the various forms of cancer [57–59]. A study shows that the 
growth of melanoma cells can be inhibited by Usp9x loss. The Ets-1 proteasomal, 
abased site-specific de-ubiquitination, is inhibited by Usp9x, which leads to Ets-1 
aggregation and increases tumorigenicity of melanoma [60]. Moreover, in malignant 
melanoma, about 15–20% of NRAS mutations have been identified [61]. Harish Potu 
et al. also revealed that inhibition of BRAF and/or MEK kinase pathway can increase 
Ets-1 expression. The increased Ets-1 expression upregulates NRAS levels by 
activating the NRAS promoter. In all, Usp9x plays a critical role in Ets-1 regulation 
and melanoma tumorigenicity through mediating NRAS transcription [60]. UCHL1 
(ubiquitin C-terminal hydrolase 1) belongs to the ubiquitin carboxy terminal hydro-
lase family of DUBs. It catalyzes hydrolysis of C-terminal ubiquitin esters to regulate 
protein degradation [62]. Eun Young Seo et al. have investigated that UCHL1 influ-
ences melanogenesis by regulating stability of MITF in human melanocytes, which 
provides a framework for the further researches to evaluate potent therapeutic 
approaches for melanoma and other dyspigmentation disorders [63]. BAP1 (BRCA1-
associated protein-1) belongs to the UCH subfamily of DUBs, and is known as a 
tumor suppressor gene [64, 65]. BAP1 mutations were first identified in a small 
number of lung and breast cancer samples, and have recently been described as 
leading to the pathogenesis of melanoma [66, 67]. The germline mutations in BAP1 
are more prone to malignant melanoma [68]. In 2010, a study reported that 84% of 
inactivating somatic BAP1 mutations were identified in metastasizing uveal melano-
mas, including 15 premature protein termination mutations, and six affecting their 
ubiquitin UCH domains, which were associated with a decrease in BAP1 mRNA level 
[69]. However, in cutaneous melanoma, the germline mutations in BAP1 were less 
than 1% and its effect was unknown [70]. A recent study reported that low BAP1 
mRNA predicted a better OS in older than 50 years cutaneous melanoma patients 
after adjusting for ulceration or Breslow depth [71]. The different function of BAP1 
in cutaneous melanoma and uveal melanoma needs to be studied further.
3.  Ubiquitination in melanoma immunological microenvironment 
modulation
Tumor microenvironment (TME) is consisted of cancer cells, cancer-associated 
fibroblasts, immune cells, and stromal cells. TME emerges as a key mechanism that 
mediate tumor progression [72]. A previous study reported that protein ubiquity-
lation plays a critical role in modulating immune responses and TME [73].
The Cbl proteins are a family of ubiquitin ligases (E3s). Cbl-b, a member of the 
family, functions as a negative regulator that regulates CD8 T cells costimulatory 
pathway and natural killer cell function [74]. In recent years, Cbl-b prone to be one 
of the hotspot targets of tumor immunotherapy because Cbl-b deletion can cause 
spontaneous or induced autoimmune call, and Cbl-b overexpression can result in the 
tumor immune tolerance in infiltrated lymphocytes in TME [75]. A study shows that 
NK cells knocking down of Cbl-b, or targeting its E3 catalytic activity, inhibit the pro-
gression of melanomas and distant melanoma metastases. Moreover, compared with 
WT T cells, Cbl-b−/− CD8+ and CD4+ T cell proliferation are highly suppressed by 
a recombinant PD-L1 Ig, and IFN-γ production is significantly less suppressed. Cbl-b 
deficiency in mice seems to cause a functional resistance of NK cells and T cells to 
PD-L1/PD-1-mediated immune suppression [76]. Adoptive cell therapy (ACT) with 
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ubiquitin-like protein composed of 81 amino acids, with around 60% of the sequence 
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for this progression. Neddylation is involved in protein ubiquitination, and is closely 
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proteins can be modified by NEDD8, including p53 [39], MDM2 [40], and VHL [41]. 
UBA3, as the subunit of NEDD8-activating enzyme, plays a critical role in the linkage 
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tive cell lines, NEDD8 conjugation is up-regulated and increased in melanoma cell 
lines [42]. After knockdown of UBA3, the proliferation of M14 melanoma cells was 
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in multiple cancers, including melanomas. Ubc9, the single SUMO E2 conjugating 
enzyme, is overexpressed in advanced-stage melanomas where it protects melanoma 
cells from chemotherapy-induced apoptosis [45]. Moreover, SUMOylation-defective 
MITF germline mutation may be more susceptible to melanoma [46].
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pressive programs [47]. It is activated by a three steps enzymatic cascade consisting 
of a specific E1-activating enzyme (UBE1L), E2 conjugating enzyme (typically 
UBCH8) and E3 ligase (commonly HERC5A), which promotes ISG15 transfer to 
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target proteins by USP18 and then the effects of ISGylation was reversed [49, 50]. A 
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fication pathway and USP18 can regulate PTEN stability. Inhibition of ISGylation 
may be a therapeutically relevant in melanoma [47].
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To date, several DUBs have confirmed to be consistent with melanoma tumori-
genesis and metastasis. USP54 is overexpressed in intestinal stem cells, and is 
defined to promote cancer progression and regulate embryonic development and 
normal growth of adult mice. USP54 upregulates in melanoma, the loss of USP54 
is dispensable for metastasis of melanoma cells [51]. An IFN stimulated to regulate 
type-I IFN signaling in the anti-viral immune response has been reported to be 
USP18 [52]. It is also reported that IFN-γ can stimulate USP18 protein expression 
in melanoma cells. Through IFN-γ-induced USP18 expression in melanoma cells 
and -regulated CTL CD8 + immune cell activity in the tumor microenvironment, 
endogenous IFN-γ signaling influences melanoma tumorigenesis [53]. In 2014, 
Harish Potu et al. reported that USP5 mediates the change in ubiquitinylated protein 
content and unanchors Ub chains in BRAF mutant cells treated with vemurafenib. 
BRAF can activate USP5, contributing by suppressing p53 and FAS induction, to 
inhibit cell cycle checkpoint regulation and apoptosis [54]. In 2018, USP4 upregula-
tion in melanoma, especially in metastatic melanoma, was discovered by Weinan 
Guo et al. The archive of TCGA skin cutaneous melanoma (SKCM) confirms this 
finding. USP4 can protect melanoma cells from cisplatin-induced apoptosis in a 
p53-dependent manner. Moreover, USP4 up-regulation plays an important role in 
melanoma invasion and migration by promoting EMT [55]. The USP15 knockdown 
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of p53 and MDM2 target genes p21 and Puma. Moreover, Usp15−/− melanoma mice 
models have an increased frequency of CD8+ effector T cells tumor-infiltrating [56].
Ubiquitin specific peptidase 9, X-linked (Usp9x), a member of the USP family, is 
upregulated in many cancers, which has a positive and negative impact on tumori-
genicity depending on the various forms of cancer [57–59]. A study shows that the 
growth of melanoma cells can be inhibited by Usp9x loss. The Ets-1 proteasomal, 
abased site-specific de-ubiquitination, is inhibited by Usp9x, which leads to Ets-1 
aggregation and increases tumorigenicity of melanoma [60]. Moreover, in malignant 
melanoma, about 15–20% of NRAS mutations have been identified [61]. Harish Potu 
et al. also revealed that inhibition of BRAF and/or MEK kinase pathway can increase 
Ets-1 expression. The increased Ets-1 expression upregulates NRAS levels by 
activating the NRAS promoter. In all, Usp9x plays a critical role in Ets-1 regulation 
and melanoma tumorigenicity through mediating NRAS transcription [60]. UCHL1 
(ubiquitin C-terminal hydrolase 1) belongs to the ubiquitin carboxy terminal hydro-
lase family of DUBs. It catalyzes hydrolysis of C-terminal ubiquitin esters to regulate 
protein degradation [62]. Eun Young Seo et al. have investigated that UCHL1 influ-
ences melanogenesis by regulating stability of MITF in human melanocytes, which 
provides a framework for the further researches to evaluate potent therapeutic 
approaches for melanoma and other dyspigmentation disorders [63]. BAP1 (BRCA1-
associated protein-1) belongs to the UCH subfamily of DUBs, and is known as a 
tumor suppressor gene [64, 65]. BAP1 mutations were first identified in a small 
number of lung and breast cancer samples, and have recently been described as 
leading to the pathogenesis of melanoma [66, 67]. The germline mutations in BAP1 
are more prone to malignant melanoma [68]. In 2010, a study reported that 84% of 
inactivating somatic BAP1 mutations were identified in metastasizing uveal melano-
mas, including 15 premature protein termination mutations, and six affecting their 
ubiquitin UCH domains, which were associated with a decrease in BAP1 mRNA level 
[69]. However, in cutaneous melanoma, the germline mutations in BAP1 were less 
than 1% and its effect was unknown [70]. A recent study reported that low BAP1 
mRNA predicted a better OS in older than 50 years cutaneous melanoma patients 
after adjusting for ulceration or Breslow depth [71]. The different function of BAP1 
in cutaneous melanoma and uveal melanoma needs to be studied further.
3.  Ubiquitination in melanoma immunological microenvironment 
modulation
Tumor microenvironment (TME) is consisted of cancer cells, cancer-associated 
fibroblasts, immune cells, and stromal cells. TME emerges as a key mechanism that 
mediate tumor progression [72]. A previous study reported that protein ubiquity-
lation plays a critical role in modulating immune responses and TME [73].
The Cbl proteins are a family of ubiquitin ligases (E3s). Cbl-b, a member of the 
family, functions as a negative regulator that regulates CD8 T cells costimulatory 
pathway and natural killer cell function [74]. In recent years, Cbl-b prone to be one 
of the hotspot targets of tumor immunotherapy because Cbl-b deletion can cause 
spontaneous or induced autoimmune call, and Cbl-b overexpression can result in the 
tumor immune tolerance in infiltrated lymphocytes in TME [75]. A study shows that 
NK cells knocking down of Cbl-b, or targeting its E3 catalytic activity, inhibit the pro-
gression of melanomas and distant melanoma metastases. Moreover, compared with 
WT T cells, Cbl-b−/− CD8+ and CD4+ T cell proliferation are highly suppressed by 
a recombinant PD-L1 Ig, and IFN-γ production is significantly less suppressed. Cbl-b 
deficiency in mice seems to cause a functional resistance of NK cells and T cells to 
PD-L1/PD-1-mediated immune suppression [76]. Adoptive cell therapy (ACT) with 
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autologous T cells can enforce the immune-mediated tumor cell killing, and show a 
promising result in various types of cancer treatments [77, 78]. However, the thera-
peutic efficacy of ACT is still limited because of the tumor-bearing host immune-eva-
sion mechanisms, such as the secretion of transforming growth factor beta (TGFβ) or 
accumulation of Treg cells, both of which severely dampen the activation, expansion, 
and tumor homing of CD8+ T cells [79]. Another study reveals that silencing cbl-b 
reduces TGFβ sensitivity in vitro and enhances anti-tumor effects in vivo. Adoptive 
transfer of Cbl-b-silenced CD8+ T lymphocytes augments tumor vaccine to suppress 
tumor growth and prolong the survival in a B16F10 melanoma model [80].
FBXO38 belongs to the SCF family of E3 ubiquitin ligase of PD-1, and medi-
ates Lys48-linked poly-ubiquitination and substrate proteasome degradation [81]. 
Previous research investigates that FBXO38 mediates PD-1 ubiquitination and 
maintains the anti-tumour activity of T cells in melanoma cells [82]. It offers an 
alternative method to block the PD-1 and highlights the clinical potential of the 
regulation of anti-tumour immunity through ubiquitination of FBXO38.
SIAH2, potent E3 RING finger ubiquitin ligases, mediates the cell cycle, apopto-
sis, and DNA repair regulation through targeting subsequent related proteins [83]. 
Previous study finds that hypoxia activates Siah2 E3 ligase, and then enhances the 
Warburg effect and pro-tumor immune response via degrading nuclear respiratory 
factor 1 (NRF1) through ubiquitination on lysine 230 [84]. A recent study reveals 
the effect and mechanism of Siah2 on the T cells and immune therapy. As is shown 
in this article, in the one way, Siah2-deficient mice suppress melanoma growth, 
increase the infiltration of T effector cells, and decrease number of FOXP3+ 
Treg cells. Inhibition of Siah2−/− melanoma cell proliferation is p27 dependent. 
Moreover, Siah2−/− BM-transplanted mice inhibit the melanoma growth, which 
may be a clinical potential of new adoptive cell therapy. On the other hand, loss of 
Siah2 exhibits synergy with anti-PD1 therapy in melanoma.
In addition to Ub, lots of Ub-related proteins display an immune regulation func-
tion in melanoma. A family of Toll-like receptors (TLRs) involves in the recognition 
of microbial components and regulates innate immune responses [85, 86]. TNFAIP3 
(TNF-α induced protein 3), an ubiquitin-editing enzyme, can negatively regulate 
the TLRs via function as an ubiquitin-editing molecule [87]. E3 ligase NEDD4 medi-
ates the function of immune regulation. Silence of NEDD4 inhibits FOXP3+ Treg 
cells through mediating GITR degradation, and then contributes to melanoma pro-
gression [88]. A previous study finds that USP15 was highly expressed in immune 
cells through analysis of the BioGPS database. In naïve CD4+ T cells, loss of USP15 
stimulates the TCR + CD28 to produce cytokines, such as interleukin 2 (IL-2) and 
interferon-γ (IFN-γ). Moreover, USP15 inhibits the naïve CD4+ T cell activation and 
suppresses TH1 differentiation. MDM2, which is recognized as substrate protein of 
USP15, targets a T cell transcription factor, NFATc2, and negatively regulates T cell 
activation, which was independent of p53. Later, the author testifies the function of 
USP15 in B16F10 melanoma models. This study investigated that USP15−/− mice 
increase IFN-γ + CD4+ T cell infiltration to the tumors, and deficiency of USP15 
reduces melanoma tumors size and tumor-induced lethality [89].
4. Ubiquitination of key transcription factors in melanoma
4.1 Ubiquitination of p53
The tumor suppressor protein p53 is a transcription factor that can affect cell 
proliferation by regulating the expression of its target protein [90]. P53 interacts with 
E3 ligase MDM2 in the nucleus, and is transferred from the nucleus to the cytoplasm 
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following ubiquitin, resulting in proteasome degrading [91]. In 2003, Leonard Girnita 
et al. discovered that inhibition of p53 leads to ubiquitination and down-regulation 
of the IGF-1R in human malignant melanoma cells. This impact was independent of 
the p53 status (wild type or mutated) but can be rescued by coinhibition of MDM2. 
Mdm2 serves as a ligase in ubiquitination of the IGF-1R [92]. Unlike other solid 
tumors, malignant melanomas retain the expression of wild-type p53 and typically 
lack p53 mutations [93, 94]. Adil Anwar et al. reveal that the wild-type p53 is the 
target for the ubiquitin-proteasomal pathway (UPP) degradation. The residues 
serine 15 and serine 20 are also essential for the binding of MDM2, which control 
p53 destruction via UPP pathway. In this article, p53 stabilization mediated by UPP 
inhibitors is independent of phosphorylation at residues serine 15 and serine 20 of p53 
in melanoma cells [95]. MKRN2 is recognized as a novel ubiquitin E3 ligase target-
ing the p65 subunit of NF-κB to negatively regulate inflammatory responses [96]. A 
recent study indicates that the MKRN2 expression increases in the human melanoma 
cell lines, and silence of this gene leads to the suppression of melanoma proliferation 
by upregulation of p53. To investigate the mechanism of this effect, authors take 
co-immunoprecipitation and glutathione S-transferase pulldown assays to confirm 
the interaction of MKRN2 with p53 and take in vitro ubiquitination assays to study the 
ubiquitination of p53 by MKRN2. The result shows that MKRN2 interacts with p53, 
and ubiquitylates p53, leading to the influence of melanoma cell proliferation [97].
4.2 Ubiquitination of c-Myc
The transcription factor c-Myc plays an important role in cell proliferation and 
differentiation, cell cycle, metabolism, and apoptosis [98]. C-Myc is a protein that 
is very unstable and vulnerable to degradation in a proteasome-dependent manner. 
Research has identified the E3 ligase of c-Myc in melanoma. Also, c-Myc can be 
specifically bound by the E3 ligase SKP2 [99].
5.  Melanoma therapeutic strategy via targeting the  
ubiquitin-proteasome system (UPS)
In protein degradation and melanoma pathogenesis, the UPS plays a crucial role, 
as shown above. The pathogenesis of malignant melanoma leads to genetic changes, 
irregular expression, or dysfunction [100]. Hence, targeting the UPS may be a poten-
tial therapeutic strategy for melanoma. Currently, many small molecule inhibitors 
targeting different components of the UPS, including the proteasome, E3 ligases, E1 
enzymes, E2 enzymes, ubiquitin-like proteins, and DUBs, have been developed [101].
Bortezomib is the first proteasome inhibitor approved by FDA, which was 
originally used for multiple myeloma treatment [102]. However, due to the clini-
cal safety, the study in other cancer researches, including melanoma, has been 
discontinued. Compared to the proteasome inhibitor bortezomib, drugs targeting 
a particular E3 ubiquitin ligase are expected to have better selectivity with less 
associated toxicity relative to the proteasome inhibitor bortezomib [103]. MDM2 is 
an E3 ubiquitin ligase with the ability to regulate tumor suppressor p53 and poten-
tiate Notch signaling by degrading Numb [104, 105]. Nutlin-3a, an imidazoline 
compound, has been generally known as a MDM2 inhibitor. Nutlin-3a can suppress 
melanoma and other cancers, including retinoblastoma, leukemia, and neuro-
blastoma [106]. Meanwhile, WIP1 inhibitor (WIP1i), GSK2830371, can enhance 
p53-mediated tumor suppression by MDM2–p53 inhibitors, nutlin-3, RG7388, and 
HDM201 in cutaneous melanoma [107]. Therefore, more findings from the phase I 
clinical trials are needed to evaluate whether there exist any significant side effects.
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Besides, Siah2 is known as a RING finger E3 ubiquitin ligase. Inhibition of Siah2 
activity using a peptide is reported to be able to weaken its effect on hypoxia, effec-
tively leading to melanoma metastasis inhibition, while suppression of Siah2 activi-
ties prevents the tumorigenicity of melanoma by disrupting Ras/MAPK signaling 
pathways [108]. Menadione (MEN), also known as vitamin K3, is a quinone used for 
cancer chemotherapeutic agents. A recent research identifies MEN as a novel Siah2 
inhibitor, which attenuates hypoxia and MAPK signaling, and blocks melanoma 
tumorigenesis [109]. This study revealed that targeting Siah2 by MEN may be a new 
therapeutic strategy in melanoma treatment.
Cullin-RING ligases (CRLs) are a subgroup of the E3 ligases, and play an 
important role in the degradation of oncology relative proteins. It is activated by the 
neddylation pathway, such as NEDD8 conjugation [110]. The NEDD8-activating 
enzyme (NAE) is a critical regulator of the neddylation pathway [111]. Pevonedistat 
(TAK-924/MLN4924) is reported as a first-in-class, small-molecule inhibitor 
of NAE. Previous preclinical studies reveal that Pevonedistat is associated with 
tumor growth inhibition of a range of cell lines and primary human cancer cells 
derived from solid tumors, including malignant melanoma [112, 113]. A phase I 
study of Pevonedistat about patients with advanced solid tumors was undertaken. 
The results find that, in nine melanoma patients, one achieved a partial response 
(PR) while another 8 patients achieved stable disease (SD) lasting 6 months [114]. 
In addition, another phase I study (NCT01011530) was conducted to assess the 
safety, pharmacokinetics (PK), pharmacodynamic (PD), and antitumor activ-
ity of Pevonedistat in metastatic melanoma patients. The maximum tolerated 
dose (MTD) is reported as 209 mg/m2. Most patients have a well toleration to 
Pevonedistat, only 16% patients experience drug-related serious adverse event 
(SAE), such as drug-related grade 4 acute renal failure, grade 3 myocarditis, and 
grade 3 small intestinal obstruction. At the end of the research, the research results 
show that one patient achieves a partial response, and stable disease is reported in 
15 patients with lasting for 6.5 months or more in 4 patients [115].
As mentioned, ubiquitination removes the process of Ub and plays an important 
role in genomic instability regulation and tumorigenesis processes. Thus, several DUB 
inhibitors have been developed and identified as potential anticancer agents [116]. G9 
is described as small molecule Usp9x inhibitor suppressing Usp9x activity [117]. G9 can 
inhibit NRAS mutant melanoma growth by decreasing Ets-1 protein content and NRAS 
expression. G9 also has a synergistic effect with PD0325901, a MEK inhibitor [60]. For 
specific Usp9x inhibitors such as G9 targeting two other DUBs, namely Usp24 and Usp5, 
more drug testing is needed [117, 118]. In addition, Spautin-1 is recognized a potent 
USP10/13 deubiquitinating activity antagonist. A recent study revealed that Spautin-1 
plays an anti-tumor role in melanoma suppression via DNA damage by increasing ROS 
levels and has a synergistic effect with Cisplatin [119]. Targeting USP10/13 by Spautin-1 
may be a new therapeutic strategy in melanoma patient treatment.
6. Conclusions
Melanoma has a low 5-year survival rate due to being susceptible to invasion and 
metastasis. Recently, growing evidence identified the critical role of ubiquitina-
tion and de-ubiquitination in malignant melanoma progression, which may be the 
novel targets for cancer therapy. In this article, we make a brief conclusion that the 
misregulated expressions of the E2 ubiquitin conjugating-enzymes, E3 ubiquitin 
ligases, and DUBs lead to aberrant oncogenic signaling in malignant melanoma 
(Figure 1). The ubiquitination plays a vital role in melanoma not only through ubiq-
uitination of key transcription factors or key cell signaling but also immunological 
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microenvironment modulation. We also make a conclusion of the target UPS 
components, the corresponding therapeutic drugs or potential therapeutic targets, 
and the molecular mechanism (Table 1). Understanding of ubiquitination and 
Figure 1. 
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de-ubiquitination mechanisms and their regulation in melanoma will help us to 
better understand the pathogenesis of this cancer, and develop effective therapeu-
tic approaches, which lets us see a promising future for the application of these 
advancements owing to the prosperity and success of drugs targeting ubiquitination 
and de-ubiquitination in melanoma.
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Abstract
HECT E3 ubiquitin ligases selectively recognize, bind, and ubiquitylate their 
substrate proteins to target them for 26S proteasomal degradation. There is increas-
ing evidence that HECT E3 ubiquitin ligase dysfunction due to misfolding and/or 
the gene encoding the protein being mutated is responsible for the development of 
different diseases. Apart from the more prominent and well-characterized E6AP 
and members of the NEDD4 family, new studies have begun to reveal how other 
members of the HECT E3 ubiquitin ligase family function as well as their links 
to disease and developmental disorders. This chapter provides a comprehensive 
discussion on the more mysterious members of the HECT E3 ubiquitin ligase 
family and how they control intracellular processes. Specifically, AREL1, HACE1, 
HECTD1, HECTD4, G2E3, and TRIP12 will be examined as these enzymes have 
recently been identified as contributors to disease development.
Keywords: apoptosis, AREL1, cancer, HECT E3 ubiquitin ligase, G2E3, HACE1, 
HECT, HECTD1, HECTD4, neurodevelopment, proteasomal degradation, TRIP12, 
ubiquitin, ubiquitylation
1. Introduction
1.1 HECT E3 ubiquitin ligase-dependent ubiquitylation
Ubiquitylation is an essential post-translational modification that regulates 
numerous intracellular processes including protein localization and trafficking, 
DNA damage response, immune system and viral response, apoptosis and prote-
olysis [1, 2]. E3 ubiquitin ligases play an important role in recognizing, binding, 
and covalently attaching ubiquitin to their various substrates to elicit a specific 
cellular response [3]. The homologous to E6AP C-terminus (HECT) E3 ubiquitin 
ligases are a unique subfamily that use a multistep pathway to selectively target 
substrate proteins for ubiquitylation [4]. HECT-dependent ubiquitylation requires 
the recruitment of an E2 ubiquitin conjugating enzyme charged with ubiquitin to 
the N-terminal lobe of the HECT domain on the E3 ligase [5, 6]. The ubiquitin cargo 
is then transferred from the E2 enzyme to the conserved catalytic cysteine within 
the C-terminal lobe of the HECT domain via a transthiolation reaction to form a 
thioester bond. The HECT E3~ubiquitin complex will then bind to a substrate and 
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covalently attach ubiquitin on to a lysine residue of the substrate protein forming 
a stable isopeptide bond between the C-terminus of ubiquitin and the ε-amine of 
the substrate lysine [3, 5, 6]. This process can be repeated numerous times to form 
different polyubiquitin chain linkages with the specific HECT E3 ubiquitin ligase 
dictating the type(s) of ubiquitin linkages that are built [2, 7].













Chain (homotypic) M1 Innate immunity [2, 9, 16]
Linear chain formation [9]
NF-κB activation [9, 16]
Signaling cascades [9, 16]
K6 DNA damage response [14]
NF-κB regulation [14]
Mitophagy [14]
K11 Cell cycle regulation [17]









K29 DNA damage response [18]
Kinase activation [19]
Protein degradation [9]




K48 Protein degradation [1, 2, 25]
K63 DNA damage response [9, 18]
NF-κB activation [9, 16]
Protein trafficking [9]
Chain (heterotypic; branched) M1/K63 NF-κB activation [16]
K11/K48 Protein degradation [26, 27]
K29/K48 Protein degradation [26]
K48/K63 Protein degradation [26]
K11/K63 Endocytosis [28]
Table 1. 
Ubiquitin conjugation determines the intracellular fate of a substrate protein.
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1.2  Ubiquitin attachment site(s) and chain type linkages determine the fate  
of a substrate protein
The destiny of a ubiquitin-tagged protein is dependent on (i) the site(s) of ubiqui-
tin attachment on the substrate, (ii) the number of ubiquitin moieties attached to the 
substrate (i.e. mono-, multi-mono-, or polyubiquitin), and (iii) the specific type(s) 
of linkages between the different ubiquitin molecules in a polyubiquitin chain (i.e. 
K48, K63, branched, etc.) [1, 2, 7]. Potential fates of a ubiquitin-tagged substrate 
include changes in cellular localization/trafficking, enhanced/inhibited protein activ-
ity, changes in protein–protein affinity/interactions, and proteolysis [1, 2, 6–8].
Differences in ubiquitin lysine linkage specificity determine the destination and/
or fate of the targeted protein in the cell (Table 1). For example, the well-estab-
lished K48-polyubiquitylation chain, heterotypic K11/K48-polyubiquitin, K29/
K48-polyubiquitin monoubiquitin tagged peptides and multiple monoubiquitin 
tagged proteins have also been found to signal for 26S proteasomal degradation [7, 8]. 
K63-polyubiquitin chains signal for protein degradation through the initiation of 
K48/K63 polyubiquitin branch formation [5] but cannot be recognized by the 26S 
proteosome [26]. To date, many different varieties of ubiquitin chain types have 
been identified, but their distinct biological functions remain unclear.
Monoubiquitylation can occur at one site or at multiple sites (multi- 
monoubiquitylation) on a substrate. Polyubiquitylation can build off of a mono-
ubiquitin attachment site with a specific lysine linkage (homotypic) or have multiple 
chains with different lysine linkages (branch) at the end of a growing ubiquitin 
chain (heterotypic). These modifications can also influence signaling pathways, 
whether it is through enhancing or inhibiting participating proteins and processes.
2.  The “other” HECT E3 ubiquitin ligases: important players in disease, 
yet poorly understood
The HECT E3 ubiquitin ligases can be categorized into three subfamilies –
NEDD4, HERC, and “other” – based on their sequence/structure similarity and 
domain architecture [4, 5]. Of the 28 HECT E3 ubiquitin ligases identified in 
humans, there are 12 “other” HECT E3 ubiquitin ligases that do not fall under the 
well-studied NEDD4 or HERC subfamilies. Each member of the “other” HECTs 
have variable N-terminal domains that are thought to be involved in protein–protein 
interactions and/or intracellular localization [4, 5]. Having prominent responsibili-
ties in cellular homeostasis would leave the impression there is ample research on the 
HECT E3 ubiquitin ligase family as a whole, however, there remain many unan-
swered questions about the biological functions and mechanisms of this important 
E3 ligase family, particularly for members of the more mysterious “other” subfamily. 
With new research and discoveries becoming available, there is mounting evidence 
that the lesser known HECT E3 ubiquitin ligases play critical roles in regulating 
intracellular processes and their dysfunction have been suggested to contribute 
to the onset of many diseases and disorders [4, 29–32]. Here we discuss the latest 
discoveries on these lesser known members of the HECT E3 ubiquitin ligases and on 
their emerging roles in developmental and neurological abnormalities, cancers, and 
embryogenesis.
2.1 AREL1, a key regulator of apoptosis and potential oncogenic drug target
Apoptosis resistant E3 ubiquitin protein ligase 1(AREL1; 823 residues) is a 
cytosolic enzyme responsible for regulating apoptosis through the inhibition of 
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substrate (i.e. mono-, multi-mono-, or polyubiquitin), and (iii) the specific type(s) 
of linkages between the different ubiquitin molecules in a polyubiquitin chain (i.e. 
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K48-polyubiquitin monoubiquitin tagged peptides and multiple monoubiquitin 
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2.  The “other” HECT E3 ubiquitin ligases: important players in disease, 
yet poorly understood
The HECT E3 ubiquitin ligases can be categorized into three subfamilies –
NEDD4, HERC, and “other” – based on their sequence/structure similarity and 
domain architecture [4, 5]. Of the 28 HECT E3 ubiquitin ligases identified in 
humans, there are 12 “other” HECT E3 ubiquitin ligases that do not fall under the 
well-studied NEDD4 or HERC subfamilies. Each member of the “other” HECTs 
have variable N-terminal domains that are thought to be involved in protein–protein 
interactions and/or intracellular localization [4, 5]. Having prominent responsibili-
ties in cellular homeostasis would leave the impression there is ample research on the 
HECT E3 ubiquitin ligase family as a whole, however, there remain many unan-
swered questions about the biological functions and mechanisms of this important 
E3 ligase family, particularly for members of the more mysterious “other” subfamily. 
With new research and discoveries becoming available, there is mounting evidence 
that the lesser known HECT E3 ubiquitin ligases play critical roles in regulating 
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to the onset of many diseases and disorders [4, 29–32]. Here we discuss the latest 
discoveries on these lesser known members of the HECT E3 ubiquitin ligases and on 
their emerging roles in developmental and neurological abnormalities, cancers, and 
embryogenesis.
2.1 AREL1, a key regulator of apoptosis and potential oncogenic drug target
Apoptosis resistant E3 ubiquitin protein ligase 1(AREL1; 823 residues) is a 
cytosolic enzyme responsible for regulating apoptosis through the inhibition of 
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proapoptotic proteins via ubiquitylation [33]. AREL1 contains two immunoglobin-like 
folds (IGF) near its N-terminus that potentially mediate substrate binding and recog-
nition (Figure 1) [35, 36]. IGF domains assemble into a sandwich-like form consisting 
of antiparallel β-strands that allow for protein–protein interactions [36, 37].
Apoptosis (aka programmed cell death) is an important and highly regulated 
biological process that occurs during early embryonic development and the immune 
response [38, 39]. Once apoptosis is initiated the cell is committed to die, which is 
mediated by a caspase cascade [40]. Intrinsic apoptosis is turned on by the release 
of intermembrane mitochondrial proteins when cells are under oxidative stress 
[38, 39, 41]. In contrast, the extrinsic apoptotic pathway is activated by extracel-
lular signaling at the cell membrane leading to the formation of the death-inducing 
signaling complex (DISC) [42–44].
AREL1 was first identified in 2013 and was immediately recognized as an 
oncogenic target due to its inhibitory role in apoptosis [33]. Identified substrates 
for AREL1 include second mitochondrial activator of caspase (SMAC), HtrA serine 
peptidase 2 (HtrA2) and septin 4 (ARTS), which are known antagonists of inhibi-
tor of apoptosis proteins (IAPs) [45]. Studies have shown that AREL1 can build 
K48 and K63 polyubiquitin chains to target substrates for proteolysis, as well as 
atypical K33 polyubiquitin chains whose biological function is still being clarified 
[35, 46]. Various IAPs, including SMAC, HtrA1, and ARTS, are released from the 
mitochondrial intermembrane into the cytosol when the cell is triggered or stressed. 
AREL1 inhibits apoptosis by ubiquitylating these IAP antagonists with K48-linked 
polyubiquitin chains targeting the IAPs for proteasomal degradation [33].
The induction of apoptosis is thought to require the release of numerous IAPs 
in the cytosol to allow different signaling pathways to initiate apoptosis depending 
on the cell’s specific stress. For example, the release of SMAC into the cytosol allows 
it to bind cellular inhibitor of apoptosis protein 1/2 (cIAP1/2), which then targets 
cIAP1/2 for proteasomal degradation to initiate apoptosis. However, when AREL1 
is present, SMAC is ubiquitylated by AREL1 and degraded, thus blocking SMAC-
cIAP1/2 complex formation enabling cell survival [33]. Many cancer therapies are 
interested in specifically turning on apoptosis through IAPs in cancer cells [47–49], 
Figure 1. 
AREL1 domain architecture. AREL1 contains a putative immunoglobulin fold domain (IGF, residues 52-158) 
and the canonical HECT domain (436-823) as annotated on UniProt and InterPro. Representative crystal 
structures of an IGF fold (human IGF FAB in yellow/orange; PDB 7FAB [34]), which is suggested to mediate 
AREL1 substrate binding and recognition, while the AREL1 HECT domain (HECTN−lobe in green, HECTC−lobe 
in blue, catalytic cysteine C790 in red; PDB 6JX5 [35]) is required for ubiquitylation activity. Structures were 
visualized using PyMol.
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thus AREL1 could prove to be a novel enzyme in drug development. Continued 
studies on AREL1’s mechanisms in controlling cell death are warranted.
2.2 HACE1, a prominent tumor suppressor with dual function
First identified in 2004, HECT domain and ankyrin repeat containing E3 
ubiquitin protein ligase 1 (HACE1; 909 residues) has been shown to take part in 
various cellular processes. For example, HACE1 is best known as a tumor sup-
pressor as altered HACE1 expression levels have been observed in various cancers 
including colorectal, breast, liver, kidney, osteosarcoma, lymphoma and gastric 
cancer [50–54]. HACE1 contains six ankyrin repeats near its N-terminus that 
likely take part in HACE1-substrate recognition and protein–protein interactions 
(Figure 2). While it is not yet fully understood how the ankyrin repeats support 
HACE1 function, ankyrin repeats in other proteins have been shown to instigate the 
development of a wide array of diseases including cancer [56]. HACE1 also supports 
Golgi membrane biogenesis during cell division by ubiquitylating members of the 
Ras-related superfamily of small G proteins [57].
Studies have shown that HACE1 expression levels are altered when comparing 
normal and cancerous tissue. Specifically, in the Wilms’ tumor cell line, HACE1 
expression was essentially nonexistent, whereas in other cancer cell lines expression 
levels were lower than average [50]. This study concluded that HACE1 was essential 
in repressing cancer development as the lowered expression levels of HACE1 were 
not mutation dependent. Low expression levels of HACE1 have also been observed in 
other cancer cell lines. For instance, it was found that the methylation of the HACE1 
promoter resulted in decreased HACE1 expression in liver cancer cells, which in turn 
decreased HACE1’s ability to ubiquitylate its identified substrates optineurin (OPTN) 
and microtubule-associated proteins 1A/1B light chain 3B protein [53]. Many differ-
ent substrates of HACE1 have been identified to date (summarized in [4]), including 
β2-adrenergic receptor (ß2AR) [58], OPTN [59], retinoic acid receptor beta (RAR-β)  
[57], tumor necrosis factor receptor-2 (TNFR2) [60], and various Ras-related 
Figure 2. 
Predicted domain architecture of HACE1. HACE1 contains six putative ankyrin-repeats (ANK; residues 
64-258) and a HECT domain (574-909) as annotated on UniProt and InterPro. Representative crystal 
structures of an ANK repeat fold (in shades of pink, PDB 4O60 [55]), which is likely involved in HACE1 
substrate binding and recognition, and a HECT domain (HECTN-lobe in green, HECTC-lobe in blue; PDB 
6JX5 [35]) found at HACE1’s C-terminus that is required of ubiquitylation activity. Structures were visualized 
using PyMol.
Ubiquitin - Proteasome Pathway
80
proapoptotic proteins via ubiquitylation [33]. AREL1 contains two immunoglobin-like 
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is present, SMAC is ubiquitylated by AREL1 and degraded, thus blocking SMAC-
cIAP1/2 complex formation enabling cell survival [33]. Many cancer therapies are 
interested in specifically turning on apoptosis through IAPs in cancer cells [47–49], 
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thus AREL1 could prove to be a novel enzyme in drug development. Continued 
studies on AREL1’s mechanisms in controlling cell death are warranted.
2.2 HACE1, a prominent tumor suppressor with dual function
First identified in 2004, HECT domain and ankyrin repeat containing E3 
ubiquitin protein ligase 1 (HACE1; 909 residues) has been shown to take part in 
various cellular processes. For example, HACE1 is best known as a tumor sup-
pressor as altered HACE1 expression levels have been observed in various cancers 
including colorectal, breast, liver, kidney, osteosarcoma, lymphoma and gastric 
cancer [50–54]. HACE1 contains six ankyrin repeats near its N-terminus that 
likely take part in HACE1-substrate recognition and protein–protein interactions 
(Figure 2). While it is not yet fully understood how the ankyrin repeats support 
HACE1 function, ankyrin repeats in other proteins have been shown to instigate the 
development of a wide array of diseases including cancer [56]. HACE1 also supports 
Golgi membrane biogenesis during cell division by ubiquitylating members of the 
Ras-related superfamily of small G proteins [57].
Studies have shown that HACE1 expression levels are altered when comparing 
normal and cancerous tissue. Specifically, in the Wilms’ tumor cell line, HACE1 
expression was essentially nonexistent, whereas in other cancer cell lines expression 
levels were lower than average [50]. This study concluded that HACE1 was essential 
in repressing cancer development as the lowered expression levels of HACE1 were 
not mutation dependent. Low expression levels of HACE1 have also been observed in 
other cancer cell lines. For instance, it was found that the methylation of the HACE1 
promoter resulted in decreased HACE1 expression in liver cancer cells, which in turn 
decreased HACE1’s ability to ubiquitylate its identified substrates optineurin (OPTN) 
and microtubule-associated proteins 1A/1B light chain 3B protein [53]. Many differ-
ent substrates of HACE1 have been identified to date (summarized in [4]), including 
β2-adrenergic receptor (ß2AR) [58], OPTN [59], retinoic acid receptor beta (RAR-β)  
[57], tumor necrosis factor receptor-2 (TNFR2) [60], and various Ras-related 
Figure 2. 
Predicted domain architecture of HACE1. HACE1 contains six putative ankyrin-repeats (ANK; residues 
64-258) and a HECT domain (574-909) as annotated on UniProt and InterPro. Representative crystal 
structures of an ANK repeat fold (in shades of pink, PDB 4O60 [55]), which is likely involved in HACE1 
substrate binding and recognition, and a HECT domain (HECTN-lobe in green, HECTC-lobe in blue; PDB 
6JX5 [35]) found at HACE1’s C-terminus that is required of ubiquitylation activity. Structures were visualized 
using PyMol.
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proteins [57, 58, 61–65]. Expanded studies on how HACE1 binds and recognizes its 
substrates are needed to further clarify the role of HACE1 in cancer development.
HACE1 also plays an essential role in neurodevelopment as it was recently 
shown to be involved in the spastic paraplegia and psychomotor retardation with or 
without seizures (SPPRS) phenotype [66]. HACE1 also has cardiac protection func-
tion during hemodynamic stress when it was shown in mice with HACE1 deficiency, 
their susceptibility to accelerated heart failure greatly increased [67]. This suggests 
that HACE1 has a critical role in protecting the heart from various stresses, thus 
making it a potential cardiac drug target.
2.3 HECTD1, an important regulator in neurodevelopment
HECT domain containing E3 ubiquitin protein ligase 1 (HECTD1; 2610 residues) 
was discovered in 2007 as a novel and important regulator of neurodevelopment 
[68]. HECTD1 has similar domain architecture to HACE1 with four ankyrin repeats 
near its N-terminus and a C-terminal HECT domain (Figure 3). HECTD1 plays 
an important role in pulmonary fibrosis during endothelial-mesenchymal transi-
tion (EndMT) with reports of increased circular RNA HECTD1 (circHECTD1) 
transcription, which causes decreased HECTD1 protein expression in lung tissue 
[72, 73]. Elevated circHECTD1 gene expression has also been found in patients with 
acute ischemic stroke (AIS) [74]. HECTD1 also contains a Smad4 activation SAD1/
UNC (SUN) domain and a mind bomb (MIB) domain, with each having unique 
roles in intracellular signaling due to Smad-DNA complex formation and cellular 
interactions through the Notch pathway, respectively [75, 76].
HECTD1 supports fetal growth and proper placenta development. Specifically, 
HECTD1 aids in the development of the labyrinthine and junctional zones of the 
placenta, regions where the fetus acquires nutrients and disposes of waste, as well as 
a bilayer between the labyrinthine and decidual cells, respectively [77, 78]. HECTD1 
ensures the proper size development of the labyrinthine, yet the mechanisms to ensure 
this are still not fully understood. Mutations within HECTD1 lead to the onset of irreg-
ular labyrinthine development, which in turn depletes nutrients for the fetus. Fetal 
fatality can occur without proper maintenance of these placental regions, suggesting 
Figure 3. 
HECTD1 domain architecture. HECTD1 contains putative protein-protein interaction domains including two 
armadillo-repeat containing domains (ARM1, residues 8-254; ARM2 residues 892-925 in purple; PDB 4DB8 
[69]), four ankyrin-repeats (residues 395-612 in shades of pink; PDB 4O60 [56]), a SAD1/UNC domain 
(SUN, residues 1115-1244 in yellow; PDB 3UNP [70]), a mind bomb domain (MIB, residues 1266–1338 in 
red; PDB 2DK3), a helix-bundle domain (H, residues 1896–1968 in magenta; PDB 2KZS [71]) and a HECT 
domain (HECTN−lobe in green, HECTC−lobe in blue; PDB 6JX5 [35]). Domain boundaries are denoted according 
to UniProt and InterPro. Structures were visualized using PyMol.
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that HECTD1 expression is essential for the proper development and survival of 
fetuses in utero. HECTD1 also plays a role in proper neural tube closure. Anencephaly 
occurs when the neural tube does not close properly, which has been linked to 
HECTD1 control of heat shock protein 90 (Hsp90) levels [79]. When Hsp90 secretion 
levels are not properly regulated by HECTD1 ubiquitylation, abnormal neural tube 
development can occur. The continued examination of this important enzyme will 
hopefully clarify the molecular basis for HECTD1’s role in neurodevelopment.
2.4  HECTD4, a genetically linked precursor to cancer and cardiovascular 
disease
HECT domain containing E3 ubiquitin protein ligase 4 (HECTD4; 3996 residues) 
was recently discovered in 2014. A pleiotropic gene screen showed that there were 
links between metabolic syndromes and inflammation, specifically with single nucle-
otide polymorphisms (SNPs) in the HECTD4 gene [80]. Since 2014, HECTD4 has 
also been found to be associated with diabetes, hypertension and cardiovascular dis-
ease, lung adenocarcinoma, urothelial carcinoma and ovarian endometriosis [81–84].
Being one of the larger enzymes within the “other” HECT E3 ubiquitin ligase 
subfamily, it is intriguing that there have been no putative domains annotated for 
HECTD4 except the C-terminal HECT domain (residues 3627–3996). There are 
likely different domains located in the N-terminal region of the HECTD4 protein 
that need to be identified and functionally examined.
Genetic screening has identified various mutations in HECTD4 in cancer cells. 
For example, HECTD4 was recently identified as one of nine genes that correlated 
with the onset of lung adenocarcinoma [83]. Tumor genetic screens have revealed 
in patients with urothelial carcinoma in the bladder (UCB) that mutations in 
HECTD4, Fibrillin-3 Precursor (FBN3) and Citron Rho-Interacting Kinase (CIT) 
were correlated to UCB disease progression [81]. HECTD4 may also be linked to the 
development of ovarian endometriosis (OEM) [82]. However, future studies are 
still needed to verify this relationship.
Already having various genetic links to cancers and cardiovascular disease, 
HECTD4 deserves more attention by the research community to further clarify 
its biological and functional roles in the cell. Currently very little is known about 
HECTD4, therefore it will be imperative to first identify potential similarities in 
protein sequence and/or domain architecture. To better clarify HECTD4’s role in 
ubiquitin biology, it will also be important to discover HECTD4 substrates and 
annotate the sites of HECTD4-dependent ubiquitylation to answer how this myste-
rious HECT E3 ubiquitin ligase contributes to disease development.
2.5  G2E3, a unique multifunctional HECT E3 ubiquitin ligase with RING-like 
features
G2/M-phase specific E3 ubiquitin protein ligase (G2E3; 706 residues) was first 
identified in 2006 and named for its role during the G2/M phase of cell division 
and for having a conserved C-terminal HECT domain [85]. Knockout studies of 
G2E3 in mice demonstrated that this enzyme is essential in preventing apoptotic 
cell death during early embryonic development [86]. Expression levels in G2E3 were 
also observed to increase during early embryogenesis, specifically during central 
nervous system development. This enzyme is also implicated in cell cycle progres-
sion and DNA damage response [85, 87, 88].
G2E3 contains three plant homeodomain (PHD)-type zinc finger repeats, a 
domain typically known to bind to modified histones and act as epigenetic readers 
[89], making it the only known HECT E3 ubiquitin ligase to possess “RING”-like 
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identified in 2006 and named for its role during the G2/M phase of cell division 
and for having a conserved C-terminal HECT domain [85]. Knockout studies of 
G2E3 in mice demonstrated that this enzyme is essential in preventing apoptotic 
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characteristics (Figure 4). G2E3 is primarily found within the nucleus due to its 
N-terminal nucleolar localization signal sequence, while the PHD domains have been 
suggested to cause the translocation of G2E3 to the cytoplasm [85, 86]. Previous 
biochemical studies showed that the ubiquitin ligase activity of G2E3 was exclusively 
found in two of the putative N-terminal PHD domains while the C-terminal HECT 
domain of G2E3 had apparently lost its ubiquitylation activity [86]. Since the PHD 
domains of G2E3 appear to be capable of recruiting E2 enzymes to build K48-linked 
polyubiquitin chains [86], this suggests that the HECT domain of G2E3 may have 
become vestigial through evolutionary pressure. Intriguingly, G2E3 has aspects 
of the RING and HECT E3 ubiquitin ligase families, analogous to members of the 
RING-between-RING (aka RING-BRcat-Rcat) E3 ubiquitin ligases that includes 
parkin and HOIL-interacting protein (HOIP) of the LUBAC complex [91, 92].
G2E3 was recently identified as a potential drug target to increase the efficacy 
of chemotherapy drugs, specifically with Cisplatin [88]. Since Cisplatin is the most 
common chemotherapy drug, much research has been dedicated to increasing 
Cisplatin’s ability to specifically trigger the DNA damage response in cancer cells 
to initiate apoptosis while limiting its exposure time and prescribed duration for 
patients [93]. Clearly, G2E3 is an important nuclear protein whose mechanism 
is currently unresolved. Further studies are needed to clarify how this divergent 
HECT-domain containing E3 ubiquitin ligase works in the cell.
2.6  TRIP12, the multifunctioning E3 ubiquitin ligase essential for 
embryogenesis and DNA damage repair
Thyroid hormone receptor interactor 12 (TRIP12; 2040 residues), was first iden-
tified in 2001 for containing a unique tryptophan-tryptophan-glutamate (WWE) 
domain that is predicted to be involved in ubiquitylation and ADP-ribosylation [94] 
(Figure 5). It also contains two N-terminal ARM domains, similar to HECTD1, and 
Figure 4. 
Domain architecture of G2E3. G2E3 contains three putative plant homeodomain (PHD)-type domains 
(residues 78-128) and a unique HECT-like domain (371-678) as annotated on UniProt and InterPro. 
Representative crystal structures of a PHD domain (human PHD finger protein 13 in cyan with 
Zn-coordinating residues in yellow; PDB 3O70 [90]), which is suggested to interact with DNA and/or proteins 
in the nucleus, while the G2E3 HECT domain (HECTN−lobe in green, HECTC−lobe in blue; PDB 6JX5 [35]) may 
have lost its ability to catalyze the transfer of ubiquitin. Structures were visualized using PyMol.
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a conserved HECT domain at its C-terminus. TRIP12 is a novel HECT E3 ubiquitin 
ligase that has been shown to take part in various cellular pathways and processes 
including embryogenesis, DNA damage response and the neddylation pathway 
[95–97]. It has been reported that TRIP12 preferentially builds mono- as well as 
K48 and K63 polyubiquitin chains to tag its substrates for degradation and for DNA 
damage site recruitment, respectively [96].
TRIP12 has been shown to be directly and/or indirectly involved in cancer pro-
gression. For example, TRIP12 may serve as an oncogenic drug target for patients 
with acute myeloid leukemia (AML) by blocking a TRIP12 alternative splicing 
event, specifically excising exon3 from the mature TRIP12 mRNA [98]. TRIP12 
also targets pancreas transcription factor 1a (PTF1a) for proteasomal degradation, 
a protein essential for pancreatic cancer development [99]. TRIP12 forms a ternary 
complex with deubiquitylase ubiquitin-specific protease 7 (USP7) that aids in 
hepatocellular carcinoma (HCC) proliferation; when USP7 expression levels are 
heightened, TRIP12 cannot tag ARF tumor suppressor (p14ARF) for ubiquitylation 
[100]. Furthermore, TRIP12 is associated with human papillomavirus (HPV)-
positive head and neck squamous cell carcinoma (HNSCC) due to its mediation of 
p16-related radiation efficacy [101].
Members of the HECT E3 ubiquitin ligase family play important roles in neu-
rodevelopment and their malfunction may be causative in different neurological 
diseases and disorders (reviewed in [4]). Recent genetic screens have been looking 
to identify genetic markers for autism spectrum disorder (ASD) and intellectual 
disability (ID). Interestingly, a de novo mutation in TRIP12 was found in patients 
with or without ASD and displaying characteristics of ID [102]. Further studies to 
clarify the specific mechanism(s) for how mutations in the TRIP12 gene contribute 
to ASD and ID phenotypes are needed.
3. Conclusion
Although much research has and continues to be performed for E6AP and 
members of the NEDD4 family, greater attention on the mysterious “other” 
Figure 5. 
TRIP12 domain architecture. TRIP12 contains two putative armadillo-repeat containing domains (ARM1, 
residues 437-713; ARM2, residues 826-938), a tryptophan-tryptophan-glutamate (WWE)-domain (residues 
749-836) and a conserved HECT domain (1885-1992) as annotated on UniProt and InterPro. Representative 
crystal structures of an ARM domain (in purple; PDB 4DB8 [69]) and WWE domain (in orange; PDB 
6MIW), both of which are suggested to be involved in protein-protein and substrate interactions, as well as a 
HECT domain (HECTN−lobe in green, HECTC−lobe in blue; PDB 6JX5 [35]) required for ubiquitylation activity. 
Structures were visualized using PyMol.
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K48 and K63 polyubiquitin chains to tag its substrates for degradation and for DNA 
damage site recruitment, respectively [96].
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gression. For example, TRIP12 may serve as an oncogenic drug target for patients 
with acute myeloid leukemia (AML) by blocking a TRIP12 alternative splicing 
event, specifically excising exon3 from the mature TRIP12 mRNA [98]. TRIP12 
also targets pancreas transcription factor 1a (PTF1a) for proteasomal degradation, 
a protein essential for pancreatic cancer development [99]. TRIP12 forms a ternary 
complex with deubiquitylase ubiquitin-specific protease 7 (USP7) that aids in 
hepatocellular carcinoma (HCC) proliferation; when USP7 expression levels are 
heightened, TRIP12 cannot tag ARF tumor suppressor (p14ARF) for ubiquitylation 
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p16-related radiation efficacy [101].
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TRIP12 domain architecture. TRIP12 contains two putative armadillo-repeat containing domains (ARM1, 
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749-836) and a conserved HECT domain (1885-1992) as annotated on UniProt and InterPro. Representative 
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Structures were visualized using PyMol.
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HECT E3 ubiquitin ligases is warranted due to their emerging involvement in 
various diseases and neurological disorders. Combining genetic, cell biology, 
biochemical, and biophysical approaches to study these unique HECT E3 ubiquitin 
ligases will help to decipher their specific roles and/or functions in the cell as well 
as potentially aid in novel therapy development to treat rare conditions caused by 
the dysfunction of these lesser known members of the HECT E3 ubiquitin ligase 
family.
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Abnormal Ubiquitination of 
Ubiquitin-Proteasome System in 
Lung Squamous Cell Carcinomas
Xianquan Zhan and Miaolong Lu
Abstract
Ubiquitination is an important post-translational modification. Abnormal 
ubiquitination is extensively associated with cancers. Lung squamous cell carci-
noma (LUSC) is the most common pathological type of lung cancer, with unclear 
molecular mechanism and the poor overall prognosis of LUSC patient. To uncover 
the existence and potential roles of ubiquitination in LUSC, label-free quantitative 
ubiquitomics was performed in human LUSC vs. control tissues. In total, 627 ubiq-
uitinated proteins (UPs) with 1209 ubiquitination sites were identified, including 
1133 (93.7%) sites with quantitative information and 76 (6.3%) sites with qualitative 
information. KEGG pathway enrichment analysis found that UPs were significantly 
enriched in ubiquitin-mediated proteolysis pathway (hsa04120) and proteasome 
complex (hsa03050). Further analysis of 400 differentially ubiquitinated proteins 
(DUPs) revealed that 11 subunits of the proteasome complex were differentially 
ubiquitinated. These findings clearly demonstrated that ubiquitination was 
widely present in the ubiquitin-proteasome pathway in LUSCs. At the same time, 
abnormal ubiquitination might affect the function of the proteasome to promote 
tumorigenesis and development. This book chapter discussed the status of protein 
ubiquitination in the ubiquitin-proteasome system (UPS) in human LUSC tissues, 
which offered the scientific data to elucidate the specific molecular mechanisms of 
abnormal ubiquitination during canceration and the development of anti-tumor 
drugs targeting UPS.
Keywords: lung squamous cell carcinoma, ubiquitination, ubiquitinated protein 
(UP), differentially ubiquitinated protein (DUP), ubiquitin-proteasome system 
(UPS)
1. Introduction
Ubiquitination is one of the important protein post-translational modifica-
tions (PTMs) in human body, in which ubiquitin, a 76-amino-acid protein with a 
molecular weight of 8.5 KDa, is covalently attached its C-terminus to the ε-amino 
group of the substrate protein lysine residue through a multi-step enzymatic reac-
tion cascade catalyzed by ubiquitin-activating enzymes (E1), ubiquitin-conjugating 
enzymes (E2), and ubiquitin ligases (E3) [1]. As substrate proteins commonly 
contain multiple lysine residues, there are a variety of ubiquitination forms such as 
monoubiquitination (only one ubiquitin attached to a protein), multiubiquitination 
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(several lysine residues of substrate proteins were tagged with single ubiquitin), 
and polyubiquitination (a polyubiquitin chain is derived from subsequent ubiquitin 
covalently attached to lysine residues or N-terminus of the former ubiquitin) [2]. 
It is worth noting that the ubiquitin itself also has seven lysine residues to greatly 
complicate the topology of the polyubiquitin chain. Different ubiquitination forms 
perform different functions, such as monoubiquitination or multiubiquitination 
has been shown to be required for the entry of certain cargo proteins into vesicles at 
different stages of the secretory/endocytic pathway, while lysine-48 ubiquitin chain 
is mainly related to proteasome [3]. Like other PTMs, ubiquitination is a reversible 
reaction, and there are over 100 deubiquitination enzymes that regulate this process 
[4]. Ubiquitination coordinates with deubiquitination to regulate a broad host of 
cellular processes, including DNA repair, cell differentiation, signal transduction, 
enzymatic activity regulation, assembly of multiprotein complexes, protein traf-
ficking, and autophagy [5]. Therefore, abnormal ubiquitination is associated with 
many diseases, including cancer, neurodegenerative disease, infection, and immune 
disorders [6]. Considering the importance of ubiquitination in tumorigenesis, 
different components of ubiquitin-proteasome system could be regarded as targets 
for discovery of anti-tumor drugs. With the application of first and second thera-
peutic proteasome inhibitors, such as Bortezomib (FDA has approved it for multiple 
myeloma and mantle cell lymphoma) [7] and Carfilzomib (FDA has approved it for 
relapsed and refractory multiple myeloma) [8], more and more anti-tumor drugs 
targeting UPS have been developed and approved by FDA, such as thalidomide, 
lenalidomide, and pomalidomide for treatment of multiple myeloma [9, 10].
Lung squamous cell carcinoma (LUSC) is a common type of lung cancer without 
a clear molecular mechanism. Currently, surgery, radiation, and chemotherapy 
have made significant advances in lung cancer treatment, especially targeted drug 
therapy; for example, epidermal growth factor receptor (EGFR) mutation or 
EML4-ALK fusion-based targeted therapies have improved the survival time of 
patients with lung adenocarcinoma (LUAD). However, targeted therapy and early-
stage diagnosis are still a big clinical challenge in LUSC patients [11]. Although 
FGFR1 amplification and DDR2 mutation have been nominated as “druggable” 
targets in LUSC patients, the clinical efficacies of the corresponding drugs are still 
under clinical trials [12, 13]. Considering that abnormal ubiquitination will lead to 
the occurrence of a variety of tumors and the widespread clinical applications of 
anti-tumor drugs for the ubiquitin-proteasome pathway in recent years, the study 
of quantitative ubiquitinomics in LUSC tissues may provide the direction for the 
development of biomarkers and new targeted drugs.
High-resolution liquid chromatography in combination with tandem mass 
spectrometry (LC-MS/MS) has been used as a power tool for large-scale identifica-
tion of various PTMs such as ubiquitination, phosphorylation, acetylation, and 
N-glycosylation [14]. The challenge of the use of LC-MS/MS to identify endogenous 
ubiquitination sites on a large scale is the fact that ubiquitination is a low abundance 
event in vivo and the size of the modification itself. The common strategy to identify 
low-abundance ubiquitinations in a proteome is that the extracted protein sample is 
firstly digested with trypsin to form tryptic peptide mixture, then the commercially 
specific anti-K-ε-GG antibodies are used to preferentially enrich ubiquitinated 
peptides from tryptic peptide mixture before MS/MS analysis in recent years [15]. 
Anti-ubiquitin antibody (specific anti-K-ε-GG group)-based label-free quantifi-
cation coupled with LC-MS/MS has been used as an effective method to detect, 
identify, and quantify ubiquitinated proteins and ubiquitination sites, and more 
than 10,000 ubiquitination sites have been identified and quantified [16]. For lung 
cancer, ubiquitinomics is mainly carried out in lung cancer cells [17, 18], while 
the ubiquitinomics of fresh LUSC tissues is only reported recently in our research 
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group with label-free quantitative proteomics method and bioinformatics analysis 
to reveal the functions of ubiquitinome in predictive, preventive, and personalized 
medicine (PPPM) of LUSC [19].
This book chapter mainly reviewed ubiquitinated proteins (UPs) and dif-
ferentially ubiquitinated proteins (DUPs) in ubiquitin-proteasome-system (UPS) 
in LUSC, and emphasized the potential regulatory role of ubiquitination in UPS, 
which offers scientific data for further research on the regulatory mechanism of 
ubiquitination on UPS, the molecular mechanism of UPS abnormality in tumor 
development, and the development of anti-tumor drugs targeting UPS.
2. Materials and methods
2.1 Lung cancer tissues and protein extraction
Human LUSC tissues (n = 5) and tumor-adjacent control lung tissues (n = 5) were 
surgically removed from patients, immediately stored in liquid nitrogen (−196°C), 
and then stored in freezer (−80°C). Clinical characteristics of each sample were 
described previously [19]. LUSC tissues (750 mg, equally mixed 5 tumor tissues) 
and control tissues (750 mg, equally mixed 5 control tissues) were washed 5 times 
with 3 mL 0.9% NaCl to clean blood on the surface of the tissues. The washed tissues 
(LUSC; or controls) were homogenized with urea lysis buffer [2 M thiourea, 7 M 
urea, 1 mM protein inhibitor PMSF, and 100 mM dithiothreitol(DTT)], sonicated, 
and centrifuged (15,000 g, 20 min, and 4°C). The supernatant was the extracted 
protein sample. The protein content was tested with Brandford method. The detailed 
procedure of protein extraction was described previously [19].
2.2 Protein digestion and enrichment of ubiquitinated peptides
An amount of DTT (final concentration = 10 mM) was added to each extracted 
protein sample, which was mixed (600 rpm, 1.5 h, and room temperature). 
An amount of iodoacetamide (final concentration = 50 mM) was added to the 
DTT-treated protein sample, which was incubated (dark, 30 min). The uranyl 
acetate (UA) was diluted to 2 M with 50 mM Tris HCl buffer (pH 8.0) and added 
to each protein sample. An amount of trypsin was added to each protein sample 
(trypsin:protein = 1:50 at wt:wt), and then incubated (37°C, 15–18 h). A volume of 
10% trifluoroacetic acid (TFA; final concentration = 0.1%) was added, and pH was 
adjusted to ≤ 3 to stop digestion. Each tryptic peptide sample was purified with 
C18 cartridges and then lyophilized. The lyophilized tryptic peptides were resolved 
with 1.4 mL immunoaffinity purification (IAP) buffer that contained 50 mM NaCl, 
10 mM Na2HPO4, 50 mM MOPS/NaOH, and pH 7.2. The anti-K-ε-GG antibodies 
against ubiquitin remnant motif (K-ε-GG) (Cell Signal Technology) were used 
to enrich the ubiquitinated peptides, followed by purification with C18 STAGE 
Tips. The purified ubiquitinated peptide sample was used for MS/MS analysis. The 
detailed experimental procedure was described previously [19].
2.3 LC-MS/MS
The prepared ubiquitinated peptide sample was analyzed with LC-MS/MS in 
the Easy nLC and Q Exactive mass spectrometer (Thermo Scientific). The MS/MS 
data for each sample were used to search protein database using MaxQuant 1.5.3.17 
software to identify ubiquitinated proteins and ubiquitination sites and quantify the 
abundance of ubiquitination. The detailed procedure was described previously [19].
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2.4 Bioinformatics
For UPs and DUPs, DAVID software (version 6.8, https://david.ncifcrf.gov/) was 
used to carry out the gene ontology (GO) enrichment analysis, including cellular com-
ponents (CCs), molecular functions (MFs), and biological processes (BPs), and group 
those proteins into different functional clusters [20]. The statistically significant 
pathways were mined with the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway enrichment analysis. The KEGG online service tool KOBAS (http://kobas.cbi.
pku.cn) was used to annotate the KEGG database description of each protein [21].
3. Results and discussion
3.1 Proteomics analysis of lysine-ubiquitinated profile in LUSC
To identify protein lysine-ubiquitinated sites and quantify the level of 
ubiquitination in human LUSC tissues, proteins were extracted and digested 
into peptides with trypsin. Lysine-ubiquitinated peptides were immunoaffinity-
enriched with commercially specific anti-K-ε-GG antibodies and analyzed with 
high-resolution LC-MS/MS. In total, 1209 lysine-ubiquitinated sites in 627 unique 
proteins were identified. These proteins containing ubiquitinated lysine residues 
were defined as UPs. Figure 1 showed two representative MS/MS spectra of the 
ubiquitinated peptides 425ETNLDSLPLVDTHSK*R440 from vimentin (P08670; 
K* = ubiquitinated lysine residue) (Figure 1A), and 633RPVK*DGGGTNSITVR647 
from multidrug resistance-associated protein 1 (P33527; K* = ubiquitinated lysine 
residue) (Figure 1B). All other ubiquitinated sites and ubiquitinated proteins were 
identified with the same MS/MS method. The differentially ubiquitinated peptides 
were determined with amino acid sequences, ratio(tumor/control) > 2.0 or < 0.5, 
and p-value < 0.05. Proteins containing this type of ubiquitinated peptides were 
defined as DUPs. Totally, 400 DUPs with 654 ubiquitinated sites were identified in 
LUSC tissues vs. tumor-adjacent control lung tissues [19].
3.2  UPs and DUPs were significantly enriched in UPS-related biological 
processes and molecular functions in LUSC
GO functional enrichment analyses of 627 UPs and 400 DUPs were carried 
out according to BPs, MFs, and CCs. GO enrichment result-based cluster analysis 
grouped those UPs into seven clusters (Table 1), and DUPs into 10 clusters (Table 2).
Among GO enrichment results of 627 UPs, many biological processes, molecular 
functions, and cellular components related to UPS were significantly enriched, 
including negative regulation of ubiquitin-protein ligase activity involved in mitotic 
cell cycle, and positive regulation of ubiquitin-protein ligase activity involved in 
regulation of mitotic cell cycle transition in cluster 2, and proteasome-activating 
ATPase activity, positive regulation of proteasomal protein catabolic process, cyto-
solic proteasome complex, nuclear proteasome complex, and proteasome regula-
tory base complex in cluster 3 (Table 1). Interestingly, DUPs were also significantly 
enriched in the similar biological processes, molecular functions, and cellular 
components, including proteasome accessory complex, negative regulation of 
ubiquitin-protein ligase activity involved in mitotic cell cycle, positive regulation of 
ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transi-
tion, and protein polyubiquitination in cluster 2, and proteasome-activating ATPase 
activity, positive regulation of proteasomal protein catabolic process, cytosolic 
proteasome complex, nuclear proteasome complex, and proteasome regulatory 
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base complex in cluster 3 (Table 2). These findings clearly demonstrated that many 
ubiquitinated proteins were involved in UPS system, and differential ubiquitination 
occurred in UPS system in LUSC, implying that ubiquitination participated in the 
regulation of UPS, and abnormal ubiquitination might play an important role in the 
development of LUSC.
3.3 UPs involved in UPS-related molecular network alternations in LUSC
KEGG pathway network analysis of 627 UPs revealed 47 statistically significant 
ubiquitination-mediated signaling pathway alterations (P < 0.05 and FDR < 0.05) 
(Figure 2), among which were included two UPS-related pathways—ubiquitin-
mediated proteolysis pathway (hsa04120) and proteasome complex (hsa03050).
Ubiquitin-mediated proteolysis pathway showed the detailed process of protein 
ubiquitination, which involved multiple types of E1s, E2s, and E3s. This study found 
that one E1 (UBE1), two E2s (UBE2N, and UBE2O), and six E3s (ITCH, HUWE1, 
UBE4B, PML, CUL4A, and CUL5) were ubiquitinated in LUSC (Figure 3). These 
six E3s belonged to different subfamilies, in which ITCH and HUWE1 belonged to 
HECT type E3, UBE4B belonged to U-box type E3, PML belonged to single RING-
finger type E3, and both CUL4A and CUL5 belonged to multi subunit RING-finger 
type E3. E1s, E2s, and E3s are the important enzymes to catalyze the occurrence of 
ubiquitination in a protein. The ubiquitination of these enzymes definitely affects 
the quitination process of a protein. Currently, studies on these enzymes have 
focused on their roles in the ubiquitination process, and the effects of PTMs on these 
enzymes are poorly understood. There are relatively few studies on the ubiquitina-
tion of these nine enzymes. For example, ubiquitinated PML (P29590, identified 
in this study) was mediated by multiple E3s, leading to subsequent proteasomal 
degradation [22, 23]. Self-ubiquitination of ITCH (Q96J02, identified in this study) 
Figure 1. 
Representative MS/MS spectra of ubiquitinated peptides 425ETNLDSLPLVDTHSK*R440 from vimentin 
(P08670) (A) and 633RPVK*DGGGTNSITVR647 from multidrug resistance-associated protein 1 (MRP1) 
(P33527) (B). K* = ubiquitinated lysine residue. Reproduced from Lu et al. [19], with permission from Springer 
publisher open access article, copyright 2020.
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2.4 Bioinformatics
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ATPase activity, positive regulation of proteasomal protein catabolic process, cyto-
solic proteasome complex, nuclear proteasome complex, and proteasome regula-
tory base complex in cluster 3 (Table 1). Interestingly, DUPs were also significantly 
enriched in the similar biological processes, molecular functions, and cellular 
components, including proteasome accessory complex, negative regulation of 
ubiquitin-protein ligase activity involved in mitotic cell cycle, positive regulation of 
ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transi-
tion, and protein polyubiquitination in cluster 2, and proteasome-activating ATPase 
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base complex in cluster 3 (Table 2). These findings clearly demonstrated that many 
ubiquitinated proteins were involved in UPS system, and differential ubiquitination 
occurred in UPS system in LUSC, implying that ubiquitination participated in the 
regulation of UPS, and abnormal ubiquitination might play an important role in the 
development of LUSC.
3.3 UPs involved in UPS-related molecular network alternations in LUSC
KEGG pathway network analysis of 627 UPs revealed 47 statistically significant 
ubiquitination-mediated signaling pathway alterations (P < 0.05 and FDR < 0.05) 
(Figure 2), among which were included two UPS-related pathways—ubiquitin-
mediated proteolysis pathway (hsa04120) and proteasome complex (hsa03050).
Ubiquitin-mediated proteolysis pathway showed the detailed process of protein 
ubiquitination, which involved multiple types of E1s, E2s, and E3s. This study found 
that one E1 (UBE1), two E2s (UBE2N, and UBE2O), and six E3s (ITCH, HUWE1, 
UBE4B, PML, CUL4A, and CUL5) were ubiquitinated in LUSC (Figure 3). These 
six E3s belonged to different subfamilies, in which ITCH and HUWE1 belonged to 
HECT type E3, UBE4B belonged to U-box type E3, PML belonged to single RING-
finger type E3, and both CUL4A and CUL5 belonged to multi subunit RING-finger 
type E3. E1s, E2s, and E3s are the important enzymes to catalyze the occurrence of 
ubiquitination in a protein. The ubiquitination of these enzymes definitely affects 
the quitination process of a protein. Currently, studies on these enzymes have 
focused on their roles in the ubiquitination process, and the effects of PTMs on these 
enzymes are poorly understood. There are relatively few studies on the ubiquitina-
tion of these nine enzymes. For example, ubiquitinated PML (P29590, identified 
in this study) was mediated by multiple E3s, leading to subsequent proteasomal 
degradation [22, 23]. Self-ubiquitination of ITCH (Q96J02, identified in this study) 
Figure 1. 
Representative MS/MS spectra of ubiquitinated peptides 425ETNLDSLPLVDTHSK*R440 from vimentin 
(P08670) (A) and 633RPVK*DGGGTNSITVR647 from multidrug resistance-associated protein 1 (MRP1) 
(P33527) (B). K* = ubiquitinated lysine residue. Reproduced from Lu et al. [19], with permission from Springer 
publisher open access article, copyright 2020.
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Category GO term p -value
Annotation cluster 1
GOTERM_MF_DIRECT Cadherin binding involved in cell-cell adhesion 1.43E-29
GOTERM_CC_DIRECT Cell-cell adherens junction 3.72E-29
GOTERM_BP_DIRECT Cell-cell adhesion 1.13E-23
Annotation cluster 2
GOTERM_BP_DIRECT Wnt signaling pathway, planar cell polarity pathway 5.78E-11
GOTERM_BP_DIRECT Regulation of cellular amino acid metabolic process 4.14E-09
GOTERM_BP_DIRECT Stimulatory C-type lectin receptor signaling pathway 4.43E-09
GOTERM_BP_DIRECT NIK/NF-kappa B signaling 1.37E-08
GOTERM_BP_DIRECT Tumor necrosis factor-mediated signaling pathway 2.96E-08
GOTERM_BP_DIRECT Negative regulation of ubiquitin-protein ligase activity 
involved in mitotic cell cycle
3.70E-08
GOTERM_BP_DIRECT Positive regulation of ubiquitin-protein ligase activity 
involved in regulation of mitotic cell cycle transition
9.13E-08
GOTERM_BP_DIRECT Anaphase-promoting complex-dependent catabolic 
process
1.52E-07
GOTERM_BP_DIRECT T cell receptor signaling pathway 9.74E-07
GOTERM_BP_DIRECT Positive regulation of canonical Wnt signaling pathway 1.13E-06
GOTERM_BP_DIRECT Negative regulation of canonical Wnt signaling pathway 1.57E-05
Annotation cluster 3
GOTERM_CC_DIRECT Proteasome regulatory particle, base subcomplex 1.29E-08
GOTERM_CC_DIRECT Nuclear proteasome complex 1.70E-08
GOTERM_CC_DIRECT Cytosolic proteasome complex 1.21E-07
GOTERM_MF_DIRECT Proteasome-activating ATPase activity 1.70E-07
GOTERM_BP_DIRECT Positive regulation of RNA polymerase II 
transcriptional preinitiation complex assembly
3.45E-06
GOTERM_MF_DIRECT TBP-class protein binding 3.27E-05




GOTERM_BP_DIRECT SRP-dependent cotranslational protein targeting to 
membrane
3.56E-08
GOTERM_BP_DIRECT Viral transcription 7.74E-08
GOTERM_BP_DIRECT Nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay
1.92E-07
GOTERM_BP_DIRECT Translational initiation 6.60E-06
GOTERM_CC_DIRECT Ribosome 3.32E-05
GOTERM_MF_DIRECT Structural constituent of ribosome 1.68E-03
Annotation cluster 5
GOTERM_CC_DIRECT Haptoglobin-hemoglobin complex 9.95E-05
Annotation cluster 6
GOTERM_BP_DIRECT Nucleotide-excision repair, DNA damage recognition 6.40E-04
Annotation cluster 7
GOTERM_CC_DIRECT Hemoglobin complex 4.59E-03
Table 1. 
The functional categories of 627 ups, identified with GO enrichment analysis.
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Category GO term p-value
Annotation cluster 1
GOTERM_MF_DIRECT Cadherin binding involved in cell-cell adhesion 3.11E-18
GOTERM_CC_DIRECT Cell-cell adherens junction 2.24E-17
GOTERM_BP_DIRECT Cell-cell adhesion 1.23E-13
Annotation cluster 2
GOTERM_CC_DIRECT Proteasome accessory complex 4.60E-12
GOTERM_BP_DIRECT Antigen processing and presentation of exogenous 
peptide antigen via MHC class I, TAP-dependent
1.59E-11
GOTERM_BP_DIRECT Regulation of cellular amino acid metabolic process 3.49E-09
GOTERM_BP_DIRECT NIK/NF-kappaB signaling 5.35E-09
GOTERM_BP_DIRECT Negative regulation of ubiquitin-protein ligase activity 
involved in mitotic cell cycle
1.27E-08
GOTERM_BP_DIRECT Stimulatory C-type lectin receptor signaling pathway 1.85E-08
GOTERM_BP_DIRECT Positive regulation of ubiquitin-protein ligase activity 
involved in regulation of mitotic cell cycle transition
2.83E-08
GOTERM_BP_DIRECT Anaphase-promoting complex-dependent catabolic 
process
4.43E-08
GOTERM_BP_DIRECT Tumor necrosis factor-mediated signaling pathway 8.37E-08
GOTERM_BP_DIRECT Positive regulation of canonical Wnt signaling pathway 1.04E-07
GOTERM_BP_DIRECT T cell receptor signaling pathway 2.37E-07
GOTERM_BP_DIRECT Fc-epsilon receptor signaling pathway 4.90E-07
GOTERM_BP_DIRECT Protein polyubiquitination 7.65E-07
GOTERM_BP_DIRECT Negative regulation of canonical Wnt signaling pathway 4.36E-06
Annotation cluster 3
GOTERM_CC_DIRECT Proteasome regulatory particle, base subcomplex 4.88E-10
GOTERM_CC_DIRECT Nuclear proteasome complex 1.00E-09
GOTERM_CC_DIRECT Cytosolic proteasome complex 7.28E-09
GOTERM_MF_DIRECT Proteasome-activating ATPase activity 1.54E-08
GOTERM_BP_DIRECT Positive regulation of RNA polymerase II transcriptional 
preinitiation complex assembly
3.41E-07
GOTERM_MF_DIRECT TBP-class protein binding 2.10E-06
GOTERM_BP_DIRECT Positive regulation of proteasomal protein catabolic 
process
1.05E-05
GOTERM_BP_DIRECT Protein catabolic process 1.41E-04
Annotation cluster 4
GOTERM_BP_DIRECT Regulation of ventricular cardiac muscle cell action 
potential
1.11E-03




GOTERM_CC_DIRECT Haptoglobin-hemoglobin complex 2.43E-05
GOTERM_CC_DIRECT Endocytic vesicle lumen 1.71E-04
GOTERM_MF_DIRECT Haptoglobin binding 1.10E-03
GOTERM_BP_DIRECT Positive regulation of cell death 1.90E-02
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GOTERM_CC_DIRECT Hemoglobin complex 1.97E-02
GOTERM_MF_DIRECT Oxygen transporter activity 2.90E-02
GOTERM_BP_DIRECT Oxygen transport 3.43E-02
Annotation cluster 6
GOTERM_BP_DIRECT SRP-dependent cotranslational protein targeting to 
membrane
9.85E-05
GOTERM_BP_DIRECT Nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay
5.83E-04
GOTERM_BP_DIRECT Viral transcription 1.69E-03
GOTERM_BP_DIRECT Translational initiation 5.82E-03
GOTERM_CC_DIRECT Ribosome 3.40E-02
Annotation cluster 7
GOTERM_MF_DIRECT Voltage-gated anion channel activity 5.30E-03
GOTERM_MF_DIRECT Porin activity 5.30E-03
GOTERM_CC_DIRECT Pore complex 1.11E-02
GOTERM_BP_DIRECT Anion transport 3.02E-02
GOTERM_BP_DIRECT Regulation of anion transmembrane transport 4.34E-02
Annotation cluster 8
GOTERM_BP_DIRECT Daunorubicin metabolic process 1.00E-02
GOTERM_BP_DIRECT Doxorubicin metabolic process 1.00E-02
Annotation cluster 9
GOTERM_BP_DIRECT Nucleotide-excision repair, DNA damage recognition 1.00E-02
GOTERM_BP_DIRECT Global genome nucleotide-excision repair 2.47E-02
Annotation cluster 10
GOTERM_MF_DIRECT Neutral amino acid transmembrane transporter activity 1.82E-02
GOTERM_BP_DIRECT Neutral amino acid transport 2.62E-02
Table 2. 
The functional categories of 400 DUPs, identified with GO enrichment analysis. Modified from Lu et al. [19], 
with permission from Springer publisher open access article, copyright 2020.
through lysine-63 linkages showed an auto-regulatory mechanism controlling ITCH 
cytoplasmic-nuclear shuffling [24]. Therefore, the effects of the currently known 
ubiquitination on these enzymes are only the tip of the iceberg. However, one should 
also realize that this study found ubiquitination of cullin proteins such as Cul4A and 
Cul5, while cullin proteins can also be modified by NEDD8 to form NEDDylation. 
It is well known that the use of the K-ε-GG antibody cannot discriminate between 
proteins modified with ubiquitin and the related proteins NEDD8 and ISG15. 
Therefore, for deep investigation of this identified ubiquitination of E3s Cul4A and 
Cul5 in LUSC in the future, additional experiments are needed to discriminate E3s 
Cul4A and Cul5 that were modified by ubiquitin, NEDD8, or ISG15 [22].
Proteasome was a pivotal component for ubiquitin-mediated proteolysis. The 
26S proteasome was a complex including two 19S regulatory particles (PA700) and 
one 20S core particle. The 20S degradation complex contained two α rings (7 sub-
units, α1-α7) and two β rings (7 subunits, β1-β7). These α rings and β rings together 
formed a hollow ground circle. The tube-like structure was highly conserved 
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from archaea to mammals [25]. Among them, the α ring was located in the outer 
layer of the cylinder-like structure, which mainly acted on the recognition of the 
substrate; the β ring was located in the inner layer of the cylinder-like structure, 
and was mainly responsible for catalyzing the degradation of the substrate [26, 27]. 
Three subunits that played a catalytic role were located on the inner surface of the 
β-ring molecule, exhibiting cysteine protease-like activity, trypsin-like activity, 
and chymotrypsin-like activity [26, 27]. The 19S regulatory complex contained 19 
different subunits, which were divided into two parts: “base” and “lid” [28]. Among 
them, the base part formed the proximal part of the 19S regulatory complex, which 
was connected to the alpha ring of the 20S degradation complex, and the lip part 
formed the distal end. The base section contained 6 ATPase-dependent subunits 
(Rpt1-Rpt6) and 2 ATPase-independent subunits (Rpn1 and Rpn2) [28]. Usually, 
Rpn10 and Rpn13 were also classified as the base [26]. The lid part consisted of 
Rpn3, Rpn5-Rpn9, and Rpn11-Rpn12 subunits [28]. The 19S regulatory complex 
recognized ubiquitin-labeled target proteins (Rpn10 and Rpn13) and before the 
target protein entered the 20S degradation complex, deubiquitinated the target 
protein (Rpn11) and opened the folded structure of the target protein [28]. This 
study discovered five UPs (Rpn3, Rpn5, Rpn6, Rpn10, and Rpn12) in PA700 (Lid), 
and seven UPs (Rpn13, Rpt1, Rpt2, Rpt3, Rpt4, Rpt5, and Rpt6) in PA700 (Base) in 
LUSC. No UPs were identified in 20S core particle in LUSC (Figure 4).
Figure 2. 
Statistically significant KEGG pathways enriched from 627 UPs. Those UPs were significantly enriched in 
47 KEGG pathways (p < 0.05 and FDR < 0.05), among which were included two UPS-related pathways—
ubiquitin-mediated proteolysis pathway (hsa04120) and proteasome complex (hsa03050). The darker dot 
means the more significant enrichment, and the size of the dot represents the number of UPs enriched in 
the pathway.
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from archaea to mammals [25]. Among them, the α ring was located in the outer 
layer of the cylinder-like structure, which mainly acted on the recognition of the 
substrate; the β ring was located in the inner layer of the cylinder-like structure, 
and was mainly responsible for catalyzing the degradation of the substrate [26, 27]. 
Three subunits that played a catalytic role were located on the inner surface of the 
β-ring molecule, exhibiting cysteine protease-like activity, trypsin-like activity, 
and chymotrypsin-like activity [26, 27]. The 19S regulatory complex contained 19 
different subunits, which were divided into two parts: “base” and “lid” [28]. Among 
them, the base part formed the proximal part of the 19S regulatory complex, which 
was connected to the alpha ring of the 20S degradation complex, and the lip part 
formed the distal end. The base section contained 6 ATPase-dependent subunits 
(Rpt1-Rpt6) and 2 ATPase-independent subunits (Rpn1 and Rpn2) [28]. Usually, 
Rpn10 and Rpn13 were also classified as the base [26]. The lid part consisted of 
Rpn3, Rpn5-Rpn9, and Rpn11-Rpn12 subunits [28]. The 19S regulatory complex 
recognized ubiquitin-labeled target proteins (Rpn10 and Rpn13) and before the 
target protein entered the 20S degradation complex, deubiquitinated the target 
protein (Rpn11) and opened the folded structure of the target protein [28]. This 
study discovered five UPs (Rpn3, Rpn5, Rpn6, Rpn10, and Rpn12) in PA700 (Lid), 
and seven UPs (Rpn13, Rpt1, Rpt2, Rpt3, Rpt4, Rpt5, and Rpt6) in PA700 (Base) in 
LUSC. No UPs were identified in 20S core particle in LUSC (Figure 4).
Figure 2. 
Statistically significant KEGG pathways enriched from 627 UPs. Those UPs were significantly enriched in 
47 KEGG pathways (p < 0.05 and FDR < 0.05), among which were included two UPS-related pathways—
ubiquitin-mediated proteolysis pathway (hsa04120) and proteasome complex (hsa03050). The darker dot 
means the more significant enrichment, and the size of the dot represents the number of UPs enriched in 
the pathway.
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3.4 DUPs involved in UPS-related molecular network alternations in LUSC
KEGG pathway network analysis of 400 DUPs revealed 39 statistically significant 
ubiquitination-mediated signaling pathway alterations (P < 0.05 and FDR < 0.05) 
(Figure 5), including one UPS-related pathway – proteasome complex (hsa03050).
Figure 3. 
UPs identified in ubiquitin-mediated proteolysis pathway (hsa04120). Pink rectangle means the ubiquitinated 
proteins, and green rectangle means nonubiquitinated proteins. The pathway node in the right panel 
corresponds to the pink rectangle in the left diagram. Protein access number is the Swiss-Prot accession number. 
Modified sites refer to ubiquitinated lysine (K). Ratio (T/N) = ratio of tumors to controls. Asterisk (*) 
represents there is no quantitative intensity on this modification site in both the tumor and the control group.
Figure 4. 
UPs identified in proteasome complex (hsa03050). Pink rectangle means the ubiquitinated subunits, and green 
rectangle means non-ubiquitinated subunits. The pathway node in the right panel corresponds to the pink 
rectangle in the left diagram. Protein access number is the Swiss-Prot accession number. Modified sites refer to 
ubiquitinated lysine (K). Ratio (T/N) = ratio of tumors to controls. T+/N− indicates that this modification 
site has quantitative intensity only in tumor group, while T−/N+ means this modification site has quantitative 
intensity only in control group. Asterisk (*) represents there is no quantitative intensity on this modification site 
in both the tumor and the control group.
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In proteasome complex, this study discovered 4 DUPs (Rpn3, Rpn5, Rpn10, and 
Rpn6) in PA700 (Lid), and 7 DUPs (Rpn13, and Rpt1-Rpt6) in PA700 (Base). Their 
ubiquitination levels were significantly increased at residues K74 (Ratio = 5.16) in 
Rpn10, K34 (Ratio = 2.27) in Rpn13, K293 (T+/N−) in Rpt2, K46 (Ratio = 4.96) in 
Rpt1, K372 (T+/N−) in Rpt5, K273 (T+/N−) in Rpt4, K346 (T+/N−), K330 (T+/N−) 
and K290 (T+/N−) in Rpt6, K194 (T+/N−), K328 (T+/N−) and K62 (Ratio = 2.37) in 
Rpt4, K273 (T+/N−) in Rpn3, K32 (T+/N−) in Rpn6, and K147 (T+/N−) in Rpn5. The 
ubiquitination level was decreased at residue K53 (Ratio = 0.33) in Rpt5 (Figure 6).
The proteasome was a pivotal component of UPS to degrade the short-lived 
regulatory proteins and remove the damaged soluble proteins [29]. Consequently, 
dysfunction of proteasome might decrease the capability of protein degrada-
tion, thus resulting in the increased level of misfolded and damaged proteins, 
which was closely related to tumorigenesis [30]. The 26S proteasome had one 20S 
subunit and two 19S regulatory caps. Two 19S caps were necessary to maintain the 
normal functions of 20S subunit. For example, Rpn 13 in 19S base cap and Rpn 
10 in 19S head cap were the recognition-receptors of the ubiquitinated proteins 
[31, 32]. Further, PTMs (such as phosphorylation, acetylation, myristoylation, 
and ubiquitination) had been detected in those subunits to greatly complicate 
the mechanisms of the modulation of proteasome activity. For example, Rpn 
10 was mono-ubiquitinated to recruit substrate protein and interact with the 
shuttle factor of proteasome in drosophila [33, 34]. The multiple ubiquitinations 
in 19S cap of proteasome such as Rpn 1, Rpn 10, and Rpn 13 were necessary to 
autophage proteasome [35]. Our study [19] discovered three non-ATPase subunits 
Figure 5. 
Statistically significant KEGG pathways enriched from 400 DUPs. Those DUPs were significantly enriched in 
39 KEGG pathways (p < 0.05 and FDR < 0.05), including one UPS-related pathway – proteasome complex. 
The darker dot means the more significant enrichment, and the size of the dot represents the number of DUPs 
enriched in the pathway. Reproduced from Lu et al. [19], with permission from Springer publisher open access 
article, copyright 2020.
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subunit and two 19S regulatory caps. Two 19S caps were necessary to maintain the 
normal functions of 20S subunit. For example, Rpn 13 in 19S base cap and Rpn 
10 in 19S head cap were the recognition-receptors of the ubiquitinated proteins 
[31, 32]. Further, PTMs (such as phosphorylation, acetylation, myristoylation, 
and ubiquitination) had been detected in those subunits to greatly complicate 
the mechanisms of the modulation of proteasome activity. For example, Rpn 
10 was mono-ubiquitinated to recruit substrate protein and interact with the 
shuttle factor of proteasome in drosophila [33, 34]. The multiple ubiquitinations 
in 19S cap of proteasome such as Rpn 1, Rpn 10, and Rpn 13 were necessary to 
autophage proteasome [35]. Our study [19] discovered three non-ATPase subunits 
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Statistically significant KEGG pathways enriched from 400 DUPs. Those DUPs were significantly enriched in 
39 KEGG pathways (p < 0.05 and FDR < 0.05), including one UPS-related pathway – proteasome complex. 
The darker dot means the more significant enrichment, and the size of the dot represents the number of DUPs 
enriched in the pathway. Reproduced from Lu et al. [19], with permission from Springer publisher open access 
article, copyright 2020.
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(PSMD3, PSMD11, and PSMD12), and three ATPase subunits (PSMC1, PSMC4, 
and PSMC6) were differentially ubiquitinated in 19S regulatory cap of protea-
some in LUSC tissues. It clearly demonstrated that these ubiquitinations in 19S 
regulatory caps might influence the structure and functions of the proteasome 
complex. Some studies found that PSMD11 was necessary to assemble proteasome 
complex and elevate the activity of proteasome in embryonic stem cells [36]. 
Acetylation [37], phosphorylation [38], and SUMO [39] had been reported to 
occur in PSMD11, and our study first discovered that PSMD11 was ubiquitinated 
at residue K32 in LUSC tissues but not in control lung tissues [19]. Currently, few 
literature studies are found regarding the study on the relationship of ubiquitina-
tion and function of proteasome subunits. However, the abnormal ubiquitination 
of proteasome subunits might cause the functional abnormalities of proteasome 
complex in LUSC tissues and further lead to the imbalance of synthesis and degra-
dation of intracellular proteins. These findings offer the new clues to deeply study 
and understand the regulation of UPS functions in LUSC.
4. Conclusions
Label-free quantitative ubiquitinomics was an effective approach to identify 
ubiquitinated proteins and ubiquitination sites and quantifies the levels of ubiqui-
tination in human LUSC tissues. In total, 627 UPs and 400 DUPs were identified, 
providing the first (differential) ubiquitinome profile based on fresh human LUSC 
tissues. GO and KEGG analyses of UPs and DUPs revealed the statistically signifi-
cant ubiquitination-mediated molecular network alternations, among which several 
proteins in two UPS-related pathways (ubiquitin-mediated proteolysis pathway, and 
proteasome complex) underwent ubiquitination in LUSC. Furthermore, 11 subunits 
Figure 6. 
DUPs identified in proteasome complex (hsa03050). The red rectangle means the intensities of all identified 
ubiquitination sites in one protein were increased, and yellow rectangle means at least two ubiquitination sites 
in a protein with inconsistent ubiquitination intensities. The pathway node in the right panel corresponds to 
the red and yellow rectangle in the left diagram. Protein access number is the Swiss-Prot accession number. 
Modified sites refer to ubiquitinated lysine (K). Ratio (T/N) = ratio of tumors to controls. T+/N− indicates that 
this modification site has quantitative intensity only in tumor group, while T−/N+ means this modification site 
has quantitative intensity only in control group. Reproduced from Lu et al. [19], with permission from Springer 
publisher open access article, copyright 2020.
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of proteasome complex were differentially ubiquitinated in LUSC. These findings 
demonstrated that ubiquitination was widely present in UPS in LUSC. At the same 
time, abnormal ubiquitination might affect the functions of the proteasome to 
promote tumorigenesis and development. This book chapter focused on the status 
of protein ubiquitination in UPS-related pathways in human LUSC tissues, and pro-
vided the scientific data for the elucidation of the specific molecular mechanisms 
of abnormal ubiquitination during canceration and the development of anti-tumor 
drugs targeting UPS for lung cancer.
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The ubiquitin-proteasome pathway consists of ubiquitin, substrate proteins, E1 
enzymes, E2 enzymes, E3 enzymes, and proteasome, which acts in a series of 
enzymatic reaction chains to ubiquitinate substrate proteins such as surplus and 
misfolded proteins for degradation by the proteasome to maintain the balance between 
protein synthesis and degradation in a cell and tissue. Moreover, deubiquitinating 
enzymes can remove the attached ubiquitin chain, which results in a reverse 
ubiquitination-deubiquitination process involved in multiple biological processes in 
a cell and tissue. The changes of components in the ubiquitin-proteasome pathway 
are associated with multiple pathophysiological processes, such as cancers and 
neurodegenerative diseases. This book presents the new advances in concepts, 
analytical methodology, and application of ubiquitin-proteasome pathway for 
clarification of molecular mechanisms and discovery of new therapeutic targets and 
drugs in different diseases.
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